{"meta":{"query_hash":"43ac0f224e9c","filters":{"venue":"Future Oncology"},"cohort_total":184,"direct_labels_cover":2,"predictions_cover":184,"exported":184,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/43ac0f224e9c","api":"https://metacan.xera.ac/api/v1/cohort?venue=Future+Oncology"},"results":[{"id":"W1940218692","doi":"10.2217/fon.15.220","title":"The Development of Stereotactic Body Radiotherapy in the Past Decade: A Global Perspective","year":2015,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Stereotactic radiotherapy; Radiation therapy; Radiation oncology; Perspective (graphical); Ablative case; Radiosurgery; Medical physics; Internal medicine","score_opus":0.016226992022652185,"score_gpt":0.3502143212516804,"score_spread":0.3339873292290282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1940218692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5857747,0.011625567,0.19226946,0.037765235,0.0025529694,0.0038730742,0.00005340703,0.00021369802,0.16587186],"genre_scores_gemma":[0.94920576,0.000042236752,0.04841244,0.00040465765,0.0015975477,0.00020368311,0.0000053935364,0.000021703301,0.000106599255],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990336,0.00020952597,0.00023107824,0.0001603303,0.000143826,0.0002216664],"domain_scores_gemma":[0.99935377,0.00012827842,0.00015449256,0.00023313874,0.00009119453,0.00003912546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038980326,0.00012822154,0.00019894759,0.000024407254,0.00009134157,0.000014613716,0.00036320288,0.000064684165,0.00002460351],"category_scores_gemma":[0.000005832221,0.00007109354,0.000047791968,0.00021024769,0.000106590756,0.000056885903,0.000024560642,0.00020911502,0.0000015458467],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090162357,0.0010797743,0.16951153,0.000009431915,0.0005857796,0.000016640077,0.06298019,0.00002396936,0.0008027687,0.46618786,0.01431201,0.2835884],"study_design_scores_gemma":[0.0015474752,0.00043843882,0.0224117,0.000008293001,0.00001310839,0.000014908371,0.022739248,0.000029806079,0.0002720625,0.011457845,0.94089115,0.0001759618],"about_ca_topic_score_codex":0.00005134577,"about_ca_topic_score_gemma":0.00011390722,"teacher_disagreement_score":0.9265791,"about_ca_system_score_codex":0.000615452,"about_ca_system_score_gemma":0.00037044814,"threshold_uncertainty_score":0.28991106},"labels":[],"label_agreement":null},{"id":"W1972785878","doi":"10.2217/fon.10.145","title":"Novel Targeted Agents on the Horizon for Castration-Resistant Prostate Cancer","year":2010,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Medicine; Androgen receptor; Androgen deprivation therapy; Cancer research; Testosterone (patch); Orchiectomy; Androgen; Prostate; Cancer; Oncology; Internal medicine; Bioinformatics; Hormone; Biology","score_opus":0.09929114834197945,"score_gpt":0.43647364871926125,"score_spread":0.3371825003772818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972785878","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004260023,0.9809052,0.0000040428604,0.0067508807,0.002514531,0.006299425,0.001038665,0.00003994384,0.002404714],"genre_scores_gemma":[0.000011025813,0.98047173,0.0003014391,0.00034737884,0.0035573223,0.0045341016,0.0012528597,0.00008280664,0.009441308],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815935,0.00010221828,0.00042883563,0.0005071103,0.00028767926,0.0005148206],"domain_scores_gemma":[0.9984998,0.0003548759,0.0003103962,0.00044952965,0.00021660786,0.00016878001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039100705,0.00041754925,0.0012811357,0.0001430728,0.00022811875,0.000027494041,0.00022285347,0.0007683067,0.00037994568],"category_scores_gemma":[0.00008238874,0.00020413654,0.00041422714,0.00025741983,0.00013350224,0.000024523582,0.00004058696,0.0011279882,0.00005219829],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007287523,0.0003023234,0.000002085497,0.0043367445,0.0004823449,0.00006505571,0.000114969516,9.621629e-8,0.00017806128,0.00075685553,0.04206216,0.95097053],"study_design_scores_gemma":[0.0017504161,0.0022284375,0.000024519848,0.001942849,0.00096600625,0.000040589075,0.000054523145,0.0000020602133,0.000034156183,0.000021817323,0.9927471,0.00018748388],"about_ca_topic_score_codex":0.000043527605,"about_ca_topic_score_gemma":0.00030737635,"teacher_disagreement_score":0.9507831,"about_ca_system_score_codex":0.0007556236,"about_ca_system_score_gemma":0.0030415715,"threshold_uncertainty_score":0.8324446},"labels":[],"label_agreement":null},{"id":"W1977865587","doi":"10.2217/fon.10.105","title":"The Potential of Immunomodulatory Drugs in the Treatment of Solid Tumors","year":2010,"lang":"en","type":"review","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Solid tumor; Intensive care medicine; Oncology; Pharmacology; Internal medicine; Cancer","score_opus":0.02649924056177988,"score_gpt":0.38462041893369553,"score_spread":0.35812117837191565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977865587","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027016504,0.9929841,3.2831466e-7,0.00032866295,0.00059996126,0.0019479604,0.00008692034,0.000006394215,0.0013440207],"genre_scores_gemma":[0.0023916294,0.9958476,0.00007431249,0.0000153395,0.00078132574,0.0003235626,0.00014940755,0.000028999599,0.00038784975],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977933,0.00052494014,0.0007252089,0.00025256092,0.00033196513,0.00037201933],"domain_scores_gemma":[0.99806976,0.0005138139,0.000467141,0.000784819,0.00008620813,0.00007826147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041358423,0.00030956956,0.0018898138,0.00016924125,0.00008005248,0.000004652078,0.00035431742,0.000484258,0.00005989314],"category_scores_gemma":[0.000045466335,0.00012614335,0.0006531037,0.00021640271,0.00032299725,0.000013641704,0.000039336937,0.00057474873,0.0000246628],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022032094,0.0011179713,0.000028474236,0.0011070292,0.00044869518,0.00021749857,0.00039529195,5.3756285e-8,0.000013355462,0.0000936114,0.0002215614,0.9961361],"study_design_scores_gemma":[0.00203959,0.002800766,0.0016992743,0.00065728155,0.0006716332,0.0002596124,0.00034006964,0.00000193714,0.000011473898,0.000018071152,0.99142253,0.000077749646],"about_ca_topic_score_codex":0.00011566666,"about_ca_topic_score_gemma":0.00015275026,"teacher_disagreement_score":0.9960584,"about_ca_system_score_codex":0.0003216358,"about_ca_system_score_gemma":0.0012644381,"threshold_uncertainty_score":0.5143976},"labels":[],"label_agreement":null},{"id":"W1987659344","doi":"10.2217/fon.14.167","title":"Stereotactic Body Radiotherapy: An Effective Local Treatment Modality for Hepatocellular Carcinoma","year":2014,"lang":"en","type":"review","venue":"Future Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Western University; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Radiation therapy; Oncology; Radiology; Liver cancer; Internal medicine","score_opus":0.07164260666451745,"score_gpt":0.3592313822499008,"score_spread":0.28758877558538337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987659344","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025299639,0.9816128,0.0011279462,0.0003755581,0.0012362744,0.01218946,0.00018533925,0.00016962185,0.0005730495],"genre_scores_gemma":[0.01421112,0.96758395,0.0011955411,0.0002485507,0.0057521462,0.007002408,0.003037466,0.00029011167,0.0006787228],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951946,0.0014235093,0.00093054713,0.00134028,0.00026681923,0.00084420666],"domain_scores_gemma":[0.9967115,0.00072714465,0.0005802695,0.0011901434,0.00016744653,0.0006234901],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00056068535,0.0012424059,0.005673141,0.0003418172,0.00020146945,0.000037952213,0.00026327645,0.0018287245,0.00018779903],"category_scores_gemma":[0.000027901791,0.00086186937,0.002036998,0.00026874302,0.00018343345,0.000081042235,0.000040686293,0.00054939033,0.0000847275],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063070253,0.0014036319,0.005668874,0.0107465815,0.0023823213,0.0007921938,0.00022379438,3.5420186e-8,0.0000034020347,0.00025575398,0.0003531612,0.97753954],"study_design_scores_gemma":[0.0053401166,0.020217251,0.00020029013,0.000865244,0.010965552,0.0008172501,0.000032174154,0.00095117395,0.000025383713,0.00003344133,0.9598979,0.000654229],"about_ca_topic_score_codex":0.00015074934,"about_ca_topic_score_gemma":0.00004168116,"teacher_disagreement_score":0.9768853,"about_ca_system_score_codex":0.003670229,"about_ca_system_score_gemma":0.0011706259,"threshold_uncertainty_score":0.99946713},"labels":[],"label_agreement":null},{"id":"W1988301011","doi":"10.2217/fon.09.58","title":"If Cancer Stem Cells are Resistant to Current Therapies, What’s Next?","year":2009,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Cancer; Metastasis; Medicine; Tumor microenvironment; Cancer stem cell; Cancer research; Oncology; Internal medicine; Library science; Computer science","score_opus":0.02391622463582073,"score_gpt":0.3389130197994513,"score_spread":0.3149967951636306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988301011","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012530934,0.18265979,0.000008087552,0.011035549,0.8040291,0.00096860324,0.00042075722,0.0000817948,0.00067098025],"genre_scores_gemma":[0.000037564045,0.1793225,0.00024940266,0.0017825011,0.81167245,0.0002285488,0.00022411362,0.00009866632,0.0063842577],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964429,0.00019642583,0.00065963104,0.0010146641,0.000910693,0.0007756871],"domain_scores_gemma":[0.9972931,0.00021572251,0.000539988,0.0008455097,0.000554324,0.00055135053],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00036494122,0.00066310546,0.0018327684,0.00027645967,0.00011665628,0.00015630423,0.00038124964,0.0015357159,0.00084240973],"category_scores_gemma":[0.00002849375,0.0005324299,0.00039647368,0.0003738387,0.00008664351,0.00015838064,0.00010393589,0.0019151202,0.00014151887],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012200202,0.00019359666,0.0000010315271,0.00031441337,0.00015905738,0.00015078692,0.00044316732,0.0000013923524,0.0004706054,0.0000104967885,0.596806,0.40022945],"study_design_scores_gemma":[0.0021312945,0.0016510542,0.00003730134,0.0013571368,0.0007367537,0.000005055945,0.0017238931,2.6739957e-7,0.0003069546,0.000013136256,0.9915462,0.000490962],"about_ca_topic_score_codex":0.0002474972,"about_ca_topic_score_gemma":0.0024341005,"teacher_disagreement_score":0.3997385,"about_ca_system_score_codex":0.0021802022,"about_ca_system_score_gemma":0.0032479584,"threshold_uncertainty_score":0.9997605},"labels":[],"label_agreement":null},{"id":"W1996531785","doi":"10.2217/fon.09.26","title":"Role of The<i>MTHFR</i>Polymorphisms in Cancer Risk Modification and Treatment","year":2009,"lang":"en","type":"review","venue":"Future Oncology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Methylenetetrahydrofolate reductase; Single-nucleotide polymorphism; Medicine; Pharmacogenetics; Pharmacology; Antimetabolite; Cancer; Methotrexate; Bioinformatics; Cancer research; Allele; Internal medicine; Genetics; Biology; Genotype; Gene","score_opus":0.053843940651838354,"score_gpt":0.40758050055623274,"score_spread":0.3537365599043944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996531785","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001739075,0.9941538,1.0741133e-7,0.00065006677,0.00013869414,0.0010415685,0.000052159416,0.000007081774,0.0022174774],"genre_scores_gemma":[0.00037275764,0.99766576,0.00004509379,0.000050132345,0.0005282871,0.000173225,0.000040704712,0.000017555605,0.0011064634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99879414,0.00024357132,0.00034953115,0.00027107142,0.00013794159,0.00020375501],"domain_scores_gemma":[0.9992269,0.00007772002,0.0002431751,0.00034725852,0.000038736955,0.00006617563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014589028,0.00020167016,0.0011977308,0.00017238283,0.00003388717,0.0000032460712,0.000110865614,0.00051073515,0.000058348243],"category_scores_gemma":[0.000019667068,0.0001079809,0.0001910268,0.00030501263,0.00008284147,0.000015224861,0.000032439624,0.0004185176,0.000009436604],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036641075,0.00024762255,0.00025055147,0.0004706648,0.000094161376,0.0000098400615,0.00015355328,1.800059e-7,0.000029178502,0.000054949698,0.00032325488,0.9983294],"study_design_scores_gemma":[0.0006947025,0.0008000761,0.004613889,0.0011994854,0.00066102046,0.000060680413,0.00003426823,0.0000068577315,0.000015062532,0.000027328277,0.9918059,0.000080721096],"about_ca_topic_score_codex":0.0007658069,"about_ca_topic_score_gemma":0.0010211865,"teacher_disagreement_score":0.9982487,"about_ca_system_score_codex":0.0005853696,"about_ca_system_score_gemma":0.0008219743,"threshold_uncertainty_score":0.44033334},"labels":[],"label_agreement":null},{"id":"W1999540397","doi":"10.2217/fon.14.163","title":"On the Contribution of S100A10 and Annexin A2 to Plasminogen Activation and Oncogenesis: An Enduring Ambiguity","year":2014,"lang":"en","type":"review","venue":"Future Oncology","topic":"S100 Proteins and Annexins","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Carcinogenesis; Ambiguity; Annexin A2; Cancer research; Annexin; Cancer; Internal medicine; Pathology; Linguistics; Philosophy","score_opus":0.023088523636378807,"score_gpt":0.3250235927638751,"score_spread":0.3019350691274963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999540397","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11072029,0.8859933,0.00038513067,0.00040322298,0.000344805,0.0015073164,0.00009593376,0.000016520522,0.0005334535],"genre_scores_gemma":[0.056997683,0.9399232,0.00013771858,0.00060395245,0.0016343446,0.00021746203,0.00035933306,0.0000451838,0.00008108299],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856615,0.00036602464,0.00031263978,0.00045466135,0.00008897931,0.00021153592],"domain_scores_gemma":[0.99909234,0.00008167173,0.00028907278,0.00034871188,0.000083332176,0.000104865074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042815198,0.00027383876,0.00071360456,0.00007458468,0.000112450805,0.000016557591,0.00017880536,0.0006683611,0.00000974304],"category_scores_gemma":[0.00013842424,0.00018455785,0.00010673974,0.00008456854,0.00008037503,0.0000037684695,0.00013667066,0.00018996572,0.0000029910245],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019008014,0.00012435138,0.000017068112,0.00089495006,0.00017718058,0.0000028755007,0.00007180638,0.000001462682,0.012059553,0.004336083,0.0011333192,0.98099124],"study_design_scores_gemma":[0.00027696672,0.0016378001,0.00011498801,0.00049359485,0.00012070805,0.000029163297,0.00004981063,0.0000017874889,0.0061380356,0.00006379717,0.99086565,0.00020771548],"about_ca_topic_score_codex":0.0000224195,"about_ca_topic_score_gemma":0.00010893279,"teacher_disagreement_score":0.9897323,"about_ca_system_score_codex":0.000041968997,"about_ca_system_score_gemma":0.00015004085,"threshold_uncertainty_score":0.7526051},"labels":[],"label_agreement":null},{"id":"W2000905384","doi":"10.2217/14796694.4.6.779","title":"The Future in Psychosocial Oncology: Screening for Emotional Distress – The Sixth Vital Sign","year":2008,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Alberta Heritage Foundation for Medical Research; Australian Government","keywords":"Biopsychosocial model; Psychosocial; Medicine; Survivorship curve; Distress; Healthcare system; Health care; Sign (mathematics); Pediatric oncology; Population; Intensive care medicine; Oncology; Psychiatry; Internal medicine; Clinical psychology; Cancer; Environmental health","score_opus":0.042005071059260594,"score_gpt":0.38833188258826906,"score_spread":0.34632681152900846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000905384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008943519,0.96292824,0.00010855765,0.01794286,0.010708786,0.0024089513,0.00040749047,0.000048293645,0.0054378835],"genre_scores_gemma":[0.000032407403,0.9609646,0.00018848856,0.0011397424,0.03433113,0.0011621173,0.000982692,0.0000848826,0.0011139399],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996878,0.00070182583,0.0007657119,0.0006124365,0.00037597955,0.00066599733],"domain_scores_gemma":[0.99706495,0.0015698716,0.00051524094,0.00052660645,0.0001702625,0.00015309402],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005760952,0.00054669793,0.0019916217,0.00012421775,0.00059687335,0.000030573356,0.00059052394,0.0016613376,0.00009343736],"category_scores_gemma":[0.000089544,0.00028928832,0.0010912074,0.00047959705,0.00037430957,0.0000390701,0.00010506049,0.0018909395,0.00002031779],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035579962,0.00013454816,0.000017064644,0.001011957,0.00023897446,0.000104251936,0.00061579066,2.1658494e-7,1.0806967e-7,0.0011216819,0.10034089,0.89605874],"study_design_scores_gemma":[0.0014287062,0.0007971578,0.00020207069,0.0011709137,0.00049923937,0.00071707903,0.002022984,0.0000013382831,5.966895e-8,0.00008542559,0.99279237,0.0002826494],"about_ca_topic_score_codex":0.000048929465,"about_ca_topic_score_gemma":0.008657132,"teacher_disagreement_score":0.8957761,"about_ca_system_score_codex":0.0010113672,"about_ca_system_score_gemma":0.0020232126,"threshold_uncertainty_score":0.99995595},"labels":[],"label_agreement":null},{"id":"W2007775064","doi":"10.2217/14796694.1.4.511","title":"Notch Signaling in T-Cell Acute Lymphoblastic Leukemia","year":2005,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Chromosomal translocation; Lymphoblastic Leukemia; Leukemia; Gene; Disease; Cancer research; Etiology; Immunology; T cell; Bioinformatics; Biology; Genetics; Internal medicine; Immune system","score_opus":0.012584580818678671,"score_gpt":0.30736543521473103,"score_spread":0.29478085439605234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007775064","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033194278,0.9951825,0.000083625884,0.00006788412,0.0012239383,0.00058528973,0.000043564498,0.000020930745,0.002460304],"genre_scores_gemma":[0.00021881984,0.9899648,0.00066795235,0.00012163202,0.0060134707,0.00013793906,0.0011765839,0.00009953101,0.0015992885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977083,0.00025038383,0.0006806778,0.0007538878,0.00013876367,0.0004679745],"domain_scores_gemma":[0.9988678,0.000047437585,0.00043408066,0.00048943015,0.00005637403,0.000104841325],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0002089989,0.00049540907,0.0011770265,0.00021121654,0.00005021357,0.000015816628,0.00036876794,0.0022160506,0.00009593193],"category_scores_gemma":[0.00001963571,0.0004678426,0.0004031747,0.0003092888,0.00006216877,0.0000032331743,0.00015278379,0.0004829127,0.00012743728],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005159042,0.00005871221,9.2995407e-7,0.00090005033,0.00016558506,0.000035046443,0.000023630393,0.00043484627,0.0031018811,0.000012277986,0.006460242,0.9887552],"study_design_scores_gemma":[0.0007928958,0.0002871183,0.0000023534633,0.00062305486,0.00052160583,0.0002012974,0.000010934399,0.000021435591,0.00032148027,0.000004385852,0.9967666,0.00044680474],"about_ca_topic_score_codex":0.000011570971,"about_ca_topic_score_gemma":0.00021459769,"teacher_disagreement_score":0.9903064,"about_ca_system_score_codex":0.0013150715,"about_ca_system_score_gemma":0.0023477324,"threshold_uncertainty_score":0.9997773},"labels":[],"label_agreement":null},{"id":"W2011966810","doi":"10.2217/14796694.3.5.539","title":"Targeting the Rna-Binding Protein Sam68 As A Treatment For Cancer?","year":2007,"lang":"en","type":"review","venue":"Future Oncology","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Suppressor; RNA-binding protein; Oncogene; RNA; Biology; Carcinogenesis; Cancer research; Cancer; Breast cancer; Mammary tumor; Haploinsufficiency; Cell biology; Genetics; Gene; Phenotype","score_opus":0.05321973433173025,"score_gpt":0.42035839195967767,"score_spread":0.3671386576279474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011966810","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00052898814,0.994003,0.0001307273,0.00047303308,0.000541962,0.0029196448,0.00009673699,0.000013466145,0.0012924466],"genre_scores_gemma":[0.000008826874,0.9763903,0.000660206,0.00012445229,0.0056016995,0.0024017985,0.0005400649,0.000069785536,0.014202849],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796337,0.00027304448,0.00040377886,0.0005487921,0.0001340006,0.00067700905],"domain_scores_gemma":[0.9989792,0.00012369723,0.00029990711,0.00037803123,0.0000862916,0.00013284013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072689576,0.00039144763,0.0008590763,0.00008087662,0.00029446388,0.000031656262,0.00042406103,0.00080425513,0.00004572498],"category_scores_gemma":[0.000156889,0.00022442685,0.0005005094,0.0001394424,0.00007875642,0.0000017995646,0.000120248325,0.00032383125,0.000026883781],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008468241,0.000047164944,5.25157e-7,0.0010114898,0.0003114418,0.000019677065,0.000020814048,6.5604826e-7,0.009153759,0.00012885696,0.004438709,0.9847822],"study_design_scores_gemma":[0.00042796918,0.0012393364,7.586839e-8,0.00050808425,0.00017529813,0.000043003343,0.00010212399,0.000002593878,0.0012156798,0.000006845269,0.9960435,0.00023548624],"about_ca_topic_score_codex":0.0000917813,"about_ca_topic_score_gemma":0.00026639702,"teacher_disagreement_score":0.9916048,"about_ca_system_score_codex":0.00040635632,"about_ca_system_score_gemma":0.001361499,"threshold_uncertainty_score":0.91518617},"labels":[],"label_agreement":null},{"id":"W2013307793","doi":"10.2217/14796694.2.5.627","title":"Tumor Dormancy and the Role of Metastasis Suppressor Genes In Regulating Ectopic Growth","year":2006,"lang":"en","type":"review","venue":"Future Oncology","topic":"Mechanisms of cancer metastasis","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Metastasis; Ectopic expression; Metastasis suppressor; Suppressor; Dormancy; Metastasis Suppressor Gene; Cancer research; Medicine; Malignancy; Gene; Primary tumor; Cancer; Biology; Oncology; Internal medicine; Genetics; Botany","score_opus":0.011695508575961067,"score_gpt":0.2927156381989339,"score_spread":0.28102012962297285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013307793","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00048003768,0.9967188,0.00002085116,0.00009752535,0.00028801672,0.000645647,0.00008861031,0.0000059948675,0.0016544731],"genre_scores_gemma":[0.0005111053,0.99559397,0.0023442882,0.00006541405,0.0009487113,0.00023138282,0.000169336,0.00004654247,0.000089230205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776036,0.00064933725,0.00068287854,0.00047573252,0.00013664651,0.00029505623],"domain_scores_gemma":[0.99870884,0.00010203759,0.000604585,0.00046957246,0.000069219255,0.000045725734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005705583,0.00035192375,0.0015527799,0.00013575256,0.000047834084,0.000011803151,0.00040128783,0.00041881512,0.000027346921],"category_scores_gemma":[0.00007765736,0.00022969206,0.0003216994,0.00018608583,0.00017906057,0.0000034447748,0.00026392995,0.00025747583,0.000001687074],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076756405,0.000043048927,0.000012194773,0.0023015076,0.00021454119,0.0000081274175,0.000023639064,9.105202e-7,0.0007011303,0.0031454037,0.00041397897,0.99305874],"study_design_scores_gemma":[0.0009190853,0.00016169887,0.0000120315535,0.00029394022,0.000527507,0.00010670044,0.000048866976,0.0000018335354,0.0038808768,0.0005250507,0.99331045,0.00021195864],"about_ca_topic_score_codex":0.00008980921,"about_ca_topic_score_gemma":0.00025171478,"teacher_disagreement_score":0.9928965,"about_ca_system_score_codex":0.00003753832,"about_ca_system_score_gemma":0.00026961273,"threshold_uncertainty_score":0.9366571},"labels":[],"label_agreement":null},{"id":"W2040148468","doi":"10.2217/fon.15.14","title":"Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction","year":2015,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Ablative case; Medicine; Prostate cancer; Radiation therapy; Radiosurgery; Prostate; Clinical trial; Medical physics; Cancer; Oncology; Stereotactic radiotherapy; Radiology; Internal medicine","score_opus":0.14483361662746125,"score_gpt":0.5161428575992442,"score_spread":0.3713092409717829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040148468","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003589494,0.9844264,0.0000033502506,0.0037514186,0.0042515607,0.0060536526,0.0012360711,0.000026970749,0.00021469241],"genre_scores_gemma":[0.0000021736478,0.98646885,0.00092607865,0.00028951117,0.0087721115,0.00236562,0.00066604733,0.000069430804,0.0004401885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961763,0.0011352985,0.0016766873,0.0005873073,0.0001495,0.00027488283],"domain_scores_gemma":[0.9957645,0.0014521658,0.0019428805,0.00029528246,0.00031239114,0.00023278671],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025742508,0.00044651655,0.006130058,0.00015608319,0.00004835161,0.000012294093,0.00007647875,0.0008619106,0.000119579374],"category_scores_gemma":[0.00017149866,0.0002715006,0.0007510821,0.00018351768,0.00013373984,0.000053469234,0.000025867557,0.00043189534,0.0000019601937],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010050834,0.0003473203,0.0002936989,0.0067780977,0.003218742,0.000018637396,0.00022452541,3.4415926e-8,2.8767258e-7,0.000065160784,0.020749392,0.96729904],"study_design_scores_gemma":[0.005452508,0.0052646454,0.0001372545,0.0027246787,0.006318661,0.000081858634,0.00008849826,0.0000016917736,0.0000024542455,0.00004339998,0.97967875,0.00020559064],"about_ca_topic_score_codex":0.000030900843,"about_ca_topic_score_gemma":0.00004857415,"teacher_disagreement_score":0.9670934,"about_ca_system_score_codex":0.0008248878,"about_ca_system_score_gemma":0.0019052636,"threshold_uncertainty_score":0.9999737},"labels":[],"label_agreement":null},{"id":"W2059728548","doi":"10.2217/14796694.3.5.575","title":"Role of Dead Box 1 In Retinoblastoma and Neuroblastoma","year":2007,"lang":"en","type":"review","venue":"Future Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Retinoblastoma; Neuroblastoma; Cancer research; Medicine; Pediatric cancer; Gene; Cancer; Biology; Genetics; Internal medicine","score_opus":0.034367962801752076,"score_gpt":0.39189299673970984,"score_spread":0.35752503393795776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059728548","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023784258,0.98629874,4.7461367e-7,0.00014375952,0.00019632821,0.0012297169,0.000032360214,0.000036833884,0.009683381],"genre_scores_gemma":[0.00030986842,0.998047,0.0004398487,0.000122048004,0.00047592164,0.00007884452,0.000043423042,0.0000775376,0.00040550675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974588,0.00030280254,0.00074774335,0.0005878334,0.00030934936,0.00059347507],"domain_scores_gemma":[0.9984265,0.00041582406,0.0003257212,0.00042672578,0.00007729138,0.00032794697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002719323,0.0004457246,0.0024530233,0.0008240686,0.000031055304,0.000006480798,0.00016747181,0.00077785854,0.00010191501],"category_scores_gemma":[0.00010627146,0.0003395523,0.00029313358,0.0005832228,0.00020221256,0.000035742763,0.00017294855,0.0010634378,0.00007812054],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003679535,0.00046073078,0.0000798275,0.006943439,0.00013850477,0.0020918865,0.00004431729,1.9172152e-8,0.000041047257,0.00014695787,0.0005083383,0.989177],"study_design_scores_gemma":[0.0015792475,0.0035498694,0.00095947454,0.003723094,0.00037044962,0.0026451708,0.00004025259,0.0000010878246,0.000035850324,0.000023067016,0.9869,0.00017248903],"about_ca_topic_score_codex":0.000021652742,"about_ca_topic_score_gemma":0.00019122004,"teacher_disagreement_score":0.9890045,"about_ca_system_score_codex":0.0002548331,"about_ca_system_score_gemma":0.000742086,"threshold_uncertainty_score":0.99990565},"labels":[],"label_agreement":null},{"id":"W2068549807","doi":"10.2217/fon.14.208","title":"Dovitinib (CHIR258, TKI258): Structure, Development and Preclinical and Clinical Activity","year":2015,"lang":"en","type":"article","venue":"Future Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Sorafenib; Platelet-derived growth factor receptor; Tyrosine-kinase inhibitor; Receptor; Pharmacology; VEGF receptors; Receptor tyrosine kinase; Cancer research; Tyrosine kinase; Oncology; Cancer; Internal medicine; Growth factor; Hepatocellular carcinoma","score_opus":0.062285287748175884,"score_gpt":0.40467768940545695,"score_spread":0.3423924016572811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068549807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621737,0.0005052194,0.000063303436,0.0010208448,0.00053629925,0.00023680256,0.000019497318,0.000015805297,0.0013848618],"genre_scores_gemma":[0.9915535,0.00012479081,0.0062178965,0.00031568776,0.0014350901,0.000011663033,0.0000548726,0.000023850394,0.00026264513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827075,0.0003603731,0.00030726724,0.0005666674,0.00016457024,0.00033038986],"domain_scores_gemma":[0.99897546,0.00010436689,0.000099489895,0.0003081688,0.0000992645,0.0004132586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066964683,0.00018312826,0.00031492466,0.00004033979,0.00007124243,0.000023155411,0.00019690384,0.00064974633,0.000018969267],"category_scores_gemma":[0.00055083825,0.0001546711,0.00004435047,0.000056735393,0.00031170802,0.0000062423323,0.0006188701,0.0004150815,0.000009177131],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005068912,0.00071352534,0.3680168,0.00013285576,0.00052988157,0.00009496544,0.00043729923,0.0000016329942,0.08371187,0.00044245974,0.04582447,0.49502534],"study_design_scores_gemma":[0.0027075,0.0023128276,0.20003645,0.000008334062,0.000020695026,0.00014550399,0.00011960632,0.000024799303,0.0162348,0.0001581407,0.77794987,0.00028149804],"about_ca_topic_score_codex":0.0000098065775,"about_ca_topic_score_gemma":0.00040195705,"teacher_disagreement_score":0.73212534,"about_ca_system_score_codex":0.000036692443,"about_ca_system_score_gemma":0.00055416307,"threshold_uncertainty_score":0.63073045},"labels":[],"label_agreement":null},{"id":"W2102549074","doi":"10.2217/fon.13.149","title":"Best of International Stereotactic Radiosurgery Society Congress 2013: Stereotactic Body Radiation Therapy. Part II: Nonspinal Tumors","year":2013,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Radiosurgery; Medicine; Radiation oncology; Medical physics; Radiation therapy; Radiology","score_opus":0.010822688223576593,"score_gpt":0.28988377291502876,"score_spread":0.2790610846914522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102549074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97246766,0.0017800326,0.003504782,0.005703287,0.0056152223,0.0014088621,0.00010858233,0.00017204139,0.0092395535],"genre_scores_gemma":[0.988127,0.0010020807,0.0045836875,0.0005625435,0.0037349863,0.00032208394,0.00014056776,0.000060903698,0.0014661304],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985908,0.00012023307,0.0004610974,0.000313089,0.00020017072,0.00031461168],"domain_scores_gemma":[0.998707,0.00015103228,0.00055084185,0.00030384242,0.00019541201,0.00009185154],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016115673,0.0002457466,0.00043200218,0.00008705293,0.00013052628,0.0000316075,0.00029067797,0.00014368548,0.005193791],"category_scores_gemma":[0.000005126143,0.0002196621,0.00022891515,0.0001288895,0.00014550866,0.0004849314,0.000053914042,0.0003321281,0.000022439042],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043244622,0.0031142358,0.38847622,0.000065422326,0.00258813,0.000021833337,0.0023285183,0.00003471238,0.022590399,0.009174045,0.23902212,0.3321519],"study_design_scores_gemma":[0.0023675812,0.001164645,0.020246679,0.000060563812,0.000050933635,0.000036744557,0.0004962785,0.00051180524,0.0061912835,0.00079040875,0.9675836,0.0004995064],"about_ca_topic_score_codex":0.00016645949,"about_ca_topic_score_gemma":0.00000287233,"teacher_disagreement_score":0.72856146,"about_ca_system_score_codex":0.00013449321,"about_ca_system_score_gemma":0.00016213793,"threshold_uncertainty_score":0.9957156},"labels":[],"label_agreement":null},{"id":"W2104167520","doi":"10.2217/fon.12.100","title":"Targeting Tumoral Hypoxia: Finding Opportunity in Complexity","year":2012,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"MEDLINE; Medicine; Hypoxia (environmental); Oncology; Internal medicine; Library science; Biology; Computer science","score_opus":0.02862364299242163,"score_gpt":0.3121951409280845,"score_spread":0.28357149793566283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104167520","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005874002,0.012907379,0.000032345153,0.0002738311,0.97427386,0.0003780825,0.00043000552,0.000031389187,0.0057990863],"genre_scores_gemma":[0.002842101,0.0038727557,0.0009818177,0.00028564493,0.9848171,0.0000832152,0.005488134,0.00008862869,0.0015405983],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99699587,0.00040090425,0.00059746293,0.00074969075,0.00034242152,0.0009136512],"domain_scores_gemma":[0.99839604,0.00009763084,0.0004585279,0.00051692233,0.00018849214,0.00034237903],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009684619,0.0005172194,0.0009318166,0.00015944331,0.00014214336,0.000026357271,0.00053849455,0.002751735,0.00025318353],"category_scores_gemma":[0.000745786,0.0005289862,0.00023213176,0.00015430305,0.00021286061,0.000008462146,0.0004064058,0.0015512077,0.00003126864],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022571815,0.00016207679,0.000093059214,0.00008161838,0.00006113389,0.000016337437,0.00009774913,0.0000032547646,0.010697991,0.000081303806,0.98412406,0.004355719],"study_design_scores_gemma":[0.0013233749,0.00024467634,0.00041597045,0.000024872063,0.00007678759,0.000016813483,0.00017271185,0.000002368577,0.00027483382,0.00007321699,0.9968351,0.0005392399],"about_ca_topic_score_codex":0.00019483286,"about_ca_topic_score_gemma":0.0012009474,"teacher_disagreement_score":0.012711096,"about_ca_system_score_codex":0.00022931288,"about_ca_system_score_gemma":0.0016927851,"threshold_uncertainty_score":0.99971616},"labels":[],"label_agreement":null},{"id":"W2110353604","doi":"10.2217/fon.09.43","title":"Screening for Distress (The Sixth Vital Sign) in A Global Recession: Sustainable Approach to Maintain Patient-Centered Care","year":2009,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Cancer Foundation","funders":"","keywords":"Distress; Medicine; Psychosocial; Psychological intervention; Recession; Great recession; Risk analysis (engineering); Intensive care medicine; Actuarial science; Psychiatry; Clinical psychology; Economics","score_opus":0.012508076597762697,"score_gpt":0.30319609214047266,"score_spread":0.29068801554270995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110353604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7891694,0.0049527627,0.027072137,0.059536032,0.0031012944,0.009504226,0.000480983,0.00027297443,0.10591019],"genre_scores_gemma":[0.9930965,0.0000069846024,0.0016707192,0.0035351217,0.000873618,0.00022141349,0.0002795362,0.000013766189,0.00030239718],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856377,0.00011361769,0.00024104325,0.00036737826,0.00018227079,0.0005318948],"domain_scores_gemma":[0.99928343,0.00004646941,0.000069470334,0.00027481263,0.00015642299,0.00016939447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015120732,0.00017936029,0.00036135176,0.00006144987,0.00012645796,0.000022378983,0.00016952999,0.00021304535,0.000021787322],"category_scores_gemma":[0.00005785828,0.00012855462,0.000116410716,0.0004182553,0.00003408412,0.000050873314,0.00006620873,0.00022586575,0.0000021030307],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009571024,0.0009352221,0.010036795,0.0004500591,0.00006552054,0.00040484357,0.021705,0.0001240538,0.00013456542,0.01210774,0.024878921,0.91958624],"study_design_scores_gemma":[0.005004513,0.004866911,0.018572358,0.00014540808,0.000089744855,0.00010465602,0.2735143,0.00006510634,0.00010692752,0.000513565,0.69669235,0.0003241313],"about_ca_topic_score_codex":0.00025054024,"about_ca_topic_score_gemma":0.0013676073,"teacher_disagreement_score":0.9192621,"about_ca_system_score_codex":0.00084106036,"about_ca_system_score_gemma":0.00018649315,"threshold_uncertainty_score":0.5242305},"labels":[],"label_agreement":null},{"id":"W2110984210","doi":"10.2217/fon.10.163","title":"Do Anthracyclines Still Have a Role in Adjuvant Chemotherapy of Breast Cancer?","year":2010,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Anthracycline; Trastuzumab; Cardiotoxicity; Medicine; Breast cancer; Taxane; Oncology; Internal medicine; Chemotherapy; Cancer; Metastatic breast cancer","score_opus":0.029723272581336946,"score_gpt":0.4338935815551031,"score_spread":0.40417030897376616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110984210","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004620576,0.9905129,3.1504868e-7,0.0022430615,0.0021392,0.0013076311,0.00042284414,0.000028586379,0.0028833754],"genre_scores_gemma":[0.00019930786,0.9930361,0.00015853056,0.0004557966,0.0046927426,0.00041813517,0.0001892418,0.00007385757,0.0007762924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801207,0.00018532491,0.00075708353,0.0005074837,0.00014761613,0.0003904357],"domain_scores_gemma":[0.9985563,0.00020944863,0.00059954665,0.00037397761,0.000111258174,0.00014948261],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021731482,0.0004803126,0.0035096905,0.00034437745,0.000020574293,0.0000039907336,0.00020709069,0.001279927,0.0022188053],"category_scores_gemma":[0.0000117053105,0.0003382387,0.00046896026,0.00028352696,0.00017744623,0.00002883212,0.000048181624,0.0011201003,0.000021380261],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000481544,0.0010385797,0.0008486987,0.0036728976,0.0003329655,0.00017308051,0.00030791046,1.0577314e-7,0.000052626543,0.000030348165,0.0032180743,0.9898432],"study_design_scores_gemma":[0.003754795,0.00066182,0.0010270512,0.002788174,0.0014903584,0.00075459684,0.00007510332,0.0000018817133,0.000014723742,0.00001813334,0.9891763,0.00023709919],"about_ca_topic_score_codex":0.00038980294,"about_ca_topic_score_gemma":0.0022225773,"teacher_disagreement_score":0.9896061,"about_ca_system_score_codex":0.00049089204,"about_ca_system_score_gemma":0.0017282227,"threshold_uncertainty_score":0.99990696},"labels":[],"label_agreement":null},{"id":"W2118840104","doi":"10.1517/14796694.1.2.265","title":"DNA Repair Protein: Endo-Exonuclease as a new Frontier in Cancer Therapy","year":2005,"lang":"en","type":"review","venue":"Future Oncology","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; BioPhage Pharma (Canada); Montreal General Hospital","funders":"","keywords":"DNA repair; Homologous recombination; Genome instability; Biology; DNA damage; Carcinogenesis; Cell cycle; Cancer cell; DNA repair protein XRCC4; Cell biology; Non-homologous end joining; Mutagenesis; DNA; Cancer research; Genetics; Cell; Mutation; Cancer; Nucleotide excision repair; Gene","score_opus":0.02811935777475067,"score_gpt":0.34946138741982097,"score_spread":0.3213420296450703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118840104","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024500556,0.99073374,0.000011081441,0.00052168505,0.001270643,0.0021651688,0.000046522367,0.000082930404,0.004923198],"genre_scores_gemma":[0.0000054077946,0.97015893,0.002759133,0.0013562122,0.0070692073,0.0010284432,0.0002714758,0.00015626772,0.017194942],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969653,0.0004628675,0.00067220745,0.0010915431,0.00018810158,0.00061999273],"domain_scores_gemma":[0.9982638,0.00001560417,0.00042269798,0.00092396484,0.000056777775,0.00031716618],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00027979183,0.00067544053,0.0015691676,0.00017119119,0.000050220206,0.00001759253,0.00057744223,0.0020059797,0.00083193637],"category_scores_gemma":[0.000083308834,0.0005662189,0.0008072673,0.00022403405,0.000064689695,0.0000052963146,0.00021324855,0.0006369304,0.0001743601],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013515429,0.00019458968,0.0000015512113,0.00048340176,0.00025464827,0.00011625362,0.000037951526,4.0598204e-7,0.0008645388,0.00012401448,0.0631264,0.9346611],"study_design_scores_gemma":[0.0011352499,0.00093317986,0.0000015696978,0.0007104845,0.00013774223,0.0001351179,0.000022963051,7.60907e-7,0.000551203,0.00004412574,0.9957635,0.00056409434],"about_ca_topic_score_codex":0.00015120736,"about_ca_topic_score_gemma":0.00062882516,"teacher_disagreement_score":0.934097,"about_ca_system_score_codex":0.00035923542,"about_ca_system_score_gemma":0.0036684023,"threshold_uncertainty_score":0.9996789},"labels":[],"label_agreement":null},{"id":"W2122558264","doi":"10.2217/fon.12.3","title":"The Current Role of Circulating Tumor Cells in the Diagnosis and Management of Bone Metastases in Advanced Prostate Cancer","year":2012,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Circulating tumor cell; Management of prostate cancer; Oncology; Cancer; Prostate-specific antigen; Prostate; Internal medicine; Disease; Disease monitoring; Metastasis","score_opus":0.05575054018666093,"score_gpt":0.4170604696478369,"score_spread":0.36130992946117596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122558264","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020107497,0.99387693,8.3258755e-8,0.00035658682,0.00027146083,0.00301263,0.0001283184,0.0000032803703,0.00033994293],"genre_scores_gemma":[0.0018125629,0.99525356,0.00007385667,0.000015321404,0.0001450558,0.0025858488,0.000057160705,0.000019561234,0.00003706117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998151,0.0004377527,0.00059520884,0.00023591513,0.00023064042,0.00034948386],"domain_scores_gemma":[0.9987797,0.000448967,0.00041157368,0.00026609722,0.00004530281,0.000048343165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008706891,0.00022031128,0.0012060516,0.0001544811,0.000040686853,0.0000051588877,0.0001348883,0.000077125864,0.000016739532],"category_scores_gemma":[0.000013908819,0.000102124395,0.00013695854,0.000404025,0.00014629922,0.000029939321,0.00010855071,0.00045677525,0.0000011814399],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010165046,0.00030121175,0.0008911734,0.01742276,0.00016497269,0.00007724339,0.00056954875,8.371467e-7,0.0000036556107,0.0001293456,0.000096277494,0.9802413],"study_design_scores_gemma":[0.0011368798,0.00021672428,0.0012138569,0.007729141,0.0008734205,0.00001568298,0.00091858703,0.0000011483957,0.000023816938,0.00003159659,0.9877528,0.000086341875],"about_ca_topic_score_codex":0.00006388861,"about_ca_topic_score_gemma":0.000268491,"teacher_disagreement_score":0.98765653,"about_ca_system_score_codex":0.00027006172,"about_ca_system_score_gemma":0.00027522547,"threshold_uncertainty_score":0.4164512},"labels":[],"label_agreement":null},{"id":"W2123883580","doi":"10.1517/14796694.1.1.125","title":"Therapeutic implications of DNA methylation","year":2005,"lang":"en","type":"review","venue":"Future Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"DNA methylation; Epigenome; Epigenetics; Reprogramming; Epigenomics; Biology; Cancer research; Gene silencing; Cancer epigenetics; Genetics; Gene; Gene expression","score_opus":0.044460952282246086,"score_gpt":0.38730355226829977,"score_spread":0.3428425999860537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123883580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028132881,0.9920991,0.00087629014,0.00017450588,0.00038342833,0.00044257674,0.000060054466,0.000009218433,0.0059266696],"genre_scores_gemma":[0.0001906426,0.99509776,0.0011218296,0.000059207698,0.0020028166,0.00009818106,0.0010321734,0.00004479887,0.00035257533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985492,0.00026807867,0.000544397,0.00037021507,0.00008180931,0.00018627748],"domain_scores_gemma":[0.998713,0.000053999534,0.00053846295,0.0005200323,0.000116324045,0.000058166093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000262161,0.00025261866,0.0007544249,0.00011139943,0.000048131977,0.00000632667,0.00026006575,0.0009523859,0.00005590434],"category_scores_gemma":[0.000028733664,0.00021410297,0.00035170803,0.00017218923,0.00006149476,0.0000017168894,0.0000720562,0.00018032458,0.000019898887],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000051566467,0.000058275647,0.00000338915,0.00039295616,0.000118418815,1.9094509e-7,0.000011833621,0.00000202811,0.0026911104,0.000705241,0.00029010302,0.9957213],"study_design_scores_gemma":[0.00013724314,0.0002649442,0.000058046207,0.00009016505,0.00035808276,0.000006888677,0.000007040062,4.5662972e-7,0.00065757387,0.00018709007,0.99804205,0.00019042498],"about_ca_topic_score_codex":0.0000017821769,"about_ca_topic_score_gemma":0.000033124885,"teacher_disagreement_score":0.99775195,"about_ca_system_score_codex":0.000060147882,"about_ca_system_score_gemma":0.0004197229,"threshold_uncertainty_score":0.8730866},"labels":[],"label_agreement":null},{"id":"W2125382892","doi":"10.2217/fon.11.63","title":"A New Frontier in Personalized Cancer Therapy: Mapping Molecular Changes","year":2011,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Cancer; Targeted therapy; Medicine; Computational biology; Precision medicine; Cancer therapy; Personalized medicine; Gene; Cancer research; Bioinformatics; Biology; Genetics; Internal medicine; Pathology","score_opus":0.040486513429424095,"score_gpt":0.33086589345659917,"score_spread":0.29037938002717506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125382892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003885204,0.994325,0.00022035647,0.00031879437,0.0017250057,0.00067359983,0.00009123862,0.000009917322,0.0025972682],"genre_scores_gemma":[0.0000021229287,0.9914128,0.0015023655,0.0010585416,0.0034108134,0.00037105064,0.0003213698,0.00009198185,0.001828948],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983422,0.00015940604,0.00034449602,0.000646577,0.00007719138,0.00043010784],"domain_scores_gemma":[0.99907696,0.00002200853,0.0002860398,0.0004265521,0.000046368445,0.00014209579],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014155691,0.00045498178,0.0012248979,0.0001636126,0.000032664037,0.000016848524,0.0004058864,0.0011064649,0.00034597891],"category_scores_gemma":[0.000023170667,0.00040032263,0.00034646835,0.00017451668,0.00005670685,0.0000013685575,0.00016540526,0.000347123,0.000019016023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051303057,0.0000444851,0.000008574254,0.00047735524,0.00023383019,0.000040959883,0.0001534037,3.1184018e-7,0.00018901705,0.00024985475,0.028157914,0.970393],"study_design_scores_gemma":[0.0008638631,0.0002752717,0.0000070283736,0.00056641264,0.00012908113,0.000031739506,0.00004640132,2.318756e-7,0.000048848244,0.00004484037,0.99755067,0.00043562357],"about_ca_topic_score_codex":0.00034111392,"about_ca_topic_score_gemma":0.0015574967,"teacher_disagreement_score":0.96995735,"about_ca_system_score_codex":0.00019275605,"about_ca_system_score_gemma":0.0016552261,"threshold_uncertainty_score":0.99984485},"labels":[],"label_agreement":null},{"id":"W2127753540","doi":"10.2217/14796694.2.1.15","title":"Dexrazoxane Use In the Prevention of Anthracycline Extravasation Injury","year":2006,"lang":"en","type":"review","venue":"Future Oncology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Dexrazoxane; Anthracycline; Medicine; Cardiotoxicity; Extravasation; Doxorubicin; Epirubicin; Daunorubicin; Idarubicin; Pharmacology; Chemotherapy; Internal medicine; Pathology; Cancer; Cyclophosphamide; Breast cancer","score_opus":0.06209249161300837,"score_gpt":0.4201365793525218,"score_spread":0.3580440877395134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127753540","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011678408,0.99425197,0.000063004,0.0005427388,0.00051526225,0.0018845152,0.000035625286,0.00003110581,0.0015079707],"genre_scores_gemma":[0.00025398008,0.9957844,0.0010648228,0.00019123853,0.0012488978,0.00008195233,0.0006620288,0.00004933577,0.0006633684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746674,0.0006526587,0.00104087,0.00035079528,0.00025501236,0.00023389664],"domain_scores_gemma":[0.99808717,0.0004462305,0.00079422956,0.0005610243,0.00007418524,0.000037159807],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007519569,0.00032032616,0.0017555645,0.0003280824,0.000028420993,0.000007369826,0.00020931431,0.0012998496,0.00017812969],"category_scores_gemma":[0.00012863574,0.00020599415,0.0004239269,0.0006156974,0.00011295527,0.000064365195,0.000027402986,0.0010394716,0.000018490939],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011289774,0.00087710994,0.000045375433,0.0035337955,0.00012333858,0.00006855903,0.000118690376,3.7430723e-7,0.00005487569,0.0001431965,0.007177082,0.9877447],"study_design_scores_gemma":[0.0009063615,0.00064908765,0.0006393199,0.0035996626,0.0009955799,0.00030877625,0.000025261932,0.0000020338302,0.000027627462,0.00006826833,0.9926289,0.00014913872],"about_ca_topic_score_codex":0.00007967713,"about_ca_topic_score_gemma":0.00040850887,"teacher_disagreement_score":0.98759556,"about_ca_system_score_codex":0.00037482413,"about_ca_system_score_gemma":0.0005247962,"threshold_uncertainty_score":0.99999666},"labels":[],"label_agreement":null},{"id":"W2129628525","doi":"10.2217/fon.12.67","title":"Regulation of Plasmin Generation by the Annexin A2 Heterotetramer: A Shift in Perspective","year":2012,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"S100 Proteins and Annexins","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Heterotetramer; Annexin A2; Medicine; Plasmin; Perspective (graphical); Biochemistry; Annexin; Immunology; Chemistry; Protein subunit; Enzyme","score_opus":0.007370285439260643,"score_gpt":0.27712821912352315,"score_spread":0.2697579336842625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129628525","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07410895,0.02060411,0.0006394071,0.0030610908,0.89418757,0.0017337766,0.0009670632,0.000026493555,0.004671556],"genre_scores_gemma":[0.19223814,0.00048659352,0.00021453005,0.0001211242,0.8035165,0.00014434237,0.002472662,0.000051686882,0.00075442134],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984151,0.00030196758,0.00034184667,0.00042718847,0.00022555792,0.0002883394],"domain_scores_gemma":[0.9990137,0.000060619142,0.0003287191,0.00038026,0.00016700874,0.000049660317],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0003809005,0.00025904362,0.0003540325,0.00007442906,0.000063027306,0.0000139436415,0.00027383733,0.0017243123,0.000054694694],"category_scores_gemma":[0.0001916885,0.00019951096,0.0001312792,0.00010572973,0.00013476606,0.000005966511,0.000088857305,0.0005293458,0.0000063898797],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001978171,0.00014578403,0.00002176506,0.000017415807,0.000054105927,0.0000012088166,0.00036458077,0.000010613385,0.11243373,0.00020845934,0.88476634,0.0017781499],"study_design_scores_gemma":[0.0007080057,0.0008147419,0.00021669402,0.000015413809,0.000032517368,0.0000033597596,0.00028674796,0.000014287178,0.017677572,0.000098549135,0.9799225,0.00020965534],"about_ca_topic_score_codex":0.00024379317,"about_ca_topic_score_gemma":0.0014735052,"teacher_disagreement_score":0.11812918,"about_ca_system_score_codex":0.00015179602,"about_ca_system_score_gemma":0.00032627213,"threshold_uncertainty_score":0.9995717},"labels":[],"label_agreement":null},{"id":"W2131759521","doi":"10.2217/fon.11.134","title":"Oncolytic Viruses: Smart Therapeutics for Smart Cancers","year":2011,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Oncolytic virus; Medicine; Cancer research; Cancer; Oncology; Internal medicine","score_opus":0.0324954202615448,"score_gpt":0.35812391936696386,"score_spread":0.3256284991054191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131759521","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022881632,0.008495476,0.00021045937,0.00048875465,0.977102,0.001996191,0.001226013,0.00007103024,0.008121951],"genre_scores_gemma":[0.00033909595,0.0060652494,0.0008146631,0.002350313,0.977949,0.001080352,0.0025334607,0.00031907475,0.008548754],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964506,0.00036235357,0.0005498696,0.0011364514,0.00048963394,0.001011104],"domain_scores_gemma":[0.99729764,0.00027535943,0.00038242617,0.0011547739,0.00064409815,0.00024567245],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0008200903,0.00066898536,0.0008459663,0.00016667874,0.0002174345,0.000041472962,0.0011519673,0.0038779902,0.00021678692],"category_scores_gemma":[0.00019777201,0.0006332148,0.00045178863,0.00015988991,0.00030636773,0.000004709016,0.0002340902,0.0010862834,0.00009084377],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010082202,0.00015496161,0.00001254683,0.00011122552,0.00075600046,0.00001323635,0.00011483567,0.0000031768877,0.023171254,0.000018800018,0.9515583,0.014003484],"study_design_scores_gemma":[0.0026136423,0.016979361,0.0000036511938,0.000026754307,0.00021486227,0.000005888749,0.00008889151,0.0000057033535,0.017687807,0.00010935702,0.96161944,0.00064461684],"about_ca_topic_score_codex":0.00016496336,"about_ca_topic_score_gemma":0.009027575,"teacher_disagreement_score":0.0168244,"about_ca_system_score_codex":0.00072092126,"about_ca_system_score_gemma":0.0066042994,"threshold_uncertainty_score":0.9996119},"labels":[],"label_agreement":null},{"id":"W2132123971","doi":"10.2217/fon.09.65","title":"Physical Activity, Obesity and Risk for Esophageal Adenocarcinoma","year":2009,"lang":"en","type":"review","venue":"Future Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital","funders":"Nova Scotia Health Research Foundation; Saskatchewan Health Research Foundation","keywords":"Medicine; Esophageal adenocarcinoma; Obesity; Physical activity; Esophageal cancer; Internal medicine; Adenocarcinoma; Oncology; Cancer; Physical therapy","score_opus":0.045424014411943936,"score_gpt":0.4123853684843281,"score_spread":0.36696135407238417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132123971","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00070558814,0.99486154,0.000012924471,0.00038231636,0.00023312368,0.002757385,0.00023496497,0.00005393162,0.00075820374],"genre_scores_gemma":[0.00075797376,0.99220365,0.0005099358,0.00006518539,0.0049611134,0.0004498768,0.0001732418,0.000050341914,0.00082869566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811107,0.00027363232,0.00020643628,0.0006570847,0.00022971674,0.0005220446],"domain_scores_gemma":[0.99848235,0.00042256006,0.00023615682,0.00038350085,0.00007007492,0.0004053569],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019781242,0.00045559125,0.0025356465,0.0001514081,0.00014894477,0.00001778496,0.00013516466,0.00060070085,0.000034369816],"category_scores_gemma":[0.000059558595,0.00031331976,0.0005983182,0.00016204649,0.000118515745,0.000042005653,0.00009139237,0.0009661463,0.000045963225],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026459646,0.0008594777,0.00029888272,0.0061661336,0.00049090886,0.00064030907,0.000043570748,8.283333e-9,6.336078e-8,0.00026294304,0.0030076376,0.98796546],"study_design_scores_gemma":[0.00228212,0.007012637,0.0064301854,0.0007272591,0.003937971,0.000570926,0.000007314426,0.0000040597088,0.0000033350334,0.00020316837,0.97861487,0.00020613757],"about_ca_topic_score_codex":0.000037193266,"about_ca_topic_score_gemma":0.000047612953,"teacher_disagreement_score":0.98775935,"about_ca_system_score_codex":0.0006849602,"about_ca_system_score_gemma":0.0010393847,"threshold_uncertainty_score":0.9999319},"labels":[],"label_agreement":null},{"id":"W2138368669","doi":"10.2217/fon.15.251","title":"Current State of Biomarkers in Ovarian Cancer Prognosis","year":2015,"lang":"en","type":"review","venue":"Future Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Medicine; Ovarian cancer; Carboplatin; Paclitaxel; Tumor microenvironment; Disease; Drug resistance; Oncology; Chemotherapy; Cancer; Serous fluid; Internal medicine; Bioinformatics; Cisplatin; Biology","score_opus":0.07496433028108566,"score_gpt":0.43021415235169136,"score_spread":0.3552498220706057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138368669","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000133382355,0.99215144,0.0000010146575,0.0012675648,0.0024869482,0.0021890313,0.0002844228,0.000017910448,0.0015883495],"genre_scores_gemma":[0.000017045031,0.9965738,0.00034977793,0.000059050686,0.0009489468,0.0017017297,0.00023227339,0.000055520264,0.00006185438],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977921,0.00024014927,0.0008316871,0.00052465603,0.00024471042,0.00036668684],"domain_scores_gemma":[0.99860156,0.00009201274,0.0005747785,0.0003665265,0.00014637479,0.00021874839],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035876204,0.00041694497,0.0029877576,0.00040440712,0.000014994115,0.000005470462,0.0001485093,0.00034445943,0.00019871525],"category_scores_gemma":[0.000021040669,0.00028981105,0.00039400885,0.0006160852,0.000082273924,0.000025999401,0.000068828274,0.00047456118,0.00003295451],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008324492,0.0009469806,0.0007486064,0.012004341,0.0010786754,0.00017334615,0.00011587569,1.5780518e-7,8.0362355e-8,0.000041303152,0.015489007,0.9693184],"study_design_scores_gemma":[0.0020535074,0.00066740834,0.001051424,0.0130878035,0.0024118545,0.000048632886,0.000011124025,4.650679e-7,0.0000014617563,0.000025370624,0.98043656,0.00020439186],"about_ca_topic_score_codex":0.00020483218,"about_ca_topic_score_gemma":0.0006241944,"teacher_disagreement_score":0.969114,"about_ca_system_score_codex":0.0019678113,"about_ca_system_score_gemma":0.0044969167,"threshold_uncertainty_score":0.9999554},"labels":[],"label_agreement":null},{"id":"W2138828358","doi":"10.2217/fon.09.119","title":"Nimotuzumab in Pediatric Glioma","year":2009,"lang":"en","type":"review","venue":"Future Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Nimotuzumab; Medicine; Context (archaeology); Glioma; Monoclonal antibody; Epidermal growth factor receptor; In vivo; Oncology; Cancer research; Pharmacology; Internal medicine; Immunology; Receptor; Antibody; Biology","score_opus":0.03178295124147681,"score_gpt":0.3674432645124994,"score_spread":0.33566031327102264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138828358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014182446,0.9854043,1.5528168e-7,0.000999853,0.00093094,0.0011735724,0.000015034258,0.00005482942,0.011279508],"genre_scores_gemma":[0.00004099573,0.99465615,0.000227012,0.00023481165,0.0041692434,0.0002627406,0.00024881025,0.00004953412,0.00011070789],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800164,0.00017420838,0.00066092046,0.0005364009,0.00018778411,0.00043903125],"domain_scores_gemma":[0.998858,0.00016906323,0.00029444564,0.000450023,0.000041847597,0.00018663848],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015600241,0.00047031313,0.002877462,0.00085252017,0.00003072204,0.000009602446,0.00015789398,0.0011394526,0.00024711926],"category_scores_gemma":[0.000040543662,0.0003265226,0.0005702275,0.000916734,0.000023187784,0.000022678589,0.000046817433,0.00065154984,0.00047748673],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016888247,0.00097411795,0.00011703645,0.0036070957,0.000087132445,0.0057115047,0.000022105372,3.2289172e-8,8.369304e-8,0.00024656078,0.016773302,0.9724441],"study_design_scores_gemma":[0.0018582002,0.0010666953,0.0008379912,0.0014960439,0.002458529,0.0013085237,0.000009320405,1.4183236e-7,3.1752958e-7,0.000030550542,0.990707,0.0002266941],"about_ca_topic_score_codex":0.000009125846,"about_ca_topic_score_gemma":0.000060227543,"teacher_disagreement_score":0.9739337,"about_ca_system_score_codex":0.0010501122,"about_ca_system_score_gemma":0.0009937547,"threshold_uncertainty_score":0.9999187},"labels":[],"label_agreement":null},{"id":"W2146149726","doi":"10.2217/fon.11.27","title":"Uroporphyrinogen Decarboxylase: Optimizing Radiotherapy for Head and Neck Cancer","year":2011,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Cancer; Head and neck cancer; Radiation therapy; Head and neck; MEDLINE; Library science; Gerontology; Internal medicine; Surgery; Biology; Computer science","score_opus":0.02470930482241154,"score_gpt":0.35983239870967565,"score_spread":0.33512309388726413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146149726","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008215084,0.089759715,0.00009138341,0.0031366157,0.8988249,0.0012046599,0.00032053,0.00010112774,0.0057395725],"genre_scores_gemma":[0.0000306678,0.057439968,0.0102290455,0.00093769794,0.9275661,0.0006655558,0.00018797319,0.00012631898,0.0028166359],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980773,0.00007089214,0.0003806036,0.00067145174,0.00025198044,0.0005478007],"domain_scores_gemma":[0.9984755,0.0004299787,0.00022978519,0.00032125824,0.0003047047,0.00023878977],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00024936962,0.00044784963,0.0016028936,0.00013545777,0.00015913551,0.000012467954,0.00014045728,0.0015316915,0.0002189179],"category_scores_gemma":[0.000134416,0.00036469195,0.00019853511,0.00009954856,0.0001572629,0.00003588515,0.000062502986,0.00079467875,0.0000043058712],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020059648,0.00010721035,0.00011836452,0.00048258575,0.000520928,0.00007254946,0.0008062816,2.9230287e-7,0.00021019776,0.000041951276,0.9543882,0.04124545],"study_design_scores_gemma":[0.006412478,0.003768379,0.00016703022,0.00029513796,0.00048393576,0.000025717412,0.00008319014,0.000008205121,0.00008457581,0.00001835366,0.9883176,0.0003353776],"about_ca_topic_score_codex":0.00029007197,"about_ca_topic_score_gemma":0.0007875858,"teacher_disagreement_score":0.040910073,"about_ca_system_score_codex":0.00059034996,"about_ca_system_score_gemma":0.0015733212,"threshold_uncertainty_score":0.9998805},"labels":[],"label_agreement":null},{"id":"W2150622576","doi":"10.2217/fon.11.68","title":"An Essential Role for Programmed Death-1 in the Control of Autoimmunity: Implications for the Future of Hematopoietic Stem Cell Transplantation","year":2011,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Autoimmunity; Immune system; Haematopoiesis; Stem cell; Antigen; Receptor; Lymphocyte; Immunology; Chimeric antigen receptor; Biology; Transplantation; Medicine; T cell; Cancer research; Cell biology; Internal medicine","score_opus":0.00991838873223511,"score_gpt":0.27529923583842625,"score_spread":0.26538084710619114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150622576","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023314855,0.01381159,0.010841648,0.0019425049,0.96337503,0.005952113,0.0010860843,0.000057460235,0.00060210977],"genre_scores_gemma":[0.7135565,0.0035676896,0.0003287638,0.00036981812,0.2572806,0.0072854017,0.015431,0.00014710081,0.0020330835],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980575,0.0006202499,0.00069205207,0.0002805648,0.00005152715,0.00029813414],"domain_scores_gemma":[0.99625653,0.0019690308,0.00078322145,0.0005337203,0.00044619793,0.000011281451],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007659399,0.00025689503,0.00061526103,0.00013506117,0.00023406987,0.00001107874,0.0006495038,0.0016237082,0.00007560512],"category_scores_gemma":[0.000023183247,0.00016266122,0.0003004111,0.00011274346,0.0001662577,0.000072896495,0.0000129787,0.0008291721,0.0000051558786],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012481309,0.0028217754,0.000097252574,0.0012095707,0.00084146514,9.0964886e-7,0.01796922,0.000013464777,0.108602576,0.010768089,0.8002238,0.044970524],"study_design_scores_gemma":[0.0041127806,0.0020140533,0.0004449645,0.000028211587,0.00070690695,0.000020341871,0.005502403,0.000007858375,0.0057849186,0.00021210557,0.98101413,0.00015131735],"about_ca_topic_score_codex":0.000113780545,"about_ca_topic_score_gemma":0.00035311998,"teacher_disagreement_score":0.7112251,"about_ca_system_score_codex":0.0000655119,"about_ca_system_score_gemma":0.00038519825,"threshold_uncertainty_score":0.9996724},"labels":[],"label_agreement":null},{"id":"W2152890358","doi":"10.2217/fon.11.37","title":"Improving Oncology Outcomes Through Targeted Therapeutics Will Require Electronic Delivery Systems","year":2011,"lang":"en","type":"review","venue":"Future Oncology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Oncology; Delivery system; Medical physics; Internal medicine; Pharmacology","score_opus":0.13691078854025826,"score_gpt":0.4455667963993569,"score_spread":0.30865600785909864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152890358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000063215984,0.9681877,0.00006234695,0.0020536603,0.0053155916,0.0019836214,0.000051197792,0.00018074518,0.022158839],"genre_scores_gemma":[0.000047467758,0.9897322,0.00044386336,0.003707162,0.003730435,0.00034834925,0.00014391533,0.00013807321,0.0017085529],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952221,0.0010832552,0.0012418316,0.00085917144,0.00027836714,0.0013152664],"domain_scores_gemma":[0.9962356,0.0013100026,0.0013358697,0.00064822333,0.00022920295,0.00024109935],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00075924746,0.0008890686,0.0049607554,0.00014255484,0.00027232556,0.000027179112,0.0004818845,0.0021782417,0.00047364336],"category_scores_gemma":[0.00013098036,0.00057713065,0.0008657243,0.0003778774,0.00024568682,0.00030056195,0.00030348374,0.0029841214,0.0002667032],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002479883,0.00041480153,0.000017445404,0.0095187565,0.003443564,0.00032097904,0.00026687622,5.462932e-8,0.000003820692,0.0045251716,0.002907578,0.97833294],"study_design_scores_gemma":[0.0012658264,0.002627445,0.000005701289,0.0008758153,0.008903552,0.0010691787,0.00034207085,0.000006549935,6.932201e-7,0.00007130876,0.9843035,0.000528357],"about_ca_topic_score_codex":0.00022028778,"about_ca_topic_score_gemma":0.000096504526,"teacher_disagreement_score":0.9813959,"about_ca_system_score_codex":0.002156484,"about_ca_system_score_gemma":0.0026523531,"threshold_uncertainty_score":0.999668},"labels":[],"label_agreement":null},{"id":"W2159471993","doi":"10.2217/14796694.2.6.765","title":"Erbb Receptors and Epithelial-Cadherin–Catenin Complex In Human Carcinomas","year":2006,"lang":"en","type":"review","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Cadherin; Medicine; Receptor; Catenin; ErbB; Cancer research; Signal transduction; Internal medicine; Biology; Cell biology; Cell; Wnt signaling pathway; Genetics","score_opus":0.1385490509996071,"score_gpt":0.46228533226736784,"score_spread":0.3237362812677608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159471993","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025790793,0.9620643,0.0000010658687,0.0010851618,0.0009791148,0.0018744034,0.00008312137,0.00006793749,0.03358697],"genre_scores_gemma":[0.00009160034,0.9885082,0.0005681449,0.00017988503,0.004188462,0.00026573124,0.0006641167,0.00014742283,0.0053863935],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962773,0.00071255973,0.0009773178,0.0008594119,0.00038059047,0.000792827],"domain_scores_gemma":[0.99851924,0.00021440779,0.00029917678,0.0005711103,0.00009650674,0.00029954812],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006912357,0.00057809585,0.0033058191,0.00061024976,0.00009609414,0.000020723335,0.00034195042,0.001451502,0.0012208739],"category_scores_gemma":[0.000057299207,0.00046624822,0.0003054508,0.00061159366,0.00043425316,0.000029010329,0.00017802304,0.0020295195,0.00017842991],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037936636,0.00021618545,0.00024621628,0.010556607,0.00008069934,0.0006406705,0.000162156,7.3309145e-8,0.00003205761,0.00037884535,0.074056715,0.91359186],"study_design_scores_gemma":[0.0012049628,0.00096948957,0.00081421336,0.0040624365,0.00033084815,0.0005773322,0.00007001243,8.5855476e-7,0.0000032546889,0.000052544405,0.99155277,0.00036128977],"about_ca_topic_score_codex":0.0006533348,"about_ca_topic_score_gemma":0.0010528505,"teacher_disagreement_score":0.917496,"about_ca_system_score_codex":0.0019800502,"about_ca_system_score_gemma":0.0015802461,"threshold_uncertainty_score":0.99984485},"labels":[],"label_agreement":null},{"id":"W2162077153","doi":"10.2217/fon.15.153","title":"Rapid Access Palliative Radiation Therapy Programs: An Efficient Model of Care","year":2015,"lang":"en","type":"review","venue":"Future Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Multidisciplinary approach; Palliative care; Narrative review; Radiation therapy; Radiation oncology; Medical physics; Intensive care medicine; Nursing; Internal medicine","score_opus":0.1773303789361742,"score_gpt":0.46115102360392446,"score_spread":0.28382064466775025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162077153","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058096015,0.98999184,0.0001368181,0.00020627273,0.00058055564,0.004530762,0.000105921725,0.00006738189,0.0043223323],"genre_scores_gemma":[0.00006718,0.99415815,0.0017741756,0.00025552776,0.00070625375,0.00057504326,0.00227252,0.00007160269,0.00011956026],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973663,0.00052018824,0.0007280157,0.00054097193,0.00053801417,0.00030652434],"domain_scores_gemma":[0.99763083,0.000046283036,0.0008883406,0.0006897598,0.00044667895,0.0002980905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051180215,0.0004407597,0.0024626395,0.00031888724,0.000034796685,0.00001970781,0.00041065607,0.00046526597,0.000111286594],"category_scores_gemma":[0.000052974003,0.0003137877,0.0004264811,0.00036829463,0.000097539356,0.000061820734,0.00009877082,0.00038091862,0.000016934591],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024308746,0.0009380589,0.0000074666273,0.016800273,0.00040773145,0.000028940944,0.0012673842,0.00004151282,6.397711e-8,0.0002998174,0.0016603894,0.9783053],"study_design_scores_gemma":[0.002303201,0.0021283133,0.000018204417,0.0017015691,0.002373497,0.00000392792,0.00072397944,0.00086216285,3.1190385e-7,0.0000295726,0.98961246,0.00024277609],"about_ca_topic_score_codex":0.0000070535903,"about_ca_topic_score_gemma":0.0000067509977,"teacher_disagreement_score":0.9879521,"about_ca_system_score_codex":0.00055023417,"about_ca_system_score_gemma":0.0021078053,"threshold_uncertainty_score":0.9999314},"labels":[],"label_agreement":null},{"id":"W2163739312","doi":"10.2217/fon.14.254","title":"The Role of Oncolytic Virus Immunotherapies to Subvert Cancer Immune Evasion","year":2015,"lang":"en","type":"review","venue":"Future Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Oncolytic virus; Immunotherapy; Cancer immunotherapy; Evasion (ethics); Medicine; Immune system; Virotherapy; Cancer; Cancer treatment; Cancer therapy; Immunology; Immunity; Cancer vaccine; Cancer research; Internal medicine","score_opus":0.029638523226770033,"score_gpt":0.39245854366549215,"score_spread":0.36282002043872214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163739312","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005648972,0.99553454,0.000001984338,0.00028687622,0.0009618201,0.0012214215,0.00012745788,0.000013013728,0.0012879662],"genre_scores_gemma":[0.00006698942,0.99541944,0.000058351445,0.00014324764,0.0017811278,0.0006354085,0.00016010233,0.00011081032,0.001624542],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971079,0.000750746,0.0006864232,0.00054198835,0.0003526888,0.0005602117],"domain_scores_gemma":[0.99783987,0.00009706713,0.00041966338,0.0011426539,0.00033840115,0.0001623759],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010702251,0.00046248554,0.0013578204,0.00012816594,0.00016420841,0.000024215928,0.0011924566,0.0009252129,0.00010466684],"category_scores_gemma":[0.00006794056,0.0003001553,0.0004947876,0.00033132787,0.00020672946,0.0000026648997,0.0003876901,0.00048489252,0.00009201911],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014120103,0.00008838261,9.713613e-7,0.00033481704,0.0004928124,0.0000034275945,0.00008104525,0.0000025565732,0.028455958,0.00002541702,0.0043018213,0.9648008],"study_design_scores_gemma":[0.00043690615,0.004464917,0.0000018657485,0.0003965872,0.00016088838,0.000022847547,0.000120797005,6.594241e-7,0.008189047,0.00003690581,0.98586255,0.0003059984],"about_ca_topic_score_codex":0.0001492915,"about_ca_topic_score_gemma":0.0018376556,"teacher_disagreement_score":0.98156077,"about_ca_system_score_codex":0.00037511237,"about_ca_system_score_gemma":0.0029766704,"threshold_uncertainty_score":0.99994504},"labels":[],"label_agreement":null},{"id":"W2163922475","doi":"10.2217/14796694.5.1.85","title":"Subcellular Dynamics of The VHL Tumor Suppressor: On The Move for HIF Degradation","year":2009,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Suppressor; Medicine; Dynamics (music); Cancer research; Degradation (telecommunications); Cell biology; Internal medicine; Cancer; Biology; Computer science","score_opus":0.018503948500397605,"score_gpt":0.2979376063545767,"score_spread":0.2794336578541791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163922475","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001279575,0.9895678,0.00011964508,0.0011104624,0.0055194497,0.0014847127,0.000494742,0.000007146021,0.0015680663],"genre_scores_gemma":[0.000044845852,0.98825336,0.00017277735,0.00070994976,0.007555559,0.00020979348,0.0010660348,0.000049269518,0.0019384271],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984175,0.00030472843,0.00043294177,0.0004159593,0.0001427483,0.00028614793],"domain_scores_gemma":[0.998359,0.00010785831,0.0005746994,0.00080390286,0.00010834957,0.000046138444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031584856,0.00034055434,0.00088182365,0.00004394052,0.00012145633,0.000011751549,0.0006619203,0.000675616,0.000021838352],"category_scores_gemma":[0.00012557983,0.00018531756,0.0007375277,0.0001364213,0.00012216614,0.0000016993587,0.00009921938,0.00035117436,0.0000041443564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010500743,0.0001511547,6.0561354e-7,0.0011894703,0.00023428525,0.0000010640991,0.000025369389,0.000003448998,0.0008350268,0.012447333,0.072697915,0.91230935],"study_design_scores_gemma":[0.00031363065,0.00032268045,0.000007334889,0.00022532232,0.00052707334,0.00003345916,0.00003137529,0.0000058780374,0.0006905309,0.00019067038,0.99745584,0.00019619362],"about_ca_topic_score_codex":0.000008713865,"about_ca_topic_score_gemma":0.00018092405,"teacher_disagreement_score":0.92475796,"about_ca_system_score_codex":0.00010021171,"about_ca_system_score_gemma":0.000575794,"threshold_uncertainty_score":0.7557031},"labels":[],"label_agreement":null},{"id":"W2166859022","doi":"10.2217/fon.09.157","title":"Potential Use of Ultrasound for the Detection of Cell Changes in Cancer Treatment","year":2009,"lang":"en","type":"review","venue":"Future Oncology","topic":"Ultrasound and Hyperthermia Applications","field":"Engineering","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Toronto Metropolitan University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Ultrasound; Oncology; Cancer; Internal medicine; Radiology","score_opus":0.03504508620806288,"score_gpt":0.3067117270932862,"score_spread":0.2716666408852233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166859022","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012186189,0.99766207,0.00044778085,0.000039443115,0.00044991454,0.0009619018,0.0002066233,0.00002017992,0.000090244066],"genre_scores_gemma":[0.0009357361,0.99726325,0.00023519703,0.000008940078,0.00061881775,0.0007749598,0.0000435883,0.00002591852,0.00009358979],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994369,0.000030714422,0.00024513525,0.00011817451,0.000039288716,0.00012980172],"domain_scores_gemma":[0.9992589,0.0003964758,0.0001269059,0.0001762822,0.00002447525,0.000016959231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041186937,0.00016876111,0.00067486474,0.00008581614,0.000024236757,0.000004128053,0.00010178861,0.0003137694,0.000021795737],"category_scores_gemma":[0.000004318933,0.00010715487,0.00017632825,0.00014344619,0.000025634019,0.000014673413,0.0000034685347,0.00011565004,0.0000011565164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005072227,0.0000729323,6.1920537e-7,0.0012105284,0.00008439389,3.1928488e-7,0.00010149989,0.00020896351,0.0019453708,0.000018930801,0.00009109066,0.9962603],"study_design_scores_gemma":[0.00018780447,0.00018325749,0.000027769162,0.00016025451,0.00057332485,0.000009587398,0.0000279044,0.000026273094,0.00039339086,0.000007409512,0.9983162,0.00008679172],"about_ca_topic_score_codex":0.00009162353,"about_ca_topic_score_gemma":0.002813127,"teacher_disagreement_score":0.99822515,"about_ca_system_score_codex":0.00022953853,"about_ca_system_score_gemma":0.00007650507,"threshold_uncertainty_score":0.43696487},"labels":[],"label_agreement":null},{"id":"W2167775617","doi":"10.1517/14796694.1.2.149","title":"Zoledronic Acid: Past, Present and Future Roles in Cancer Treatment","year":2005,"lang":"en","type":"review","venue":"Future Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Zoledronic acid; Medicine; Breast cancer; Prostate cancer; Bone resorption; Bone metastasis; Osteoclast; Oncology; Multiple myeloma; Bone Density Conservation Agents; Cancer; Internal medicine; Bone disease; Clinical trial; Osteoporosis; Bone density","score_opus":0.044508007308810625,"score_gpt":0.42026815001778395,"score_spread":0.37576014270897334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167775617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006003323,0.9807364,1.0745687e-7,0.013683917,0.0010506443,0.0021432568,0.00009031226,0.000044492095,0.0021908397],"genre_scores_gemma":[0.000010479823,0.9787143,0.00020027191,0.00045910676,0.01685124,0.0014468739,0.0003023903,0.00006705129,0.0019483188],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772227,0.0002257067,0.00062037737,0.0006349733,0.00015952239,0.0006371623],"domain_scores_gemma":[0.9988252,0.00006842741,0.00028630093,0.0003954652,0.000030642168,0.00039397305],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000093100185,0.00060880644,0.002730549,0.00026575165,0.0000674829,0.000008498468,0.00008643871,0.0011914743,0.0003288126],"category_scores_gemma":[0.0000016470042,0.00038594648,0.0002733637,0.00022289144,0.000059411857,0.000035511246,0.000048694557,0.0006413567,0.000079262245],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009455387,0.00067954796,0.0002584866,0.0030385267,0.00034637327,0.00046013697,0.00017412998,6.847188e-8,4.3461576e-8,0.000031464308,0.005811478,0.98910517],"study_design_scores_gemma":[0.0035491611,0.0014602547,0.00076170906,0.0017538972,0.0017661602,0.0006231959,0.000062590116,8.744077e-7,2.5976993e-7,0.0000042327347,0.98978966,0.00022798959],"about_ca_topic_score_codex":0.00028646537,"about_ca_topic_score_gemma":0.003376681,"teacher_disagreement_score":0.9888772,"about_ca_system_score_codex":0.0025802203,"about_ca_system_score_gemma":0.0020096754,"threshold_uncertainty_score":0.9998593},"labels":[],"label_agreement":null},{"id":"W2180994109","doi":"10.2217/fon.15.122","title":"The use of Myocardial Strain and Newer Echocardiography Imaging Techniques in Cancer Patients","year":2015,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Women's College Hospital; St. Michael's Hospital","funders":"","keywords":"Medicine; Cancer; Radiology; Internal medicine; Strain (injury); Cardiology","score_opus":0.031183008621275602,"score_gpt":0.3107000548060012,"score_spread":0.2795170461847256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2180994109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99243164,0.00076823786,0.000067051216,0.0036269638,0.0005401875,0.00054020685,0.000026179621,0.000033339573,0.0019662054],"genre_scores_gemma":[0.9963511,0.0007412725,0.00094590045,0.0012569388,0.00060674554,0.00004518949,0.000016154936,0.000012780004,0.000023898545],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99932176,0.00009488713,0.00016919704,0.00013536093,0.00013718939,0.00014159665],"domain_scores_gemma":[0.9995354,0.00006348326,0.00007061022,0.00012846573,0.00013207708,0.000070008544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002394736,0.000084777166,0.00024804767,0.000097949895,0.000028407087,0.000009017565,0.000037053524,0.00012850716,0.0000023510136],"category_scores_gemma":[0.00005244519,0.000060717688,0.00007663831,0.00017383776,0.00011772247,0.00007199218,0.000020418149,0.00018481708,2.5581718e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049998454,0.00013456203,0.25122,0.000023798571,0.00013479966,0.000015724741,0.0016453917,0.0000041947674,0.026171394,0.00021398053,0.01186379,0.70807236],"study_design_scores_gemma":[0.003682582,0.00062491914,0.3835202,0.00007657177,0.00009772842,0.000022768303,0.000946548,0.00002816451,0.021019535,0.0004267703,0.58940285,0.00015138985],"about_ca_topic_score_codex":0.00015430767,"about_ca_topic_score_gemma":0.00009515468,"teacher_disagreement_score":0.707921,"about_ca_system_score_codex":0.0001171424,"about_ca_system_score_gemma":0.0001392239,"threshold_uncertainty_score":0.24759956},"labels":[],"label_agreement":null},{"id":"W2265842034","doi":"10.2217/fon.15.339","title":"Addressing Future Challenges for Cancer Services: Part I","year":2016,"lang":"en","type":"article","venue":"Future Oncology","topic":"Healthcare Systems and Challenges","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Officer; Cancer survivorship; Family medicine; Public health; Survivorship curve; Management; Cancer; Nursing; Political science; Law","score_opus":0.27899764140582284,"score_gpt":0.5165407456196554,"score_spread":0.2375431042138325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265842034","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028876519,0.10000223,0.00010337123,0.78406143,0.039480284,0.0029650906,0.00047485286,0.00045899622,0.043577224],"genre_scores_gemma":[0.3154882,0.22312653,0.0021957606,0.033194784,0.383899,0.013958345,0.00010312368,0.0004262725,0.027607962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996995,0.0007721838,0.00060050975,0.0005159405,0.00017594281,0.00094045565],"domain_scores_gemma":[0.9978384,0.00067331485,0.0003984038,0.0004284126,0.00038173996,0.00027974593],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008891005,0.00025061393,0.0006182137,0.000076595235,0.00071567117,0.0000040424934,0.000267688,0.0013605056,0.0009461293],"category_scores_gemma":[0.000027551909,0.0001473323,0.000107235115,0.000072019466,0.00004435421,0.00011732667,0.000081468665,0.00051455543,0.0001998389],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024696902,0.000084344705,0.001365464,0.0043491907,0.00009764237,0.0000132420455,0.018144017,1.0856017e-7,0.0003234483,0.024618415,0.06944169,0.88131547],"study_design_scores_gemma":[0.0015171176,0.00027651616,0.0033116187,0.001108368,0.000021638623,0.000004042012,0.039716728,0.0000014953754,0.000010170595,0.0005285758,0.9533098,0.00019398364],"about_ca_topic_score_codex":0.000166066,"about_ca_topic_score_gemma":0.025740081,"teacher_disagreement_score":0.88386804,"about_ca_system_score_codex":0.00046277247,"about_ca_system_score_gemma":0.00085590105,"threshold_uncertainty_score":0.99996716},"labels":[],"label_agreement":null},{"id":"W2339030197","doi":"10.2217/fon-2016-0130","title":"ROBUST: Lenalidomide-R-Chop Versus Placebo-R-Chop in Previously Untreated Abc-Type Diffuse Large B-Cell Lymphoma","year":2016,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lenalidomide; Medicine; CHOP; Diffuse large B-cell lymphoma; Internal medicine; Clinical endpoint; Lymphoma; Oncology; Placebo; Pathology; Clinical trial; Multiple myeloma","score_opus":0.024355709995883844,"score_gpt":0.28347919032453645,"score_spread":0.2591234803286526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339030197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96845037,0.0024291996,0.0000102976755,0.006883131,0.002154956,0.0011196929,0.000037146478,0.00015307411,0.018762155],"genre_scores_gemma":[0.9905221,0.0025505272,0.0004343421,0.0011924971,0.0010224404,0.00020755651,0.00006568826,0.00006694995,0.0039378842],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99733293,0.0002353896,0.0005285006,0.00070549175,0.00028940564,0.0009082848],"domain_scores_gemma":[0.99798095,0.00065347744,0.00020283845,0.0006440457,0.00014802534,0.00037067244],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031808412,0.00043533792,0.00086998,0.00024364328,0.000105721745,0.000019511106,0.00020014164,0.00058426405,0.00074968836],"category_scores_gemma":[0.00020243789,0.00027016335,0.00020249681,0.0004347922,0.00009475267,0.00011398789,0.00011305035,0.00014383545,0.0009097147],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12062939,0.087269805,0.24304566,0.0005055662,0.001993947,0.01724965,0.0041893837,0.0000159528,0.011382488,0.005073534,0.24533741,0.2633072],"study_design_scores_gemma":[0.34771484,0.0048646037,0.05373899,0.0002459192,0.0005085582,0.00025285778,0.00036772722,0.000036855272,0.0028488734,0.000034873134,0.58890384,0.00048205888],"about_ca_topic_score_codex":0.00014761719,"about_ca_topic_score_gemma":0.0010933022,"teacher_disagreement_score":0.34356645,"about_ca_system_score_codex":0.0020598127,"about_ca_system_score_gemma":0.0007126404,"threshold_uncertainty_score":0.9999751},"labels":[],"label_agreement":null},{"id":"W2345789793","doi":"10.2217/fon-2016-0089","title":"The Continuing Evolution of Technology in Cancer Care","year":2016,"lang":"en","type":"review","venue":"Future Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; MEDLINE; Cancer; Oncology; Family medicine; Library science; Internal medicine; Computer science","score_opus":0.0127996165468772,"score_gpt":0.4311993263114619,"score_spread":0.4183997097645847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345789793","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012262773,0.99135923,0.000046489666,0.00224387,0.003334678,0.0008885418,0.000026211228,0.00003515077,0.0020535653],"genre_scores_gemma":[0.000039191546,0.9960355,0.00045092095,0.00005016182,0.0022781447,0.00037024776,0.000010079957,0.000034631026,0.0007311299],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99846774,0.00019236021,0.0006009146,0.00031156235,0.0000921644,0.00033524667],"domain_scores_gemma":[0.9983913,0.00048021125,0.0005621147,0.00040216013,0.0001273547,0.000036876027],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00021551475,0.00025240035,0.0018747059,0.0003355226,0.000053513093,0.0000012504298,0.00027763468,0.001643466,0.00007419819],"category_scores_gemma":[0.000112024485,0.00012481942,0.0002403767,0.00043968568,0.00058058463,0.00002110194,0.000053049553,0.00083020475,0.000013661274],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007752745,0.000036614238,0.00014953283,0.0020537365,0.00011690104,0.000050822804,0.00016097847,7.4755086e-8,0.0000043907244,0.0047621415,0.0006189235,0.99196833],"study_design_scores_gemma":[0.0009386366,0.0005267632,0.00002981944,0.008780824,0.000252759,0.00023401044,0.0004979537,1.350589e-7,0.0000015950428,0.00029535158,0.9883235,0.00011866053],"about_ca_topic_score_codex":0.000007646563,"about_ca_topic_score_gemma":0.0002654281,"teacher_disagreement_score":0.9918497,"about_ca_system_score_codex":0.0024808086,"about_ca_system_score_gemma":0.0013174919,"threshold_uncertainty_score":0.9996526},"labels":[],"label_agreement":null},{"id":"W2564757287","doi":"10.2217/fon-2016-0444","title":"Phase II Trial of Capecitabine Plus Erlotinib Versus Capecitabine Alone in Patients with Advanced Colorectal Cancer","year":2017,"lang":"en","type":"article","venue":"Future Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lions Gate Hospital; Centre Hospitalier de l’Université de Montréal; Cancer Care Ontario; Western University","funders":"","keywords":"Capecitabine; KRAS; Medicine; Erlotinib; Colorectal cancer; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Gastroenterology; Cancer; Epidermal growth factor receptor","score_opus":0.018529053030290565,"score_gpt":0.3391485561134127,"score_spread":0.32061950308312215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564757287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838446,0.00065464067,9.1924244e-7,0.002209309,0.0028951615,0.0019177115,0.00011768841,0.000024889434,0.008335105],"genre_scores_gemma":[0.99748915,0.00028190442,0.0003530172,0.00007179285,0.0009089728,0.00045090055,0.00008527251,0.00002979649,0.00032918344],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99843246,0.00004949544,0.00040494846,0.0004126964,0.00030335653,0.00039704493],"domain_scores_gemma":[0.99872607,0.000091846625,0.00041775746,0.0003798603,0.00025639313,0.00012805122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000118359116,0.00028429885,0.0010888671,0.00011496755,0.0002756497,0.0000076206984,0.00016640198,0.000183208,0.00026571203],"category_scores_gemma":[0.00014831181,0.00020132122,0.000100756086,0.00013411032,0.00027452348,0.00011171375,0.00013023181,0.00026113092,0.000003289817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8193308,0.007596023,0.014891016,0.000047564943,0.0005206355,0.000119049604,0.0013091277,0.0000065099257,0.0003319672,0.000052491727,0.00083294575,0.15496185],"study_design_scores_gemma":[0.6889963,0.10141896,0.1830203,0.00007669998,0.00031759322,0.0000033551821,0.00033262442,0.000013557955,0.00038543195,0.000004569258,0.025219122,0.00021149973],"about_ca_topic_score_codex":0.00046920526,"about_ca_topic_score_gemma":0.010300375,"teacher_disagreement_score":0.16812927,"about_ca_system_score_codex":0.00079487904,"about_ca_system_score_gemma":0.00052340544,"threshold_uncertainty_score":0.8209641},"labels":[],"label_agreement":null},{"id":"W2585002192","doi":"10.2217/fon-2016-0479","title":"A Multinational Report of Technical Factors on Stereotactic Body Radiotherapy for Oligometastases","year":2017,"lang":"en","type":"article","venue":"Future Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Elekta","keywords":"Medicine; Multinational corporation; Medical physics; Stereotactic radiotherapy; Radiation therapy; Radiosurgery; Oncology; Radiology","score_opus":0.03774357954866775,"score_gpt":0.3915182214295643,"score_spread":0.3537746418808965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585002192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.919077,0.000321111,0.0032548257,0.034017075,0.0024871472,0.0041121743,0.00031130057,0.00013957302,0.036279786],"genre_scores_gemma":[0.9747937,0.00003069007,0.021211086,0.0009513702,0.00060260884,0.00013389373,0.00020483289,0.000031408283,0.0020404593],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99884224,0.000047818296,0.00036503217,0.00027645775,0.00028323472,0.00018523465],"domain_scores_gemma":[0.99824095,0.00028953122,0.0005318581,0.00068191095,0.00013861462,0.00011710803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039598762,0.00014551649,0.0004808381,0.00015030325,0.000112559545,0.000013020153,0.00017775704,0.000108242355,0.00034894608],"category_scores_gemma":[0.0012108336,0.000111926274,0.00018041268,0.000037983293,0.00013404287,0.000061347215,0.000039623195,0.00012944386,0.0000036661381],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027119288,0.025451673,0.28736666,0.0034372665,0.0065834266,0.008475739,0.0011270018,0.000013688483,0.052918464,0.09723064,0.38123983,0.10903631],"study_design_scores_gemma":[0.006446376,0.002786681,0.49625832,0.000047383724,0.00044080525,0.0001892843,0.00014907146,0.0000677389,0.0008418331,0.00019986063,0.4924255,0.00014714354],"about_ca_topic_score_codex":0.000011558508,"about_ca_topic_score_gemma":0.00000938822,"teacher_disagreement_score":0.20889166,"about_ca_system_score_codex":0.00013419469,"about_ca_system_score_gemma":0.00017838062,"threshold_uncertainty_score":0.4564221},"labels":[],"label_agreement":null},{"id":"W2605759430","doi":"10.2217/fon-2017-0062","title":"ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study","year":2017,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Eribulin; Metastatic breast cancer; Observational study; Internal medicine; Quality of life (healthcare); Oncology; Breast cancer; Prospective cohort study; Cancer; Nursing","score_opus":0.05307339089581799,"score_gpt":0.408731362008138,"score_spread":0.35565797111232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605759430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926674,0.00039512652,3.7088793e-7,0.0045914873,0.00038492444,0.0013844843,0.00013070098,0.000014626559,0.0004308736],"genre_scores_gemma":[0.9982891,0.00023206964,0.00011782741,0.0004544971,0.00024991744,0.00029756737,0.00004483588,0.0000122121655,0.00030196054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916035,0.000071553,0.0001864295,0.000302913,0.00009155684,0.00018718134],"domain_scores_gemma":[0.99944526,0.00006405506,0.00014260333,0.00013147107,0.00011955058,0.00009704094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007786657,0.00015427476,0.00039412055,0.00006811467,0.00014277699,0.0000191023,0.00005278556,0.00007358387,0.00021533051],"category_scores_gemma":[0.000025632147,0.00011907112,0.00002196769,0.00004833073,0.00011924533,0.00011227966,0.00006658384,0.00017454411,0.000003249697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019456878,0.0029973725,0.9841417,0.000029294424,0.00027285086,0.000116315176,0.0018383423,3.019581e-7,0.0001586655,0.000025845682,0.00052930746,0.007944298],"study_design_scores_gemma":[0.02135665,0.0020950437,0.9720283,0.000022568198,0.0003346291,0.00002828362,0.000526806,0.000040977495,0.000028097395,0.000024235844,0.003421088,0.00009327665],"about_ca_topic_score_codex":0.0012558725,"about_ca_topic_score_gemma":0.0062267934,"teacher_disagreement_score":0.019410962,"about_ca_system_score_codex":0.0002798357,"about_ca_system_score_gemma":0.00012359144,"threshold_uncertainty_score":0.48555794},"labels":[],"label_agreement":null},{"id":"W2609848358","doi":"10.2217/fon-2016-0556","title":"Current status of ramucirumab in gastroesophageal adenocarcinoma","year":2017,"lang":"en","type":"review","venue":"Future Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ramucirumab; Medicine; Paclitaxel; Internal medicine; Oncology; Clinical trial; Adenocarcinoma; Gastroesophageal Junction; Chemotherapy; Cancer","score_opus":0.11055681038413291,"score_gpt":0.44322009009196317,"score_spread":0.3326632797078303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609848358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002246365,0.9904438,0.000004053928,0.00014974063,0.0027673098,0.0011714271,0.000043530606,0.000022227468,0.0053754007],"genre_scores_gemma":[0.00010086729,0.9965048,0.00023500141,0.000044206885,0.0020288653,0.000099009725,0.00024275343,0.000041677074,0.00070284907],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977116,0.00014354492,0.0008065322,0.00044442786,0.00024476583,0.0006491559],"domain_scores_gemma":[0.9981226,0.0000828929,0.0008212982,0.00073088956,0.000053429292,0.00018894428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002424413,0.00038891193,0.003297796,0.00057140493,0.000035536024,0.000010379607,0.0003393728,0.00040724038,0.00035414434],"category_scores_gemma":[0.000083190964,0.00029788073,0.00056222785,0.00021176416,0.00011355857,0.000040141495,0.00020389936,0.0008859368,0.000055810284],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000631411,0.00015552697,0.0047335904,0.0155539,0.00013266836,0.0003680088,0.000057618206,3.5681605e-8,1.3223837e-8,0.00017826758,0.009458731,0.9692985],"study_design_scores_gemma":[0.0019326137,0.0006169437,0.015845014,0.003830636,0.0012534226,0.00009083214,0.000037022088,4.0066078e-7,4.559917e-8,0.000009302275,0.97624695,0.00013684157],"about_ca_topic_score_codex":0.000049069014,"about_ca_topic_score_gemma":0.00014599873,"teacher_disagreement_score":0.9691616,"about_ca_system_score_codex":0.00084998476,"about_ca_system_score_gemma":0.0014956201,"threshold_uncertainty_score":0.9999473},"labels":[],"label_agreement":null},{"id":"W2614021025","doi":"10.2217/fon-2017-0031","title":"Venetoclax for the treatment of patients with chronic lymphocytic leukemia","year":2017,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute","keywords":"Venetoclax; Tumor lysis syndrome; Medicine; Chronic lymphocytic leukemia; Neutropenia; Oncology; Rituximab; Internal medicine; Clinical trial; Lymphoma; Leukemia; Immunology; Chemotherapy","score_opus":0.021146067308554253,"score_gpt":0.33432476656353816,"score_spread":0.3131786992549839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614021025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98963267,0.0021735295,0.00009848405,0.0009858897,0.0007464938,0.0029340875,0.000047381753,0.00003217786,0.003349269],"genre_scores_gemma":[0.9946136,0.0007027316,0.00047673873,0.00011451781,0.001745478,0.00039506488,0.000053617066,0.00003895113,0.0018593371],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987974,0.000029709428,0.00021909851,0.00027874,0.00026803667,0.00040698436],"domain_scores_gemma":[0.9979942,0.00033315938,0.00023399742,0.0011088705,0.00021398783,0.00011580535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011842699,0.00017799651,0.00046221315,0.000047803584,0.0003104861,0.00001689947,0.0003133587,0.00019731358,0.00010709074],"category_scores_gemma":[0.00007031849,0.00009180375,0.00013279755,0.00005046057,0.00041614895,0.000043856966,0.000046009274,0.00008507398,0.000023061413],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.040388968,0.0013649919,0.0234212,0.0016346555,0.004241074,0.00046867214,0.0036898234,0.002149793,0.00079335953,0.0037989875,0.03061898,0.8874295],"study_design_scores_gemma":[0.101927936,0.023057872,0.049948134,0.00007057235,0.0005266425,0.00006501268,0.00008930888,0.010204884,0.0014705727,0.000048055597,0.81242985,0.00016115008],"about_ca_topic_score_codex":0.000821863,"about_ca_topic_score_gemma":0.00072824536,"teacher_disagreement_score":0.88726836,"about_ca_system_score_codex":0.18087134,"about_ca_system_score_gemma":0.053964373,"threshold_uncertainty_score":0.9513988},"labels":[],"label_agreement":null},{"id":"W2770267656","doi":"10.2217/fon-2017-0427","title":"Utility of Molecular Tools for Extended Adjuvant Endocrine Therapy Decisions in Early Breast Cancer","year":2017,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Oncology; Adjuvant; Endocrine system; Internal medicine; Cancer; Adjuvant therapy; Gynecology; Hormone","score_opus":0.018374104836761888,"score_gpt":0.3480047210297057,"score_spread":0.3296306161929438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770267656","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049052197,0.035978388,0.0002507958,0.0026170516,0.8902145,0.0025587915,0.017465556,0.000032195436,0.0018305468],"genre_scores_gemma":[0.22294122,0.036438223,0.0011683323,0.00017280254,0.73353314,0.0019386365,0.003182849,0.000160398,0.00046442173],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776477,0.00016073268,0.00047877754,0.00083280983,0.0002755549,0.00048735936],"domain_scores_gemma":[0.9975408,0.00036959397,0.00051342195,0.0009498489,0.0005403455,0.000085998945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000237933,0.00046632224,0.0010219447,0.00008673449,0.00010856977,0.000023825713,0.0006204725,0.0011697151,0.000039475824],"category_scores_gemma":[0.0005657271,0.00039467553,0.0003417428,0.000060704122,0.00023355552,0.000008190929,0.00023977274,0.00037248098,0.0000017559771],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047728186,0.00057111913,0.0010837486,0.000051508152,0.0007219208,0.000049922906,0.000092701936,0.0000016749304,0.00798052,0.00002874656,0.6945585,0.2900868],"study_design_scores_gemma":[0.0050832317,0.00062728307,0.040962774,0.00008449443,0.000114743765,0.000011381915,0.00004043249,8.1183396e-7,0.0052433694,0.00012962201,0.9473765,0.0003253429],"about_ca_topic_score_codex":0.00063186843,"about_ca_topic_score_gemma":0.003228505,"teacher_disagreement_score":0.28976145,"about_ca_system_score_codex":0.00010995353,"about_ca_system_score_gemma":0.0013852768,"threshold_uncertainty_score":0.9998505},"labels":[],"label_agreement":null},{"id":"W2795150236","doi":"10.2217/fon-2018-0121","title":"Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies","year":2018,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Celgene; Sanofi; Genentech; Ariad Pharmaceuticals; Amgen","keywords":"Venetoclax; Medicine; Clinical trial; Refractory (planetary science); Oncology; Internal medicine; Drug development; Chronic lymphocytic leukemia; Chemotherapy; Cancer; Drug; Leukemia; Pharmacology","score_opus":0.061213522298303284,"score_gpt":0.3801271580229051,"score_spread":0.3189136357246018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795150236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959479,0.0011344595,0.000074852636,0.00021104579,0.00047031898,0.0015017799,0.0000029140617,0.000022758844,0.0006339901],"genre_scores_gemma":[0.9929671,0.00017206889,0.0048046918,0.00015395205,0.0012214972,0.00033842432,0.0000055389737,0.000030790925,0.00030590632],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977221,0.00022122236,0.00070517405,0.00042119905,0.0004013403,0.0005289494],"domain_scores_gemma":[0.9988522,0.0003291037,0.0002027132,0.00029675168,0.0002021657,0.0001170701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012061696,0.00019878765,0.0006129741,0.00048355578,0.00005566327,0.0000065892687,0.00022368378,0.00021573486,0.00017732666],"category_scores_gemma":[0.0002326879,0.00017378722,0.000033776185,0.00078924594,0.0001115192,0.00005568104,0.0001390193,0.0004479092,0.00002017352],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.028438013,0.038891833,0.3072578,0.0028452624,0.0006840225,0.006648735,0.28720582,0.0020661457,0.11601486,0.00036178486,0.020430656,0.18915506],"study_design_scores_gemma":[0.56789637,0.035894684,0.24876307,0.0011642377,0.00045294536,0.00050365087,0.029654045,0.020527465,0.034284562,0.000062132225,0.059024174,0.0017726361],"about_ca_topic_score_codex":0.0012710127,"about_ca_topic_score_gemma":0.004896155,"teacher_disagreement_score":0.5394584,"about_ca_system_score_codex":0.021939179,"about_ca_system_score_gemma":0.031923953,"threshold_uncertainty_score":0.9818154},"labels":[],"label_agreement":null},{"id":"W2810071268","doi":"10.2217/fon-2018-0133","title":"Novel Multidisciplinary Approaches in the Management of Metastatic Epidural Spinal Cord Compression","year":2018,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Spinal cord compression; Multidisciplinary approach; Spinal cord","score_opus":0.08147662196166545,"score_gpt":0.3886051679304905,"score_spread":0.30712854596882505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810071268","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004369378,0.0026168933,0.0015328601,0.0067522796,0.94778275,0.0059812027,0.0004257799,0.00007949725,0.030459374],"genre_scores_gemma":[0.011106724,0.0006816614,0.118548185,0.0005498161,0.86002105,0.001014638,0.004194868,0.00018294492,0.0037001146],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99629056,0.00042130688,0.0009133648,0.0006754247,0.0012394168,0.0004599079],"domain_scores_gemma":[0.99768597,0.00040355785,0.0007011465,0.000946243,0.00014012455,0.00012298756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001625943,0.0004719783,0.0012610349,0.00032297533,0.00007786589,0.000014640509,0.0006849277,0.00043950247,0.00018993279],"category_scores_gemma":[0.000107430256,0.00030573577,0.0002649531,0.00034860766,0.00034371507,0.000056492303,0.0004521382,0.0009871463,0.00003866132],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008135622,0.0030574359,0.000032574404,0.0058423174,0.0008344486,0.0008633359,0.00046289933,0.000002503725,0.000018230989,0.0007763565,0.9584714,0.021502873],"study_design_scores_gemma":[0.008281711,0.0051125702,0.007932634,0.0012266367,0.0030317972,0.00003319026,0.0067022373,0.00023173724,0.0000044134276,0.00021244705,0.96690613,0.00032447884],"about_ca_topic_score_codex":0.000025826706,"about_ca_topic_score_gemma":0.000029770834,"teacher_disagreement_score":0.117015325,"about_ca_system_score_codex":0.00021470881,"about_ca_system_score_gemma":0.00029634451,"threshold_uncertainty_score":0.9999395},"labels":[],"label_agreement":null},{"id":"W2811498020","doi":"10.2217/fon-2017-0670","title":"Clinical Features and Psychological Aspects of the Decision-Making Process in Stage I Testicular Germ Cell Tumors","year":2018,"lang":"en","type":"review","venue":"Future Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Germ cell tumors; Orchiectomy; Stage (stratigraphy); Multidisciplinary approach; Clinical decision making; Intensive care medicine; Clinical trial; Pathology; Surgery; Chemotherapy","score_opus":0.052891945787794444,"score_gpt":0.46689257135663637,"score_spread":0.41400062556884193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811498020","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016164731,0.97930795,0.0000027559906,0.00006630277,0.0006512957,0.001327039,0.000039238093,0.000022042139,0.002418642],"genre_scores_gemma":[0.045072198,0.9521806,0.0012761449,0.0002519113,0.0009868479,0.00008316345,0.000026063457,0.000049120277,0.000073949785],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976093,0.00037498135,0.0008175949,0.0006513621,0.00025945524,0.00028728577],"domain_scores_gemma":[0.99734443,0.0010851399,0.000747999,0.000568175,0.0000937692,0.00016047759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033288493,0.0003733169,0.0020342278,0.00011560135,0.000052186224,0.000009935641,0.00025799507,0.000823854,0.00007831348],"category_scores_gemma":[0.0012250491,0.00018503018,0.0004969345,0.0003543473,0.0003322829,0.000017408243,0.00014413909,0.00077913253,0.00001291732],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018343671,0.002659864,0.0103988955,0.008907221,0.00017841182,0.00245414,0.00005690061,3.0185737e-7,1.1917461e-7,0.0002091009,0.00086646713,0.97408515],"study_design_scores_gemma":[0.0035378712,0.004154172,0.19014017,0.03152678,0.003864677,0.0025519133,0.00011399296,0.0000031134834,5.0010465e-7,0.001138617,0.7625247,0.0004434506],"about_ca_topic_score_codex":0.00000272876,"about_ca_topic_score_gemma":0.000021420325,"teacher_disagreement_score":0.9736417,"about_ca_system_score_codex":0.00011670695,"about_ca_system_score_gemma":0.0007204414,"threshold_uncertainty_score":0.75453115},"labels":[],"label_agreement":null},{"id":"W2896248377","doi":"10.2217/fon-2018-0711","title":"Sequential treatment with afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: an observational study","year":2018,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Osimertinib; Afatinib; Medicine; T790M; Observational study; Internal medicine; Lung cancer; Oncology; Clinical trial; Chemotherapy; Retrospective cohort study; Cancer; Epidermal growth factor receptor; Erlotinib; Gefitinib","score_opus":0.024571066342871796,"score_gpt":0.35720369986363815,"score_spread":0.33263263352076633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896248377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946372,0.00011251927,0.000051784227,0.00078156195,0.00020608272,0.002279411,0.000077984485,0.000024427516,0.0018290381],"genre_scores_gemma":[0.995282,0.000015542442,0.002231317,0.00061993627,0.0005138072,0.00056132994,0.00045588365,0.0000292882,0.00029091066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988894,0.00007379366,0.00021921885,0.00040695918,0.0001781917,0.00023247248],"domain_scores_gemma":[0.9992224,0.000041226787,0.00013933638,0.00016747857,0.00029581873,0.00013373485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005086075,0.00021661783,0.00033113887,0.0000935446,0.0001466334,0.0000169894,0.000042730324,0.00008863971,0.000090785325],"category_scores_gemma":[0.000002286654,0.00014095174,0.000019492752,0.00021344509,0.00009452903,0.00012685049,0.000014199289,0.00009981366,0.00000303652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023943228,0.0037697023,0.9725625,0.000019500423,0.00044296795,0.00010241894,0.012288313,0.000020037229,0.000053980923,0.000022551783,0.00011702633,0.0082066795],"study_design_scores_gemma":[0.025982874,0.031095536,0.9378313,0.00005448252,0.000955864,0.0000128645825,0.0023189287,0.00013015624,0.00022274256,0.000003319398,0.0012273274,0.00016463579],"about_ca_topic_score_codex":0.001125043,"about_ca_topic_score_gemma":0.0075276955,"teacher_disagreement_score":0.034731228,"about_ca_system_score_codex":0.0006624966,"about_ca_system_score_gemma":0.0008531549,"threshold_uncertainty_score":0.5747845},"labels":[],"label_agreement":null},{"id":"W2897194445","doi":"10.2217/fon-2018-0671","title":"Stage III Melanoma Incidence and Impact of Transitioning to the 8th AJCC Staging System: A US Population-Based Study","year":2018,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Melanoma; Stage (stratigraphy); Incidence (geometry); Cancer registry; Population; AJCC staging system; Cancer; Oncology; Internal medicine; Cancer stage; Staging system; Cancer research; Environmental health","score_opus":0.011084545914195366,"score_gpt":0.3095916972263755,"score_spread":0.2985071513121801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897194445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436474,0.000034399363,0.0013954933,0.000995206,0.000417769,0.0010637994,0.000009175806,0.000046294233,0.0016731068],"genre_scores_gemma":[0.99837565,0.0000011318725,0.00032221054,0.00043585186,0.0005245748,0.000034863962,0.0000075445996,0.000012466408,0.00028571166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906194,0.000134486,0.0002536962,0.0002132223,0.00017074181,0.00016592792],"domain_scores_gemma":[0.9993719,0.00006652608,0.00011353466,0.0002481136,0.00010380703,0.000096148964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034252164,0.00011595614,0.00029854092,0.00012452617,0.00016516879,0.000014265935,0.000066634435,0.00006232424,0.00019284761],"category_scores_gemma":[0.000023663839,0.00007680221,0.000057151177,0.00022942385,0.000031021416,0.000027483844,0.000028839831,0.00011665672,0.000011079007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004859421,0.0008409452,0.94206005,0.000442325,0.0007031279,0.0006155849,0.018988699,0.0009982914,0.0059327856,0.0008242447,0.0016578824,0.022076635],"study_design_scores_gemma":[0.002981913,0.009880303,0.964241,0.00010395396,0.00026857693,0.00020983235,0.013175974,0.0021246765,0.00013908155,0.0000023909738,0.0067280103,0.00014428282],"about_ca_topic_score_codex":0.0017806818,"about_ca_topic_score_gemma":0.0029420678,"teacher_disagreement_score":0.022180945,"about_ca_system_score_codex":0.00032196366,"about_ca_system_score_gemma":0.00011232284,"threshold_uncertainty_score":0.3131903},"labels":[],"label_agreement":null},{"id":"W2913371045","doi":"10.2217/fon-2018-0153","title":"Hot Topics in Epigenetic Regulation of Cancer Self-Renewal for Pancreatic Tumors: Future Trends","year":2019,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Epigenetics; Medicine; Pancreatic cancer; Cancer; Oncology; Cancer research; Internal medicine; Bioinformatics; Genetics; Biology","score_opus":0.015399920328488822,"score_gpt":0.3661090874161136,"score_spread":0.3507091670876248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913371045","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04233503,0.013946163,0.00004436814,0.00731403,0.9188783,0.0033418797,0.0005897901,0.00010299122,0.013447425],"genre_scores_gemma":[0.0022235322,0.0046358253,0.004175314,0.00013660765,0.96437675,0.00079209806,0.0017554977,0.00009954989,0.021804828],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967754,0.0002725491,0.00095753703,0.0006796855,0.0006447713,0.00067006354],"domain_scores_gemma":[0.9971214,0.00093741575,0.0005943327,0.0006345607,0.0005601181,0.0001521515],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00064635836,0.0004461686,0.0025103677,0.0006205448,0.000057156656,0.00000847815,0.0003061615,0.0031695536,0.0006337852],"category_scores_gemma":[0.00034313375,0.00037397054,0.00036130616,0.00045085492,0.0001321834,0.000038129172,0.00007691744,0.0011682505,0.000014193633],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027240783,0.00052620936,0.014425986,0.002169964,0.00069784786,0.000045561,0.0008282905,0.0000052858277,0.00015822497,0.00019956073,0.9557201,0.022498889],"study_design_scores_gemma":[0.006909752,0.00355265,0.032912657,0.0004564706,0.0014799722,0.000015098742,0.0002463498,0.00015624626,0.00004477592,0.0001601889,0.95377105,0.00029480527],"about_ca_topic_score_codex":0.00041016616,"about_ca_topic_score_gemma":0.0023392006,"teacher_disagreement_score":0.045498423,"about_ca_system_score_codex":0.0013747044,"about_ca_system_score_gemma":0.0043247584,"threshold_uncertainty_score":0.9998712},"labels":[],"label_agreement":null},{"id":"W2955934677","doi":"10.2217/fon-2019-0010","title":"Utilization of Tumor Genomics in Clinical Practice: An International Survey among ASCO Members","year":2019,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Society of Clinical Oncology","keywords":"Medicine; Context (archaeology); Family medicine; Clinical Practice; Clinical trial; Clinical Oncology; Precision medicine; Personalized medicine; Internal medicine; Cancer; Pathology; Bioinformatics","score_opus":0.025159141984451617,"score_gpt":0.3726269263304013,"score_spread":0.34746778434594966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955934677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908731,0.00018389079,0.000079725,0.00016706262,0.002265868,0.0001953146,0.00006237053,0.0000031026616,0.006169572],"genre_scores_gemma":[0.99503726,0.0010204868,0.0017112854,0.00071859756,0.00078741275,0.000007135148,0.0006180326,0.000017029632,0.00008274754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988725,0.00021906743,0.00040415616,0.00029133493,0.000080590384,0.0001323219],"domain_scores_gemma":[0.9990888,0.000136146,0.00026200092,0.00027467788,0.00017909832,0.00005927224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086319476,0.0000908532,0.00019812876,0.000047905647,0.000011380113,0.000009172167,0.0002158522,0.00024201807,0.00007998779],"category_scores_gemma":[0.0005840034,0.00009565257,0.000053316653,0.00006752054,0.00006404735,0.000010113447,0.000098188255,0.000135297,0.000007899733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001172657,0.0006171712,0.96961844,0.000013276658,0.000093050694,0.000014424,0.00015485802,0.0008285463,0.00934821,0.0008998052,0.0028647676,0.014374776],"study_design_scores_gemma":[0.001168309,0.0008341852,0.6191892,0.000004111957,0.000012466125,0.000011778321,0.00029607353,0.00038943632,0.0016961421,0.000020487525,0.3762587,0.00011912051],"about_ca_topic_score_codex":0.00025537505,"about_ca_topic_score_gemma":0.0041400045,"teacher_disagreement_score":0.37339392,"about_ca_system_score_codex":0.00006575064,"about_ca_system_score_gemma":0.00033907217,"threshold_uncertainty_score":0.39005986},"labels":[],"label_agreement":null},{"id":"W3011939837","doi":"10.2217/fon-2019-0796","title":"Quality of Life with Second or Third Line <i>Nab</i> -Paclitaxel-Based Regimens in Advanced Non-Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Durvalumab; Quality of life (healthcare); Lung cancer; Paclitaxel; Internal medicine; Oncology; Nab-paclitaxel; Cancer; Physical therapy; Nursing; Immunotherapy","score_opus":0.022359610082821304,"score_gpt":0.36557717145172036,"score_spread":0.3432175613688991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011939837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9535688,0.0026691998,0.0005051317,0.028475141,0.00035860276,0.0013358311,0.00017023656,0.000054011245,0.012863037],"genre_scores_gemma":[0.97517824,0.00013421752,0.0068794135,0.015080751,0.00062297226,0.0002692991,0.0001019408,0.000036799116,0.0016963701],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987229,0.0000976188,0.00041965686,0.00035572323,0.00014555022,0.00025854493],"domain_scores_gemma":[0.99892676,0.00016422545,0.00026904562,0.00024511162,0.00015364877,0.00024118139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013243867,0.00019290119,0.0006897111,0.000064080734,0.00003685069,0.000003652604,0.00008702176,0.00017966192,0.0005553398],"category_scores_gemma":[0.000055438173,0.00012895186,0.00007246634,0.00035787534,0.00006654707,0.000045433117,0.000021648633,0.00028368126,0.0000054135367],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06130116,0.0072506475,0.71631,0.011446071,0.0024403627,0.0031832242,0.03544961,0.004478276,0.05492184,0.0006561246,0.082560845,0.02000183],"study_design_scores_gemma":[0.14531735,0.02451228,0.2506939,0.0009691589,0.002114287,0.00006379229,0.013278371,0.0019029321,0.02704068,0.000030944888,0.53270423,0.001372083],"about_ca_topic_score_codex":0.00021605761,"about_ca_topic_score_gemma":0.0045875297,"teacher_disagreement_score":0.46561614,"about_ca_system_score_codex":0.00029818047,"about_ca_system_score_gemma":0.0026197154,"threshold_uncertainty_score":0.60805815},"labels":[],"label_agreement":null},{"id":"W3012293314","doi":"10.2217/fon-2020-0044","title":"MIRROS: A Randomized, Placebo-Controlled, Phase III Trial of Cytarabine ± Idasanutlin in Relapsed or Refractory Acute Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Cytarabine; Myeloid leukemia; Refractory (planetary science); Internal medicine; Placebo; Oncology; Randomized controlled trial; Myeloid; Pathology","score_opus":0.025895685441203825,"score_gpt":0.34770532389991754,"score_spread":0.3218096384587137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012293314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94490933,0.0010939685,0.00022538986,0.031158065,0.0011425934,0.0125360275,0.00007783485,0.00017949917,0.008677267],"genre_scores_gemma":[0.9629622,0.0036140005,0.0066284533,0.009326775,0.007870532,0.0026771068,0.0004176801,0.00021816601,0.0062850984],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994016,0.001581616,0.002015001,0.00083088345,0.00072227267,0.0008342284],"domain_scores_gemma":[0.9953237,0.0024269836,0.0007347366,0.0006363766,0.00028609647,0.00059207604],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026642838,0.0005248872,0.004723516,0.00050648476,0.000075377764,0.0000144852675,0.00048526755,0.0010463442,0.0017762933],"category_scores_gemma":[0.0031860892,0.00035910998,0.000623839,0.00089563616,0.00051722996,0.00011338971,0.00019378276,0.0020865577,0.00014632416],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9368089,0.0011319924,0.0000060926545,0.0001404567,0.00092522654,0.0025510557,0.0019834575,0.000011072099,0.022597397,0.00014522369,0.024597138,0.009102022],"study_design_scores_gemma":[0.8974115,0.013636057,0.000007499333,0.00007082944,0.00078940846,0.0001634441,0.0007497107,0.0031826224,0.0010675928,0.000031893826,0.082610525,0.00027888865],"about_ca_topic_score_codex":0.00019690364,"about_ca_topic_score_gemma":0.00016547999,"teacher_disagreement_score":0.058013387,"about_ca_system_score_codex":0.0019838621,"about_ca_system_score_gemma":0.005715582,"threshold_uncertainty_score":0.9999211},"labels":[],"label_agreement":null},{"id":"W3016845792","doi":"10.2217/fon-2020-0247","title":"NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"NuCana","keywords":"Gemcitabine; Medicine; Cisplatin; Tolerability; Oncology; Internal medicine; Gallbladder cancer; Chemotherapy; Cancer; Adverse effect","score_opus":0.0405994358779115,"score_gpt":0.337366737760424,"score_spread":0.2967673018825125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016845792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.900304,0.0147624165,0.00006396603,0.058655757,0.0023094544,0.0014938291,0.0001471151,0.00024193324,0.022021485],"genre_scores_gemma":[0.9883777,0.001252781,0.0020032034,0.0058320467,0.0016754045,0.00023316432,0.00012503171,0.000074753734,0.0004259342],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99750316,0.00014118073,0.00064409064,0.0007288453,0.00032601523,0.0006567176],"domain_scores_gemma":[0.9986441,0.00034501255,0.00020587843,0.00031792623,0.0001480339,0.00033900776],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000157669,0.000436701,0.0010891494,0.00017768986,0.00009611345,0.000015238745,0.00019503858,0.0002554138,0.00088925945],"category_scores_gemma":[0.0001985464,0.00037070148,0.0001878924,0.00082645833,0.00015254313,0.00014317465,0.00010479526,0.00078644976,0.00012551824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037413135,0.0020557712,0.30235204,0.0014240297,0.0016656376,0.009927508,0.015585793,0.00067178794,0.011614305,0.00071930664,0.12658706,0.48998362],"study_design_scores_gemma":[0.04683111,0.008117936,0.596069,0.0003653695,0.0010561397,0.00021151523,0.005577694,0.0014058414,0.00074142753,0.00009124204,0.33855537,0.0009773588],"about_ca_topic_score_codex":0.0002912914,"about_ca_topic_score_gemma":0.0020359363,"teacher_disagreement_score":0.48900625,"about_ca_system_score_codex":0.0005865345,"about_ca_system_score_gemma":0.000659376,"threshold_uncertainty_score":0.9998745},"labels":[],"label_agreement":null},{"id":"W3032832010","doi":"10.2217/fon-2020-0184","title":"Pembrolizumab Given Concomitantly with Chemoradiation and as Maintenance Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: KEYNOTE-412","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Rosetrees Trust; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; Head and neck; Oncology; Basal cell; Internal medicine; Head and neck cancer; Radiation therapy; Surgery; Immunotherapy; Cancer","score_opus":0.013909977618455905,"score_gpt":0.2772550983325816,"score_spread":0.2633451207141257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032832010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9417488,0.008609402,0.00017089046,0.04350508,0.00017036406,0.0010507723,0.00002202169,0.0000496472,0.0046730284],"genre_scores_gemma":[0.9866399,0.0010457833,0.0021083602,0.009101905,0.0007041886,0.00011741823,0.000017729764,0.00003206502,0.00023261966],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99896884,0.000032711378,0.0001930041,0.0003975817,0.00010245534,0.00030542162],"domain_scores_gemma":[0.99929655,0.00013320765,0.000103695354,0.0001192805,0.00013282435,0.0002144521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006203996,0.00020718315,0.0006256194,0.000029554601,0.00011126172,0.000009133338,0.0000507655,0.00015675461,0.000016343849],"category_scores_gemma":[0.000050015788,0.00015082365,0.00004037125,0.00010184785,0.00013338742,0.00005824809,0.00002590281,0.00020066311,0.0000036723739],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24854611,0.0013807544,0.09401625,0.003297301,0.00043779478,0.0014502192,0.04219198,0.00004147838,0.06050072,0.0025655539,0.08594459,0.45962724],"study_design_scores_gemma":[0.10445533,0.05747252,0.12519275,0.000084363135,0.00017686587,0.0003680726,0.0033381928,0.00062148686,0.0048174076,0.00012629534,0.70283633,0.00051039015],"about_ca_topic_score_codex":0.000029131303,"about_ca_topic_score_gemma":0.00010111592,"teacher_disagreement_score":0.61689174,"about_ca_system_score_codex":0.00011051575,"about_ca_system_score_gemma":0.00032794187,"threshold_uncertainty_score":0.615041},"labels":[],"label_agreement":null},{"id":"W3039747873","doi":"10.2217/fon-2020-0248","title":"Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Nivolumab; Meta-analysis; Lung cancer; Oncology; Internal medicine; Systematic review; MEDLINE; Intensive care medicine; Cancer; Immunotherapy","score_opus":0.022236132718494908,"score_gpt":0.3398117127824406,"score_spread":0.3175755800639457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039747873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029928588,0.9909628,0.00000409244,0.00014323836,0.00008695137,0.008181556,0.00012881556,0.000012649291,0.00044994694],"genre_scores_gemma":[0.000057024776,0.997223,0.00010138492,0.00027068553,0.00005250004,0.0018477131,0.00017185269,0.000049504226,0.00022628772],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99649197,0.0012541886,0.0012078513,0.00057618925,0.00023432408,0.0002354743],"domain_scores_gemma":[0.9975032,0.00040035543,0.0013071162,0.0005366925,0.00015137802,0.00010121374],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00081909413,0.00051981665,0.015400716,0.0004641303,0.000024997467,0.000006300362,0.00019304645,0.00031866762,0.00017322465],"category_scores_gemma":[0.000021078127,0.00029491185,0.0015771688,0.0021060153,0.00007129652,0.000024994553,0.00005440998,0.00044146733,0.0000017160006],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041355696,0.00015704177,0.0003268685,0.8643276,0.13098386,0.000033235166,0.00004418462,9.714994e-8,1.5026811e-7,0.0000020679547,0.00012280216,0.0035885083],"study_design_scores_gemma":[0.0020232978,0.00071394164,0.0006072711,0.09817518,0.8443317,0.000007769431,0.000008904536,7.337133e-7,4.0341433e-7,1.604824e-7,0.0538879,0.00024277813],"about_ca_topic_score_codex":0.00062227785,"about_ca_topic_score_gemma":0.001461585,"teacher_disagreement_score":0.76615244,"about_ca_system_score_codex":0.00076313555,"about_ca_system_score_gemma":0.00088042294,"threshold_uncertainty_score":0.9999503},"labels":[],"label_agreement":null},{"id":"W3049532301","doi":"10.2217/fon-2020-0573","title":"POLARIS: a Prospective, Multicenter, Noninterventional Study Assessing Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Palbociclib; Medicine; Metastatic breast cancer; Oncology; Internal medicine; Clinical trial; Breast cancer; Hormone receptor; Cancer; Clinical Practice; Gynecology; Family medicine","score_opus":0.015351142844713004,"score_gpt":0.35120742469913363,"score_spread":0.3358562818544206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049532301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.957333,0.005618417,0.000742047,0.032139767,0.0008703047,0.0022782097,0.00018166486,0.00017646742,0.00066008064],"genre_scores_gemma":[0.99217206,0.00011727988,0.0037246027,0.0018352087,0.0015894641,0.00037133228,0.000032623135,0.000058750426,0.00009869035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979001,0.00025110203,0.00046518634,0.0006530354,0.0002943464,0.00043618694],"domain_scores_gemma":[0.9990193,0.00008219909,0.00024552082,0.00018597613,0.00024429208,0.00022270557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018159563,0.00029921246,0.00068734906,0.00011414451,0.00009224335,0.000022509977,0.00014950994,0.00018095339,0.00047898336],"category_scores_gemma":[0.000049981914,0.00027092703,0.00013715873,0.0004733921,0.00011429496,0.00034187484,0.00010519778,0.00075609813,0.00003273169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020748599,0.0053407247,0.682323,0.00012850921,0.00081727526,0.00061542046,0.015293539,0.00006234835,0.051887587,0.00017504168,0.0007237517,0.2218842],"study_design_scores_gemma":[0.020954205,0.002313231,0.9533736,0.00023522253,0.00011657433,0.000108944245,0.013136749,0.00010972961,0.00044465292,0.000029091496,0.008897285,0.00028070048],"about_ca_topic_score_codex":0.00010460236,"about_ca_topic_score_gemma":0.00030479347,"teacher_disagreement_score":0.2710506,"about_ca_system_score_codex":0.0011206974,"about_ca_system_score_gemma":0.00034634597,"threshold_uncertainty_score":0.9999743},"labels":[],"label_agreement":null},{"id":"W3082658746","doi":"10.2217/fon-2020-0740","title":"Sequential Afatinib and Osimertinib in Patients with <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Boehringer Ingelheim","keywords":"Afatinib; Osimertinib; Medicine; Lung cancer; Internal medicine; Oncology; T790M; Clinical trial; Cancer; Adenocarcinoma; Erlotinib; Epidermal growth factor receptor","score_opus":0.010261673574810951,"score_gpt":0.31282478021966725,"score_spread":0.3025631066448563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082658746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946353,0.0001987892,0.000038929673,0.00269572,0.00012891345,0.0012513576,0.00009448544,0.000007863936,0.0009486511],"genre_scores_gemma":[0.9982992,0.000012996862,0.00023574554,0.0010711293,0.00011420023,0.00010401304,0.000086953245,0.00001156784,0.000064183725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991128,0.00008571818,0.00024350677,0.00025883978,0.00016032674,0.00013884374],"domain_scores_gemma":[0.9994278,0.000049856175,0.00018474553,0.00012537502,0.00013574606,0.000076468954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044870958,0.0001274778,0.00040241514,0.00009041099,0.00006410906,0.0000060235684,0.00006270648,0.000066962035,0.000066900626],"category_scores_gemma":[0.000009559428,0.000079485406,0.00006339502,0.00072181475,0.00005332015,0.00003367054,0.00003582297,0.00015361219,5.761471e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007811188,0.0008855312,0.97960246,0.00004058264,0.0017208873,0.000032279237,0.014379471,0.00035443643,0.00008736172,0.000008081589,0.00022756416,0.001880239],"study_design_scores_gemma":[0.009511874,0.0021292865,0.9781771,0.000027200274,0.0068608867,0.0000010507896,0.002196195,0.00051873643,0.00019185331,7.467892e-7,0.00030473623,0.000080373575],"about_ca_topic_score_codex":0.00052284275,"about_ca_topic_score_gemma":0.0015318693,"teacher_disagreement_score":0.012183276,"about_ca_system_score_codex":0.00016819924,"about_ca_system_score_gemma":0.00037940778,"threshold_uncertainty_score":0.32413208},"labels":[],"label_agreement":null},{"id":"W3082666946","doi":"10.2217/fon-2020-0521","title":"Belantamab Mafodotin in the Treatment of Relapsed or Refractory Multiple Myeloma","year":2020,"lang":"en","type":"review","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Janssen Biotech; Celgene; Genentech; Amgen","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Clinical trial; Oncology; Internal medicine; Antigen; Population; Chimeric antigen receptor; Antibody; Antibody-drug conjugate; Drug; Immunology; Immunotherapy; Cancer research; Cancer; Pharmacology; Monoclonal antibody","score_opus":0.08867892424622806,"score_gpt":0.4105295756180951,"score_spread":0.3218506513718671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082666946","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023655653,0.9914352,9.3809587e-7,0.0010954185,0.00039265482,0.0035851237,0.00021196075,0.000035767534,0.003006344],"genre_scores_gemma":[0.00022846051,0.9949774,0.00063536083,0.00013461274,0.001309377,0.0007419532,0.00086376915,0.00006948122,0.0010395803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966696,0.00094162655,0.0008661803,0.0005867577,0.00040981322,0.00052605785],"domain_scores_gemma":[0.9969937,0.0015578965,0.00043189232,0.00072399096,0.00005910254,0.00023338651],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002266674,0.0005612471,0.0032271883,0.0003036327,0.00006170027,0.000008924915,0.0003400524,0.0008031306,0.0003999658],"category_scores_gemma":[0.00024700156,0.00026094244,0.00065806863,0.0005979568,0.00012991273,0.000027829961,0.00005060642,0.000721372,0.00023960054],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001648923,0.0025499251,0.00024202414,0.0038574962,0.0007049023,0.007901546,0.000763528,1.9734888e-8,0.0000022156273,0.000024649475,0.0023196489,0.9799851],"study_design_scores_gemma":[0.0072731487,0.011649943,0.0008651033,0.0016756436,0.0010979124,0.00084171194,0.00031174222,0.0000038818325,0.000003357674,0.0000024816054,0.97609645,0.00017862103],"about_ca_topic_score_codex":0.00011672967,"about_ca_topic_score_gemma":0.0006762699,"teacher_disagreement_score":0.9798065,"about_ca_system_score_codex":0.0011863912,"about_ca_system_score_gemma":0.001794567,"threshold_uncertainty_score":0.99998426},"labels":[],"label_agreement":null},{"id":"W3082708938","doi":"10.2217/fon-2020-0586","title":"Avelumab and Axitinib Combination Therapy for the Treatment of Advanced Renal Cell Carcinoma","year":2020,"lang":"en","type":"review","venue":"Future Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Pfizer","keywords":"Nivolumab; Axitinib; Avelumab; Medicine; Ipilimumab; Renal cell carcinoma; Oncology; Internal medicine; Immunotherapy; Combination therapy; Cabozantinib; Tyrosine-kinase inhibitor; Targeted therapy; Sunitinib; Cancer","score_opus":0.04777237359308242,"score_gpt":0.34571873806411063,"score_spread":0.2979463644710282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082708938","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00103666,0.9907619,0.000011374704,0.0010271049,0.0004817741,0.00517405,0.00011008786,0.000021274218,0.0013757912],"genre_scores_gemma":[0.0011077109,0.9946151,0.00067574054,0.000098123935,0.00097396097,0.0012351193,0.00052485126,0.00006468182,0.0007047179],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984397,0.00016711261,0.00053470774,0.00045836344,0.00015967769,0.00024040948],"domain_scores_gemma":[0.99816877,0.0007027911,0.0005112401,0.00038349043,0.00010980166,0.00012391506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009368095,0.00045051545,0.0021573056,0.00009607081,0.00008248715,0.000006910435,0.000115125156,0.00041103314,0.000044790177],"category_scores_gemma":[0.00001275342,0.00023793343,0.0005898584,0.0001482885,0.00010652976,0.000016707627,0.000020787165,0.00018970034,0.0000074948907],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057104515,0.00067785365,0.000007276368,0.0027770507,0.00033824646,0.000086025015,0.00043959447,7.265332e-8,0.000022176357,0.00023698414,0.000626862,0.9942168],"study_design_scores_gemma":[0.0072746966,0.02285585,0.000279578,0.00030164715,0.002332824,0.0001990838,0.00012406411,0.000004644305,0.00022815306,0.000017146895,0.96622634,0.00015597363],"about_ca_topic_score_codex":0.000011093517,"about_ca_topic_score_gemma":0.0000075867815,"teacher_disagreement_score":0.9940608,"about_ca_system_score_codex":0.000615343,"about_ca_system_score_gemma":0.0006745474,"threshold_uncertainty_score":0.9702644},"labels":[],"label_agreement":null},{"id":"W3107254051","doi":"10.2217/fon-2020-0655","title":"Dostarlimab in the Treatment of Recurrent or Primary Advanced Endometrial Cancer","year":2020,"lang":"en","type":"review","venue":"Future Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Microsatellite instability; Endometrial cancer; Medicine; DNA mismatch repair; Oncology; Internal medicine; Immune checkpoint; Immune system; Cancer; Cancer research; Immunotherapy; Microsatellite; Immunology; Gene; Genetics; Biology","score_opus":0.08592308035728641,"score_gpt":0.4281559395685617,"score_spread":0.3422328592112753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107254051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024742501,0.98872644,6.9412675e-7,0.0015030751,0.002585432,0.0035053387,0.00032753398,0.000021492404,0.0033052724],"genre_scores_gemma":[0.000010499845,0.99273556,0.0002780322,0.0004125524,0.0041740187,0.0017192198,0.0004249514,0.00004248541,0.00020265738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719715,0.00057790667,0.0009411729,0.0005412311,0.00037667088,0.00036588148],"domain_scores_gemma":[0.9973606,0.0014904799,0.0005394685,0.00040407816,0.00005789425,0.00014752094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019453226,0.0005164232,0.004220629,0.00037209634,0.000033216973,0.0000061998876,0.00026132344,0.000499611,0.00067609135],"category_scores_gemma":[0.0001554322,0.0002286466,0.00081605336,0.0019108132,0.00007582454,0.000025677085,0.000039041795,0.00045725348,0.000030354291],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053038667,0.0018896855,0.0000102557915,0.004888176,0.0006055539,0.000637543,0.00032403768,5.9365643e-8,6.2990216e-7,0.000028034909,0.0005424482,0.9857697],"study_design_scores_gemma":[0.013880795,0.01563278,0.000050642808,0.0019285576,0.0030334925,0.000102441896,0.000093023555,9.0329365e-8,0.0000020451348,0.0000064870633,0.96509725,0.00017240136],"about_ca_topic_score_codex":0.000091382506,"about_ca_topic_score_gemma":0.00028733807,"teacher_disagreement_score":0.9855973,"about_ca_system_score_codex":0.0026404446,"about_ca_system_score_gemma":0.002197772,"threshold_uncertainty_score":0.9323938},"labels":[],"label_agreement":null},{"id":"W3119071615","doi":"10.2217/fon-2020-1048","title":"MOMENTUM: Momelotinib Vs Danazol in Patients with Myelofibrosis Previously Treated with JAKi Who Are Symptomatic and Anemic","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); Princess Margaret Cancer Centre","funders":"Medical Research Council; Cancer Research UK","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Anemia; Constitutional symptoms; Internal medicine; Bone marrow","score_opus":0.005068712736830131,"score_gpt":0.23042734607706353,"score_spread":0.2253586333402334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119071615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933943,0.00066046196,0.0000026728671,0.0031219753,0.0000623553,0.0012214462,0.000030435018,0.000049142414,0.0014572127],"genre_scores_gemma":[0.99644923,0.00045194526,0.00093128486,0.00087011314,0.0001236921,0.00036909978,0.00025727597,0.000046534395,0.0005008243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982703,0.00014308063,0.0003318794,0.00057062507,0.0002698331,0.00041428691],"domain_scores_gemma":[0.9989155,0.00012299661,0.00019354693,0.00032636742,0.00021778207,0.00022380691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007215623,0.0003420924,0.0009685581,0.00014720624,0.00008330367,0.000024406687,0.00005485377,0.000203524,0.00018651297],"category_scores_gemma":[0.000029376748,0.0002201206,0.000042216907,0.00042497853,0.000091675254,0.000080230624,0.00004501418,0.00023157788,0.00001449291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015119945,0.0015159528,0.98887336,0.00022972956,0.0002930254,0.00062730146,0.00084060594,0.000003500581,0.00004273865,0.00009363507,0.0011906727,0.0047774767],"study_design_scores_gemma":[0.014857665,0.0067542754,0.97137296,0.0009168236,0.0003685386,0.00015853217,0.0005917839,0.000020560788,0.0009031663,0.000007978944,0.003811434,0.00023628066],"about_ca_topic_score_codex":0.00003203894,"about_ca_topic_score_gemma":0.0006445913,"teacher_disagreement_score":0.017500406,"about_ca_system_score_codex":0.0003696101,"about_ca_system_score_gemma":0.00024878734,"threshold_uncertainty_score":0.8976257},"labels":[],"label_agreement":null},{"id":"W3120514166","doi":"10.2217/fon-2020-0544","title":"Prognostic Significance of <i>CTNNB1</i> Mutation in Recurrence of Sporadic Desmoid Tumors","year":2021,"lang":"en","type":"review","venue":"Future Oncology","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mutation; Internal medicine; Cochrane Library; Odds ratio; Oncology; Meta-analysis; Pathology; Gastroenterology; Genetics; Gene; Biology","score_opus":0.04797565248730175,"score_gpt":0.3812897989768649,"score_spread":0.33331414648956315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120514166","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006944292,0.9952897,0.000007769839,0.00012990813,0.00076999486,0.001767455,0.00005532436,0.000024548193,0.0012608998],"genre_scores_gemma":[0.0015115466,0.99563366,0.0015665336,0.000038771854,0.0005203779,0.0003238195,0.00026043487,0.000047365695,0.0000974734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99725455,0.00040147908,0.0012576903,0.00050492055,0.00028211082,0.00029923933],"domain_scores_gemma":[0.9972182,0.0009031395,0.0011143889,0.00040377525,0.00027840224,0.00008210308],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043600626,0.0003741673,0.004018305,0.00035923178,0.000019719853,0.0000019032398,0.00016850971,0.00040353552,0.00008854742],"category_scores_gemma":[0.0010968354,0.00031904396,0.00033294127,0.0011831776,0.0003163707,0.000028285951,0.00007381709,0.0006838947,0.000014115157],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060302867,0.00046346564,0.001186671,0.049188156,0.00020909676,0.0042008,0.00063302426,6.2356906e-7,0.0000100784655,0.00027183644,0.0013944473,0.9423815],"study_design_scores_gemma":[0.0007964045,0.0012765506,0.00121289,0.035757657,0.0016166948,0.0018913238,0.0006129147,6.507354e-7,0.00003009974,0.00003015452,0.95650524,0.00026943148],"about_ca_topic_score_codex":0.000035545057,"about_ca_topic_score_gemma":0.000070861475,"teacher_disagreement_score":0.9551108,"about_ca_system_score_codex":0.0003453828,"about_ca_system_score_gemma":0.0022961851,"threshold_uncertainty_score":0.99992615},"labels":[],"label_agreement":null},{"id":"W3133493210","doi":"10.2217/fon-2020-1274","title":"Molecular and Morphological Changes Induced by Ivosidenib Correlate with Efficacy in Mutant- <i>IDH1</i> Cholangiocarcinoma","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Agios Pharmaceuticals","keywords":"IDH1; Isocitrate dehydrogenase; Medicine; Cancer research; Intrahepatic Cholangiocarcinoma; Downregulation and upregulation; Mutant; Internal medicine; Oncology; Biology; Gene; Enzyme; Genetics","score_opus":0.014789206426278585,"score_gpt":0.2702181729730269,"score_spread":0.25542896654674835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133493210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96230835,0.012839368,0.0000073556403,0.02001552,0.00028663987,0.00033858427,0.000011363432,0.000052908308,0.0041398993],"genre_scores_gemma":[0.9930595,0.0005093362,0.00024884538,0.0055688415,0.0003255523,0.00006110774,0.000059938055,0.000030679537,0.0001361699],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99850255,0.00012094515,0.00020898228,0.00055785687,0.00019330114,0.0004163523],"domain_scores_gemma":[0.99927866,0.00009860549,0.00007528012,0.0002789981,0.000092864095,0.0001755859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001114401,0.00025886908,0.0006470482,0.00009677939,0.0000649279,0.000017368908,0.000077789,0.00033718537,0.000073703115],"category_scores_gemma":[0.00005221866,0.00019722829,0.0000617372,0.00036188605,0.00012367385,0.000037094716,0.00011715022,0.0005726221,0.000011475479],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018850912,0.0012358576,0.12398814,0.00013810828,0.0004684309,0.039133474,0.002985081,0.0000019757797,0.7944957,0.00040514758,0.010077791,0.025185201],"study_design_scores_gemma":[0.016001383,0.004124451,0.8501033,0.00016853184,0.00042145382,0.008219446,0.002441994,0.0000122250385,0.04436689,0.000034489756,0.07352575,0.0005800976],"about_ca_topic_score_codex":0.000057096582,"about_ca_topic_score_gemma":0.0004553935,"teacher_disagreement_score":0.7501288,"about_ca_system_score_codex":0.00013574368,"about_ca_system_score_gemma":0.00017374537,"threshold_uncertainty_score":0.80427366},"labels":[],"label_agreement":null},{"id":"W3134027539","doi":"10.2217/fon-2020-1264","title":"CDK4/6 Inhibitors in HR+/HER2- Advanced/metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies","year":2021,"lang":"en","type":"review","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; Oncology; Metastatic breast cancer; Internal medicine; Breast cancer; Trastuzumab; Real world evidence; Cancer; Gynecology","score_opus":0.061872516632544144,"score_gpt":0.45566446360252355,"score_spread":0.39379194696997943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134027539","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000016964951,0.9889974,0.000002831855,0.0027600876,0.0022002012,0.005445968,0.00025892243,0.000072263254,0.00026060943],"genre_scores_gemma":[0.0000018595275,0.9905137,0.0018030489,0.001102822,0.0015964234,0.0035527851,0.00014392188,0.0001614059,0.0011240523],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99233884,0.0018674157,0.0031909521,0.0011733292,0.00070941966,0.0007200618],"domain_scores_gemma":[0.99288094,0.0016428994,0.0027765587,0.0013325098,0.0011365263,0.00023059375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012666403,0.001164902,0.013878906,0.0008266321,0.000061719504,0.000016104834,0.00049156934,0.0004915995,0.00019832568],"category_scores_gemma":[0.00082208315,0.00081155077,0.0011318253,0.00390862,0.0003085603,0.00026108566,0.00024718206,0.001697328,0.000018028579],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006192512,0.00013220833,0.0000101737005,0.59887075,0.000842752,0.00084152207,0.00032803457,6.587494e-7,0.0000012619238,0.00009184145,0.0011600681,0.3976588],"study_design_scores_gemma":[0.0004992508,0.00019011767,0.0000105146955,0.5758204,0.0033596023,0.0020945303,0.00034519073,1.6288276e-7,7.59632e-7,0.000012788733,0.41734427,0.00032239876],"about_ca_topic_score_codex":0.000035774752,"about_ca_topic_score_gemma":0.0006079005,"teacher_disagreement_score":0.41618422,"about_ca_system_score_codex":0.003433783,"about_ca_system_score_gemma":0.003160235,"threshold_uncertainty_score":0.9994335},"labels":[],"label_agreement":null},{"id":"W3134053447","doi":"10.2217/fon-2020-1210","title":"Role of Cedazuridine/Decitabine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia","year":2021,"lang":"en","type":"review","venue":"Future Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Decitabine; Medicine; Chronic myelomonocytic leukemia; Azacitidine; Myelodysplastic syndromes; Oncology; International Prognostic Scoring System; Internal medicine; Pharmacology; Bone marrow; DNA methylation","score_opus":0.025056787831958822,"score_gpt":0.34893973370480036,"score_spread":0.32388294587284155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134053447","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015764269,0.9908758,0.0000050430494,0.000299496,0.00020170929,0.0019120021,0.000037601516,0.0000134713755,0.005078492],"genre_scores_gemma":[0.0011272336,0.9966202,0.0007376362,0.00004667026,0.00044004305,0.00028863552,0.00020198844,0.00006770244,0.00046991822],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966464,0.0005530251,0.0011322871,0.0006116252,0.0005014153,0.0005552675],"domain_scores_gemma":[0.9976426,0.00071432325,0.000501074,0.0008983252,0.0001208112,0.00012290738],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008780507,0.000483328,0.003488232,0.000552112,0.000038521437,0.0000088401475,0.0005622086,0.00074827764,0.00020092064],"category_scores_gemma":[0.00006532305,0.00031491683,0.00036877426,0.0011739058,0.00030824676,0.00003808419,0.0004308884,0.0013735157,0.000025348592],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000802444,0.00018955157,0.0000076189685,0.06405232,0.0011374288,0.003545107,0.00025148955,0.000002724602,0.000018874442,0.0033601674,0.0010356229,0.9263188],"study_design_scores_gemma":[0.002109753,0.0014083547,0.0004555416,0.015061429,0.0024447825,0.0053281677,0.0009101006,0.0000282181,0.0000046192704,0.00004461825,0.971975,0.00022939206],"about_ca_topic_score_codex":0.0000330808,"about_ca_topic_score_gemma":0.000039897757,"teacher_disagreement_score":0.9709394,"about_ca_system_score_codex":0.003281869,"about_ca_system_score_gemma":0.0040578917,"threshold_uncertainty_score":0.99993026},"labels":[],"label_agreement":null},{"id":"W3134403963","doi":"10.2217/fon-2020-1269","title":"Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Oncology; Refractory (planetary science); Carfilzomib; Internal medicine; Pomalidomide","score_opus":0.050819269986887,"score_gpt":0.3395705788726691,"score_spread":0.2887513088857821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134403963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944088,0.00025460214,0.00018870113,0.0013416512,0.00024667082,0.0018178455,0.000016628252,0.000040121227,0.0016849855],"genre_scores_gemma":[0.9942689,0.000056104494,0.0040055728,0.00022516944,0.00014254703,0.00024943193,0.00018240945,0.000037810805,0.0008320652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976762,0.00047868316,0.00038043846,0.0005365901,0.00041486748,0.0005131978],"domain_scores_gemma":[0.99880254,0.00038210413,0.00010495365,0.00036309476,0.00015566176,0.0001916246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044944594,0.00023794212,0.00057282107,0.00034670596,0.000065737404,0.000013901847,0.000113635295,0.0002548287,0.00018913565],"category_scores_gemma":[0.00027177672,0.00019208969,0.00004728402,0.00061331387,0.000056192992,0.000077305776,0.00008051984,0.0006279177,0.000052383628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052652573,0.022218524,0.9288791,0.000055422537,0.00021824839,0.014245482,0.0019888857,0.000042076448,0.0029344184,0.000053116488,0.00068273017,0.02341676],"study_design_scores_gemma":[0.056275494,0.005217661,0.9297489,0.000083056344,0.000055345736,0.00027255568,0.0029008547,0.00056630274,0.0007360177,0.000014280929,0.00396691,0.00016262503],"about_ca_topic_score_codex":0.00033762134,"about_ca_topic_score_gemma":0.0072991704,"teacher_disagreement_score":0.05101024,"about_ca_system_score_codex":0.0008829897,"about_ca_system_score_gemma":0.00071223977,"threshold_uncertainty_score":0.783319},"labels":[],"label_agreement":null},{"id":"W3156107342","doi":"10.2217/fon-2021-0284","title":"Health-Related Quality of Life and Pain with Selinexor in Patients with Advanced Dedifferentiated Liposarcoma","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Karyopharm Therapeutics","keywords":"Medicine; Quality of life (healthcare); Liposarcoma; Intensive care medicine; MEDLINE; Pathology; Nursing; Sarcoma","score_opus":0.01391288335984998,"score_gpt":0.28914602250048677,"score_spread":0.2752331391406368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156107342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98683953,0.003569974,0.000011571491,0.008899785,0.000078704266,0.00046102065,0.00001721323,0.000021749856,0.000100453915],"genre_scores_gemma":[0.9958372,0.00016881055,0.002332697,0.0013017646,0.00003789203,0.00003983919,0.0002449404,0.00001716277,0.000019681693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842155,0.00045198892,0.00045059755,0.00028709177,0.00017080667,0.00021796409],"domain_scores_gemma":[0.99897075,0.00022799142,0.00023656516,0.00021173854,0.00018473333,0.00016821583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025025188,0.00015140417,0.0007752457,0.00007182647,0.000029830182,0.0000029119465,0.000029865312,0.00013130798,0.000060000937],"category_scores_gemma":[0.00011112118,0.000097614015,0.00003155086,0.00027551746,0.0000611226,0.000026825865,0.00002355109,0.0001806231,0.000001302514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022305246,0.0029355616,0.9418656,0.00013054073,0.00018793199,0.00008388367,0.00033293184,0.0000019478173,0.000029268274,0.000111136804,0.00020546568,0.05188516],"study_design_scores_gemma":[0.017178401,0.0039383653,0.9769439,0.00014739437,0.000046680423,0.000016726823,0.00038808768,0.00000974358,0.00006551741,0.000015967316,0.001156697,0.000092507835],"about_ca_topic_score_codex":0.00014104383,"about_ca_topic_score_gemma":0.0021392498,"teacher_disagreement_score":0.051792655,"about_ca_system_score_codex":0.00012490094,"about_ca_system_score_gemma":0.0004406741,"threshold_uncertainty_score":0.39805838},"labels":[],"label_agreement":null},{"id":"W3159545343","doi":"10.2217/fon-2021-0153","title":"Real-World Genetic Testing Patterns in Metastatic Castration-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck Sharp and Dohme","keywords":"Medicine; FANCA; PALB2; Prostate cancer; Oncology; Genetic testing; Internal medicine; Cancer; DNA repair; Gene; Mutation; Fanconi anemia; Genetics; Germline mutation","score_opus":0.0559407481845942,"score_gpt":0.38897862257168647,"score_spread":0.33303787438709226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159545343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98024774,0.0028567147,0.000005747272,0.007832441,0.00042246736,0.00061936653,0.000068143054,0.00003780513,0.007909553],"genre_scores_gemma":[0.9807584,0.002425174,0.005849065,0.0005777416,0.00075510994,0.00041724357,0.00016220362,0.00003893109,0.009016085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985793,0.00017035386,0.00030280376,0.00034184757,0.00020323157,0.00040243653],"domain_scores_gemma":[0.99921834,0.0001586523,0.000076689226,0.00020430304,0.00020549473,0.00013653302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016394659,0.00014639094,0.00035975873,0.00015080707,0.00006332335,0.000018064993,0.00005323199,0.000064496584,0.00052014255],"category_scores_gemma":[0.00006143994,0.00011533868,0.00004647977,0.00059542584,0.000048692465,0.000040470557,0.00003896688,0.00029670296,0.000016768738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013614069,0.0008426367,0.7506262,0.0007646057,0.00030622797,0.030041689,0.0025077595,0.00009922433,0.059343997,0.0002734513,0.0024005251,0.15143225],"study_design_scores_gemma":[0.004233366,0.0005401294,0.9706986,0.00023512877,0.00014051615,0.0001508881,0.0012487225,0.00015625937,0.00400689,0.00015234556,0.018277386,0.00015980355],"about_ca_topic_score_codex":0.0014265752,"about_ca_topic_score_gemma":0.02863272,"teacher_disagreement_score":0.22007234,"about_ca_system_score_codex":0.0006490545,"about_ca_system_score_gemma":0.0019067733,"threshold_uncertainty_score":0.98909223},"labels":[],"label_agreement":null},{"id":"W3185533154","doi":"10.2217/fon-2021-0370","title":"Prediction and Characterization of Diffuse Large B-Cell Lymphoma Cell-of-Origin Subtypes Using Targeted Sequencing","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Foundation Medicine; H. Lundbeck A/S; Amgen; TG Therapeutics; Genentech; Celgene; F. Hoffmann-La Roche","keywords":"Exome sequencing; Somatic cell; DNA sequencing; Germinal center; Carcinogenesis; Diffuse large B-cell lymphoma; Biology; Ion semiconductor sequencing; Computational biology; Cell of origin; Germline mutation; Genetics; Cell; DNA; Mutation; Gene; B cell; Antibody","score_opus":0.018923713725034052,"score_gpt":0.262826755363928,"score_spread":0.24390304163889398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185533154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728304,0.0010306439,0.00007121759,0.00020097401,0.00046079615,0.00017701136,0.00010200356,0.000018969087,0.0006553173],"genre_scores_gemma":[0.99729764,0.0005963825,0.001166246,0.00014091372,0.00029395544,0.000008200107,0.00036685934,0.0000136415665,0.00011612835],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992121,0.000069475995,0.00026252365,0.00019915227,0.000108633576,0.00014815573],"domain_scores_gemma":[0.9994156,0.00004137379,0.00018930504,0.0001486319,0.00013817642,0.000066949484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000076815806,0.000109560184,0.00034890854,0.000071939845,0.00004310942,0.000004003524,0.000022304745,0.00018086754,0.00005339899],"category_scores_gemma":[0.000013540016,0.00009379905,0.000055625515,0.00015581638,0.000031327905,0.000054279408,0.000029063249,0.00004121023,0.0000014972517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014148025,0.002856574,0.121949375,0.000227644,0.00006961385,0.00015657359,0.00078955817,9.3191215e-7,0.87055373,0.00017130261,0.00006351331,0.0030196963],"study_design_scores_gemma":[0.015882762,0.0007183121,0.3158842,0.00010082393,0.00043144877,0.00018484502,0.0005570407,0.0006963433,0.65102535,0.000013385803,0.014399181,0.00010631163],"about_ca_topic_score_codex":0.00003864184,"about_ca_topic_score_gemma":0.00001517878,"teacher_disagreement_score":0.21952839,"about_ca_system_score_codex":0.00028646318,"about_ca_system_score_gemma":0.00045122582,"threshold_uncertainty_score":0.38250142},"labels":[],"label_agreement":null},{"id":"W3189019461","doi":"10.2217/fon-2021-0252","title":"Risk of Arterial and Venous Thromboembolic Events Among Patients with Colorectal Carcinoma: a Real-World, Population-Based Study","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Daiichi-Sankyo","keywords":"Medicine; Bevacizumab; Internal medicine; Colorectal cancer; Comorbidity; Odds ratio; Population; Cancer registry; Incidence (geometry); Cancer; Oncology; Surgery; Chemotherapy","score_opus":0.006466433573509313,"score_gpt":0.2577060622099712,"score_spread":0.25123962863646193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189019461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965864,0.000050602044,0.0000039380348,0.00015824278,0.00061973796,0.001293386,0.000039639814,0.00003173071,0.0012163587],"genre_scores_gemma":[0.9987664,0.000027330034,0.0003299821,0.00013505688,0.0003689481,0.00009445825,0.00021670507,0.00003098447,0.00003012037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984591,0.00023875138,0.00035243607,0.0003969137,0.0002893038,0.00026349947],"domain_scores_gemma":[0.9990152,0.000069347465,0.00028390426,0.00030101938,0.00020187278,0.00012863301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015260489,0.00020240973,0.0009113645,0.00014836472,0.000117507254,0.00000874546,0.00006416313,0.0001154087,0.00014304528],"category_scores_gemma":[0.000037219823,0.00016317973,0.00006875083,0.00028671385,0.000053308693,0.000046916513,0.0000667084,0.00017949696,0.0000032823607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047275296,0.0077021043,0.98844403,0.0000736228,0.0002989412,0.00010683527,0.0009454556,0.000014064231,0.000036566613,0.000083533036,0.00026424145,0.0015578513],"study_design_scores_gemma":[0.008135388,0.005469427,0.9839892,0.000039583472,0.0010268835,0.000003031284,0.0006592944,0.000017945014,0.00004924267,0.000028608078,0.00043578426,0.0001456496],"about_ca_topic_score_codex":0.0019165606,"about_ca_topic_score_gemma":0.010597389,"teacher_disagreement_score":0.008680829,"about_ca_system_score_codex":0.00017953795,"about_ca_system_score_gemma":0.00022855095,"threshold_uncertainty_score":0.6654276},"labels":[],"label_agreement":null},{"id":"W3194698214","doi":"10.2217/fon-2021-0087","title":"The Impact of the Host Intestinal Microbiome on Carcinogenesis and the Response to Chemotherapy","year":2021,"lang":"en","type":"review","venue":"Future Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"IWK Health Centre","keywords":"Microbiome; Medicine; Intestinal Microbiome; Colorectal cancer; Dysbiosis; Antibiotics; Cancer; Disease; Fecal bacteriotherapy; Gut microbiome; Probiotic; Inflammatory bowel disease; Immunology; Bioinformatics; Internal medicine; Biology; Microbiology; Genetics; Bacteria","score_opus":0.015339263636311572,"score_gpt":0.3617463239256036,"score_spread":0.346407060289292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194698214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015007214,0.9794707,0.0000019593965,0.0037986103,0.0004827721,0.0009640478,0.00010964998,0.0000033488157,0.0001617387],"genre_scores_gemma":[0.00093340466,0.99641484,0.00005332385,0.0010028855,0.0007264046,0.000066041044,0.00004361746,0.000042199787,0.0007173109],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973319,0.0014903265,0.0003916094,0.0003963896,0.000069329515,0.00032043236],"domain_scores_gemma":[0.9982683,0.00038749364,0.00033106952,0.0008265996,0.00010870945,0.000077821634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091356266,0.0003358903,0.00089875865,0.000045639194,0.00025553093,0.000024284524,0.00060161296,0.00049087376,0.000015826532],"category_scores_gemma":[0.00019903312,0.00013250903,0.0006329265,0.00025345123,0.00037181107,6.337872e-7,0.00027624686,0.00035783937,0.00000581928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006008555,0.00020628223,0.000055292796,0.0013575322,0.0012085758,0.000017343289,0.00064091384,0.0000017185754,0.16808568,0.0003373611,0.0731232,0.7489576],"study_design_scores_gemma":[0.0006232625,0.0008479785,0.000990486,0.00048241558,0.00012673516,0.0003776972,0.00006144153,8.101427e-8,0.00043789804,0.0000022550723,0.9959067,0.00014305438],"about_ca_topic_score_codex":0.000062133135,"about_ca_topic_score_gemma":0.00009897996,"teacher_disagreement_score":0.9227835,"about_ca_system_score_codex":0.00016936926,"about_ca_system_score_gemma":0.0019508973,"threshold_uncertainty_score":0.54035616},"labels":[],"label_agreement":null},{"id":"W3194931280","doi":"10.2217/fon-2021-0575","title":"Relugolix, An Oral Gonadotropin-Releasing Hormone Antagonist for the Treatment of Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Prostate cancer; Testosterone (patch); Gonadotropin-releasing hormone antagonist; Hormone antagonist; Internal medicine; Androgen deprivation therapy; Antagonist; Gonadotropin-releasing hormone; Endocrinology; Androgen; Agonist; Urology; Leuprorelin; Hormone; Cancer; Luteinizing hormone; Receptor","score_opus":0.04279694177607753,"score_gpt":0.39304045283617983,"score_spread":0.3502435110601023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194931280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88749033,0.07123756,0.00005509846,0.037452042,0.00097562704,0.0017749922,0.00024246027,0.00004314779,0.0007287237],"genre_scores_gemma":[0.81394243,0.16099529,0.003808236,0.0011491493,0.004093956,0.0014552831,0.00080560084,0.0000964361,0.013653604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891144,0.00009309168,0.0002131422,0.0002845379,0.00014853977,0.0003492509],"domain_scores_gemma":[0.9990825,0.00012356612,0.000084340696,0.00031294898,0.00027340328,0.0001232586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007677958,0.00015364545,0.00041590413,0.000042388794,0.00018019507,0.000013492865,0.00006789358,0.00012934739,0.0000975922],"category_scores_gemma":[0.000016456943,0.00008564557,0.0001342811,0.00017951961,0.00017268656,0.000041476673,0.00001735874,0.00011006013,0.000003440468],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01096189,0.0035723953,0.011320353,0.00021405205,0.0012737066,0.0006299177,0.004660785,0.00001879006,0.072739154,0.001347886,0.0103900805,0.882871],"study_design_scores_gemma":[0.0105767455,0.008630226,0.035844512,0.000030880292,0.00043427158,0.00010252675,0.002133428,0.00016537461,0.01876773,0.00012171691,0.92307395,0.00011865361],"about_ca_topic_score_codex":0.00034475498,"about_ca_topic_score_gemma":0.00052251015,"teacher_disagreement_score":0.91268384,"about_ca_system_score_codex":0.0005790001,"about_ca_system_score_gemma":0.0011756124,"threshold_uncertainty_score":0.34925252},"labels":[],"label_agreement":null},{"id":"W3195219055","doi":"10.2217/fon-2021-0598","title":"Clinical Activity and Safety of the Anti-PD-1 Monoclonal Antibody Dostarlimab for Patients with Recurrent or Advanced dMMR Endometrial Cancer","year":2021,"lang":"en","type":"letter","venue":"Future Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Endometrial cancer; Internal medicine; Regimen; Oncology; Microsatellite instability; Clinical trial; Cancer; DNA mismatch repair; Colorectal cancer","score_opus":0.03426658383925036,"score_gpt":0.38266468537824544,"score_spread":0.3483981015389951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195219055","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5653217,0.0061931796,0.00007076461,0.39329728,0.021403188,0.007865027,0.005069523,0.00005310878,0.0007262299],"genre_scores_gemma":[0.26090708,0.05021228,0.0135834,0.5219901,0.12986706,0.0031296224,0.013321486,0.0007619886,0.006226983],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969544,0.00047684202,0.0007259301,0.0008111774,0.00055038795,0.00048129616],"domain_scores_gemma":[0.9961227,0.0019836468,0.00079823076,0.00048312164,0.00047158787,0.00014070106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030680612,0.0004550722,0.0020437604,0.00015791062,0.0001215213,0.000011024486,0.00020715538,0.0011554208,0.0003758029],"category_scores_gemma":[0.00066343095,0.00023176848,0.00046170803,0.0006373246,0.00028364666,0.000055927096,0.00017008632,0.001615325,0.0000010115026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13982175,0.0033256987,0.15086548,0.0017539619,0.0033846155,0.00028797254,0.0000955588,0.0000010863287,0.00012545448,0.0000124257895,0.120735064,0.5795909],"study_design_scores_gemma":[0.043170895,0.008214966,0.16957743,0.0003883168,0.0013484237,0.000019027118,0.00001697366,0.0000020173848,0.00007086073,0.000008967295,0.7769375,0.00024464173],"about_ca_topic_score_codex":0.00007046356,"about_ca_topic_score_gemma":0.00019713979,"teacher_disagreement_score":0.65620244,"about_ca_system_score_codex":0.00044863447,"about_ca_system_score_gemma":0.0014053391,"threshold_uncertainty_score":0.94512445},"labels":[],"label_agreement":null},{"id":"W3195595411","doi":"10.2217/fon-2021-0608","title":"Brigatinib Versus Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3)","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Alectinib; Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; Oncology; Internal medicine","score_opus":0.010820770635600545,"score_gpt":0.3412207235650259,"score_spread":0.33039995292942537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195595411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9163586,0.0064115524,0.00007601746,0.0048854994,0.003986602,0.0009586391,0.00017056371,0.00007457573,0.067077935],"genre_scores_gemma":[0.98957145,0.00059804285,0.003674101,0.001482462,0.001070269,0.00046406785,0.00036062463,0.000063453415,0.0027155227],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982292,0.00011133646,0.00037850311,0.0005810018,0.00018968507,0.0005102896],"domain_scores_gemma":[0.99873185,0.00032193869,0.00016198492,0.00029991276,0.00026327532,0.00022104756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007563888,0.00028007966,0.00057905057,0.00013150055,0.00013706047,0.000018147193,0.0000912416,0.00025002373,0.00046457408],"category_scores_gemma":[0.0000861867,0.000256496,0.00012967565,0.0005617532,0.00006616612,0.00007044878,0.000050526636,0.0002538025,0.000027186517],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051506534,0.013993863,0.05569296,0.0026333511,0.0051308065,0.034282003,0.029070463,0.0013210508,0.12174693,0.0032020465,0.033675548,0.6477445],"study_design_scores_gemma":[0.13944302,0.010280994,0.5171286,0.0015716112,0.0045548114,0.00037508033,0.015586161,0.0008899372,0.04966525,0.00008978023,0.25895023,0.001464483],"about_ca_topic_score_codex":0.0003903978,"about_ca_topic_score_gemma":0.006790307,"teacher_disagreement_score":0.64628,"about_ca_system_score_codex":0.0015806122,"about_ca_system_score_gemma":0.0029126524,"threshold_uncertainty_score":0.99998873},"labels":[],"label_agreement":null},{"id":"W3197275659","doi":"10.2217/fon-2021-0856","title":"The Importance and Value of Engaging Patients in Cancer Research","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Future Earth","funders":"","keywords":"Medicine; Value (mathematics); Cancer; Oncology; Internal medicine; Statistics","score_opus":0.047100962230293676,"score_gpt":0.33322040555019083,"score_spread":0.28611944331989714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197275659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93816185,0.019637888,0.0000064150936,0.005085628,0.00085737393,0.00011169967,0.000044683657,0.000003492663,0.036090955],"genre_scores_gemma":[0.9875442,0.011031602,0.00014565513,0.00041263865,0.00032364167,0.00003191499,0.0000038024684,0.000011280324,0.0004952589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989629,0.00005322715,0.0004237545,0.00024294727,0.000025737492,0.0002914451],"domain_scores_gemma":[0.99928015,0.00020340219,0.00019049065,0.00019098507,0.00008920052,0.000045757606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009934001,0.000068595735,0.00028983908,0.000085068474,0.00012099773,0.000019342138,0.00013348852,0.00012365101,0.00009512178],"category_scores_gemma":[0.00027947032,0.00006435219,0.000032586242,0.00021407282,0.00014177879,0.000098821314,0.00008707561,0.00032265933,0.000012878105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029300403,0.000054840173,0.683409,0.000014206525,0.0000134729835,0.0000048984757,0.0005925642,0.000007429524,0.000010803259,0.29647756,0.002236941,0.017149001],"study_design_scores_gemma":[0.0005454423,0.000064639054,0.5574367,0.000010032017,0.0000010882201,0.0000010372422,0.00034276253,0.000036620553,0.00006717664,0.022856902,0.41857105,0.0000665265],"about_ca_topic_score_codex":0.0004814762,"about_ca_topic_score_gemma":0.0033241126,"teacher_disagreement_score":0.41633412,"about_ca_system_score_codex":0.0002480155,"about_ca_system_score_gemma":0.00016852621,"threshold_uncertainty_score":0.26242062},"labels":[],"label_agreement":null},{"id":"W3207977249","doi":"10.2217/fon-2021-0753","title":"Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Placebo; Randomized controlled trial; Cancer; Pathology","score_opus":0.015681021701659328,"score_gpt":0.3375341293603767,"score_spread":0.3218531076587174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207977249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91118807,0.0019306097,0.000007266065,0.07021521,0.0011990875,0.0017419744,0.00047432844,0.00007339235,0.013170065],"genre_scores_gemma":[0.9823472,0.0010141588,0.002266835,0.0073107975,0.0026868444,0.00065525906,0.0005041093,0.00015025637,0.00306455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963145,0.0006394681,0.0004947261,0.0008863491,0.0007588301,0.00090610376],"domain_scores_gemma":[0.99738306,0.0004071369,0.00019292682,0.000608436,0.0010200749,0.00038838433],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039613908,0.00037085626,0.0008729729,0.00014363922,0.00010730826,0.000029942259,0.00027725066,0.00042612912,0.002357787],"category_scores_gemma":[0.0001818849,0.00030874237,0.00007709822,0.0007468939,0.00027247006,0.00011931375,0.00018034961,0.0012458189,0.00014702666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010259191,0.0024698174,0.8467549,0.00036669624,0.00040407528,0.003564176,0.0028631776,0.000038074217,0.0010060072,0.00020047737,0.08439041,0.04768297],"study_design_scores_gemma":[0.0100707635,0.0018665749,0.9242729,0.000782846,0.00008981108,0.00030314896,0.0013195631,0.0000072176204,0.0016632008,0.000021307018,0.05924932,0.00035337172],"about_ca_topic_score_codex":0.0008689594,"about_ca_topic_score_gemma":0.014890985,"teacher_disagreement_score":0.07751795,"about_ca_system_score_codex":0.0019776842,"about_ca_system_score_gemma":0.0050058705,"threshold_uncertainty_score":0.99993646},"labels":[],"label_agreement":null},{"id":"W3209015618","doi":"10.2217/fon-2021-1110","title":"The role of Globo H and SSEA-4 in the Development and Progression of Cancer, and their Potential as Therapeutic Targets","year":2021,"lang":"en","type":"review","venue":"Future Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Office of the Chief Medical Examiner","funders":"","keywords":"Glycosylation; Carcinogenesis; Cell biology; Cancer cell; Ceramide; Glycan; Cancer; Embryonic stem cell; Galectin; Cell; Biology; Biochemistry; Glycoprotein; Apoptosis; Gene; Genetics","score_opus":0.01578068486255948,"score_gpt":0.36895346338895224,"score_spread":0.3531727785263928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209015618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005950798,0.99290514,0.0000032839189,0.0002498741,0.000070627124,0.0005471705,0.000011580974,0.0000010122203,0.0002605184],"genre_scores_gemma":[0.010344657,0.9891314,0.000103705854,0.000031367912,0.00012539855,0.00013299732,0.000061363135,0.000010314403,0.000058829162],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888617,0.00033936228,0.0002748215,0.00023523712,0.00010538612,0.00015900195],"domain_scores_gemma":[0.99949443,0.000055034456,0.00017428964,0.00017139176,0.00007097092,0.00003389168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004115538,0.00015665015,0.0004334956,0.00003655919,0.0000769388,0.0000147690325,0.00015874326,0.00032141164,0.000007516306],"category_scores_gemma":[0.000024918147,0.00007505001,0.00005198595,0.00009425379,0.00017563085,0.0000015425254,0.00018040337,0.0001959259,1.7481126e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003878444,0.000037307356,0.000045947112,0.00050397206,0.00008732774,0.0000027570477,0.00027857968,6.7751216e-8,0.0008000942,0.0001755653,0.00003529048,0.9979943],"study_design_scores_gemma":[0.00023300684,0.00023249513,0.00015673258,0.00030490346,0.000031664127,0.000052556417,0.0006978437,0.0000021388619,0.0013607547,0.000051509156,0.9967997,0.00007671321],"about_ca_topic_score_codex":0.00001701465,"about_ca_topic_score_gemma":0.0003337377,"teacher_disagreement_score":0.9979176,"about_ca_system_score_codex":0.000015235184,"about_ca_system_score_gemma":0.0005635352,"threshold_uncertainty_score":0.30604506},"labels":[],"label_agreement":null},{"id":"W3212868920","doi":"10.2217/fon-2021-0592","title":"Patterns of Colorectal Cancer Diagnosis Among Younger Adults in a Real-World, Population-Based Cohort","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Quartile; Colorectal cancer; Population; Odds ratio; Demography; Logistic regression; Retrospective cohort study; Socioeconomic status; Internal medicine; Cohort; Cancer; Confidence interval","score_opus":0.011369034094014989,"score_gpt":0.3020783204879855,"score_spread":0.29070928639397053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212868920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950624,0.00030602622,0.000015452559,0.0014050446,0.001006863,0.00038567832,0.000046836158,0.00005049806,0.0017211718],"genre_scores_gemma":[0.9975347,0.0002441991,0.00024409013,0.0003496382,0.00054746086,0.00070009136,0.00016507549,0.000020257865,0.00019451873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987927,0.00011995152,0.00034020163,0.00033073526,0.00020004789,0.00021635971],"domain_scores_gemma":[0.9992463,0.00015685247,0.00015420586,0.00016604901,0.00018539022,0.000091231464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013705142,0.0001351842,0.0004768169,0.00020718428,0.000034169934,0.0000047687518,0.000046341705,0.0002211755,0.00078437943],"category_scores_gemma":[0.000075159674,0.00012945011,0.00010935908,0.00054344157,0.00002499529,0.00004975609,0.000023950746,0.00028046413,0.0000024323917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028827316,0.00022377075,0.9836411,0.00009384997,0.00005086784,0.00014299736,0.00019442683,0.000065511944,0.00018555351,0.00001929349,0.00039846488,0.012101453],"study_design_scores_gemma":[0.0023144898,0.0010357815,0.98855114,0.00025866792,0.00009995291,0.000014262438,0.00017468067,0.00043033325,0.0043027434,0.000005639633,0.0026960813,0.00011625369],"about_ca_topic_score_codex":0.035090614,"about_ca_topic_score_gemma":0.31971812,"teacher_disagreement_score":0.28462753,"about_ca_system_score_codex":0.0006644943,"about_ca_system_score_gemma":0.00041680646,"threshold_uncertainty_score":0.9713348},"labels":[],"label_agreement":null},{"id":"W4205173478","doi":"10.2217/fon-2021-1096","title":"A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Cabozantinib; Medicine; Atezolizumab; Prostate cancer; Enzalutamide; Oncology; Internal medicine; Clinical trial; Cancer; Nivolumab; Immunotherapy; Androgen receptor","score_opus":0.057886474600819124,"score_gpt":0.3914232047436411,"score_spread":0.333536730142822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205173478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849012,0.0023650108,0.0000031737638,0.00066271255,0.00040163685,0.010246527,0.0005251385,0.000015722455,0.00087886455],"genre_scores_gemma":[0.99411684,0.00031873505,0.00027814138,0.00013372111,0.00006222759,0.0036918246,0.00035192916,0.000040168215,0.0010064116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974299,0.00046978155,0.0006429495,0.00047692488,0.0005393412,0.0004410919],"domain_scores_gemma":[0.99863726,0.00025131414,0.00039333774,0.00031819925,0.0002657612,0.00013411044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008006791,0.00028089387,0.0014014331,0.0002470112,0.00018252722,0.00002384795,0.00024365632,0.000057610137,0.0007242298],"category_scores_gemma":[0.000026211053,0.00018745866,0.000061205195,0.00053884566,0.00013609692,0.00014249979,0.00014994136,0.00046629863,0.0000014125483],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95604444,0.023296535,0.0012160551,0.000043895438,0.0015326635,0.00036484003,0.008037047,0.0000175712,0.0023945104,0.00007664809,0.0005511086,0.006424685],"study_design_scores_gemma":[0.9324665,0.051189624,0.0058668368,0.000022817607,0.00030460622,0.000007738914,0.0054778373,0.00007845699,0.00018507053,0.0000060391585,0.0042082905,0.00018615316],"about_ca_topic_score_codex":0.0019225505,"about_ca_topic_score_gemma":0.0036252849,"teacher_disagreement_score":0.027893089,"about_ca_system_score_codex":0.0008830553,"about_ca_system_score_gemma":0.0021884774,"threshold_uncertainty_score":0.7929808},"labels":[],"label_agreement":null},{"id":"W4205361646","doi":"10.2217/fon-2021-1348","title":"Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?","year":2022,"lang":"en","type":"editorial","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Pembrolizumab; Medicine; Oncology; Lung cancer; Internal medicine; Chemotherapy; MEDLINE; Cancer; Immunotherapy","score_opus":0.009674789902303988,"score_gpt":0.3116780937574068,"score_spread":0.3020033038551028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205361646","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008813682,0.02793482,0.0000043764835,0.041592337,0.91749084,0.0024916674,0.0007789192,0.00010258206,0.0007907559],"genre_scores_gemma":[0.0006158165,0.02334072,0.00046985972,0.000540476,0.95518976,0.002968889,0.0019342786,0.00014917979,0.014791008],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967974,0.0001674357,0.00075522036,0.0009273154,0.0006297117,0.0007229094],"domain_scores_gemma":[0.99826634,0.000294271,0.00039299627,0.0006690278,0.00014498236,0.00023235724],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047147178,0.0006654633,0.0016742668,0.00046591143,0.00016215029,0.000031896558,0.00032310153,0.0014839487,0.0031983058],"category_scores_gemma":[0.0001362219,0.00056186115,0.0005218985,0.0005868645,0.000081539765,0.000050418206,0.00019225212,0.0014724635,0.000013707473],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01650974,0.00076516514,0.00009951593,0.00031367491,0.0007055889,0.0006487923,0.001471473,0.000051420586,0.0010112649,0.0000013294724,0.9431281,0.03529394],"study_design_scores_gemma":[0.013631714,0.0065003484,0.0007028141,0.00033941533,0.0003644777,0.00003309251,0.0004970717,0.000018666698,0.0005612903,7.420376e-7,0.9768678,0.00048256098],"about_ca_topic_score_codex":0.004190784,"about_ca_topic_score_gemma":0.0077120354,"teacher_disagreement_score":0.04105186,"about_ca_system_score_codex":0.011320458,"about_ca_system_score_gemma":0.003397074,"threshold_uncertainty_score":0.9998123},"labels":[],"label_agreement":null},{"id":"W4220676878","doi":"10.2217/fon-2021-1633","title":"Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC","year":2022,"lang":"en","type":"review","venue":"Future Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Meta-analysis; Colorectal cancer; Hazard ratio; Microsatellite instability; Population; Adverse effect; Confidence interval; Cancer; Immunotherapy","score_opus":0.21069128582860736,"score_gpt":0.4535306718627213,"score_spread":0.24283938603411392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220676878","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.3997053e-7,0.98746604,0.000027006243,0.00039398615,0.0006059826,0.008918209,0.0016169458,0.000034440705,0.0009368593],"genre_scores_gemma":[0.000001543534,0.9773116,0.00095247384,0.00032622492,0.0002121702,0.010251074,0.0008812071,0.00007403687,0.009989636],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954857,0.0011045226,0.0018178058,0.00076727127,0.0003335618,0.0004911279],"domain_scores_gemma":[0.99500835,0.0022612328,0.0015768388,0.0007367828,0.00027562896,0.0001411952],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009617743,0.0007419394,0.015643816,0.00049836346,0.00022590302,0.000032945634,0.00024375624,0.0002650809,0.006758743],"category_scores_gemma":[0.0004720293,0.0003567815,0.005156863,0.0025442967,0.00008823388,0.00004241537,0.00020182454,0.00042340293,0.000004159616],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013874926,0.0003736177,2.1758967e-7,0.60060984,0.37057456,0.0001244235,0.00016102323,0.0000036773567,3.1639498e-9,0.00031309915,0.010812411,0.015639637],"study_design_scores_gemma":[0.0012469095,0.0032803684,3.8754285e-7,0.028844498,0.48176348,0.0001037928,0.00008380036,0.0000016162217,8.180819e-9,0.0000024798169,0.4845291,0.0001435455],"about_ca_topic_score_codex":0.000044972472,"about_ca_topic_score_gemma":0.0018875278,"teacher_disagreement_score":0.5717653,"about_ca_system_score_codex":0.00068178296,"about_ca_system_score_gemma":0.00060091517,"threshold_uncertainty_score":0.9998884},"labels":[],"label_agreement":null},{"id":"W4224311311","doi":"10.2217/fon-2022-0045","title":"A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ <i>PIK3CA</i> -mutated breast cancer","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Trastuzumab; Medicine; Fulvestrant; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer; Estrogen receptor","score_opus":0.03373686270539864,"score_gpt":0.405549785522902,"score_spread":0.37181292281750333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224311311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676818,0.0011424931,0.000019535517,0.019319264,0.0036485007,0.0026606305,0.0005486474,0.000087682194,0.0048913946],"genre_scores_gemma":[0.9940339,0.0008403607,0.00018030634,0.0011147232,0.002113022,0.0010661196,0.00014415332,0.00009417443,0.00041325568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99598217,0.00061860005,0.00090651016,0.00068884745,0.00096318586,0.000840676],"domain_scores_gemma":[0.99848807,0.00023387806,0.00027842287,0.0005369681,0.00016633091,0.00029631006],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011146184,0.00035427176,0.001236585,0.0004070307,0.00013456504,0.00001099496,0.00043451868,0.00031336778,0.0065104333],"category_scores_gemma":[0.000044199474,0.00033409445,0.00025916155,0.0012198652,0.00026180962,0.00007151088,0.00010472402,0.0014767476,0.000009070069],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6796848,0.01260008,0.00015944194,0.00016354163,0.0004214453,0.001027281,0.0045396145,0.0001150018,0.013327626,0.000115296745,0.023600336,0.2642455],"study_design_scores_gemma":[0.70637417,0.030401336,0.00094785116,0.00007256244,0.0001685039,0.0005405919,0.004477333,0.00044355416,0.0015750931,0.000025155543,0.25459933,0.0003745366],"about_ca_topic_score_codex":0.001720948,"about_ca_topic_score_gemma":0.0013106656,"teacher_disagreement_score":0.26387098,"about_ca_system_score_codex":0.0030166944,"about_ca_system_score_gemma":0.0041809576,"threshold_uncertainty_score":0.9999111},"labels":[],"label_agreement":null},{"id":"W4254354993","doi":"10.2217/fon.15.340","title":"Addressing Future Challenges for Cancer Services: Part II","year":2016,"lang":"en","type":"article","venue":"Future Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Internal medicine","score_opus":0.08915121470434152,"score_gpt":0.3078357438251544,"score_spread":0.21868452912081288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254354993","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15162775,0.26367962,0.0011510968,0.31730872,0.035793193,0.0015334182,0.0031760256,0.00031112053,0.22541906],"genre_scores_gemma":[0.66833436,0.18606907,0.0044134413,0.019006971,0.09564029,0.0018082798,0.00008445066,0.00031493852,0.024328202],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983626,0.000013351758,0.0005239623,0.00054102286,0.00002180161,0.0005372339],"domain_scores_gemma":[0.99890083,0.00007275077,0.00048592163,0.00033118503,0.00006741553,0.00014191799],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003504264,0.0002261833,0.0006503164,0.0001169766,0.00023079145,0.000023875422,0.00031547472,0.00046672547,0.0011464763],"category_scores_gemma":[0.000024223507,0.000186599,0.00016499856,0.000067126624,0.000071795075,0.00036372247,0.00007750851,0.00012978408,0.0002047177],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020365756,0.000118715274,0.0024895724,0.00016471099,0.00013009986,0.000003926481,0.001571175,0.000002843746,0.000050357332,0.47710323,0.031164518,0.4869972],"study_design_scores_gemma":[0.0014117595,0.00029243733,0.005683013,0.000062297804,0.000011472388,0.0000041787384,0.00030979002,0.000011525278,0.000050742896,0.02077893,0.97108746,0.0002963746],"about_ca_topic_score_codex":0.000058928712,"about_ca_topic_score_gemma":0.001234845,"teacher_disagreement_score":0.939923,"about_ca_system_score_codex":0.00037164558,"about_ca_system_score_gemma":0.00010716132,"threshold_uncertainty_score":0.9997666},"labels":[],"label_agreement":null},{"id":"W4281396346","doi":"10.2217/fon-2021-1629","title":"Targeting <i>FGFR3</i> Alterations with Adjuvant Infigratinib in Invasive Urothelial Carcinoma: the Phase III PROOF 302 Trial","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Helsinn","keywords":"Medicine; Placebo; Clinical endpoint; Tolerability; Metastatic Urothelial Carcinoma; Internal medicine; Oncology; Adjuvant; Bladder cancer; Cisplatin; Urothelial cancer; Urology; Randomized controlled trial; Adverse effect; Urothelial carcinoma; Cancer; Chemotherapy; Pathology","score_opus":0.019136890186583426,"score_gpt":0.3077494896688529,"score_spread":0.28861259948226947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281396346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9618933,0.0012186945,0.00007294672,0.017905654,0.002055048,0.0057369433,0.00023566933,0.00006334408,0.010818395],"genre_scores_gemma":[0.9900642,0.0000266739,0.0002550586,0.003969079,0.00252865,0.0022533692,0.00023159015,0.000033876207,0.0006375278],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825317,0.00034247077,0.00039593948,0.00035605778,0.00030656758,0.0003457995],"domain_scores_gemma":[0.999232,0.00015096125,0.00016829166,0.00028099472,0.000070864015,0.00009687667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027232472,0.00021353149,0.00047276777,0.00010523809,0.00040202375,0.000015431347,0.00015676313,0.000088256085,0.00086309673],"category_scores_gemma":[0.00004671785,0.0001329421,0.00008387653,0.0003583565,0.000093703915,0.00006202995,0.00008184727,0.00063801685,0.000008289813],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63624775,0.019505523,0.026024299,0.00022293128,0.0011932258,0.006531858,0.06946618,0.0011060741,0.023763089,0.003250044,0.15901466,0.05367439],"study_design_scores_gemma":[0.47022337,0.036730893,0.0016056669,0.0000323981,0.00052220054,0.0006462404,0.009059312,0.00017124374,0.0027959538,0.00013704418,0.47767833,0.00039734202],"about_ca_topic_score_codex":0.00028798394,"about_ca_topic_score_gemma":0.001521402,"teacher_disagreement_score":0.3186637,"about_ca_system_score_codex":0.0003802401,"about_ca_system_score_gemma":0.0018459278,"threshold_uncertainty_score":0.9450304},"labels":[],"label_agreement":null},{"id":"W4281565440","doi":"10.2217/fon-2021-1255","title":"Pregnancy and Perinatal Outcomes Following Exposure to Antineoplastic Agents Around Pregnancy within the US FDA Adverse Event Reporting System","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Ipsen; Amgen","keywords":"Medicine; Adverse Event Reporting System; Pregnancy; Abortion; Adverse effect; Obstetrics; Congenital malformations; Pharmacology","score_opus":0.020442522060643835,"score_gpt":0.31510395226613735,"score_spread":0.2946614302054935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281565440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896765,0.002258637,0.000038149425,0.0012046464,0.0047987215,0.0010197574,0.000018656807,0.000083360166,0.00090156967],"genre_scores_gemma":[0.99755204,0.000015979758,0.00019454301,0.00039484922,0.00030071224,0.0002854548,0.000015211153,0.0000346948,0.0012065206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794227,0.00012937225,0.0007849092,0.0004376005,0.00037113007,0.00033474885],"domain_scores_gemma":[0.9986698,0.0000936758,0.0006584937,0.00037863737,0.00003846152,0.00016090713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035933577,0.00022402724,0.0005864072,0.00008885402,0.000456127,0.000015452657,0.00013738532,0.000098096345,0.00007680786],"category_scores_gemma":[0.00022221265,0.00015302944,0.00020055893,0.00022037784,0.000032185966,0.000057624984,0.00027311046,0.00045869124,0.000006950636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018208139,0.00012198795,0.9764359,0.00039197318,0.00029966093,0.004035329,0.005788531,0.00040675377,0.0002559338,0.00028210986,0.0003356851,0.011464058],"study_design_scores_gemma":[0.0033263918,0.002551853,0.9293412,0.001220737,0.00045560085,0.001852932,0.019477736,0.00018012272,0.000034726072,0.000007331167,0.041223306,0.00032809481],"about_ca_topic_score_codex":0.00017193357,"about_ca_topic_score_gemma":0.00019515098,"teacher_disagreement_score":0.04709473,"about_ca_system_score_codex":0.0004648509,"about_ca_system_score_gemma":0.00027787912,"threshold_uncertainty_score":0.62403595},"labels":[],"label_agreement":null},{"id":"W4282970409","doi":"10.2217/fon-2022-0380","title":"A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an <i>in situ</i> vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"National Cancer Institute; Pfizer","keywords":"Medicine; Oncology; Cystectomy; Bladder cancer; Internal medicine; Radiation therapy; Clinical trial; Cisplatin; Neoadjuvant therapy; Immune checkpoint; Chemotherapy; Cancer; Immunotherapy; Breast cancer","score_opus":0.04402021379365379,"score_gpt":0.4166381891270673,"score_spread":0.3726179753334135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282970409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97818524,0.0021605873,0.000011141384,0.010599181,0.0028841256,0.0055400003,0.000074949574,0.000029189463,0.00051557814],"genre_scores_gemma":[0.98986435,0.0012669379,0.0001303595,0.0029090557,0.004456752,0.0008890537,0.00023542908,0.000042029074,0.00020601359],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973736,0.0006167334,0.00093135954,0.00048389754,0.0002681704,0.00032628136],"domain_scores_gemma":[0.9983121,0.0006032025,0.00043321613,0.00043204194,0.00007599318,0.00014342251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001151831,0.0002515893,0.0009839727,0.00014848361,0.00025212814,0.000011225048,0.00016891344,0.00020818443,0.00022546233],"category_scores_gemma":[0.00013302149,0.00017022828,0.00022095614,0.00026173345,0.00003158071,0.00008774545,0.000073047144,0.000469211,0.0000016071575],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81762147,0.012394495,0.0007249918,0.00002152614,0.00029404805,0.00005405147,0.0010919432,0.0000010394763,0.0023894492,0.00010595441,0.004485502,0.16081554],"study_design_scores_gemma":[0.6868937,0.15083925,0.0014563671,0.000007308576,0.0003436689,0.00009508879,0.00031215537,0.00007478007,0.00040886906,0.00018948894,0.15925917,0.00012018166],"about_ca_topic_score_codex":0.0001249967,"about_ca_topic_score_gemma":0.00016436586,"teacher_disagreement_score":0.16069536,"about_ca_system_score_codex":0.0001786526,"about_ca_system_score_gemma":0.0006578189,"threshold_uncertainty_score":0.6941708},"labels":[],"label_agreement":null},{"id":"W4285798648","doi":"10.2217/fon-2022-0450","title":"Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia","year":2022,"lang":"en","type":"review","venue":"Future Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"AbbVie","keywords":"Venetoclax; Medicine; Azacitidine; Myeloid leukemia; Internal medicine; Oncology; Maintenance therapy; Minimal residual disease; Leukemia; Chemotherapy; Chronic lymphocytic leukemia","score_opus":0.07129580869837542,"score_gpt":0.39482913439692097,"score_spread":0.32353332569854554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285798648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019121651,0.98723936,0.000060541224,0.0005504409,0.0011655506,0.008055661,0.00015631123,0.000023275474,0.00083667645],"genre_scores_gemma":[0.0001185558,0.9960525,0.0007368097,0.0002359076,0.00091051514,0.00074843585,0.00013310436,0.000086325446,0.0009778598],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952005,0.0017875197,0.0013045741,0.0006033603,0.00053748494,0.0005665639],"domain_scores_gemma":[0.99696255,0.00096237374,0.0009734917,0.000850975,0.00011353713,0.00013706178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017997718,0.00050310686,0.003931088,0.00042613735,0.00007836581,0.0000058357145,0.00070742157,0.00085268525,0.0005263799],"category_scores_gemma":[0.00022779059,0.0003080666,0.000492184,0.0010492798,0.0005430635,0.000042454412,0.00037742354,0.0020784645,0.0000032962046],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04898601,0.00031511637,0.0000014918601,0.0021132885,0.0006540946,0.00035611156,0.00030597328,0.000004269189,0.00020151038,0.00014310687,0.006245603,0.9406734],"study_design_scores_gemma":[0.10186744,0.007630353,0.0000041462117,0.001116859,0.00064836704,0.00056580716,0.00009057939,0.00004516665,0.00003879292,0.00003362601,0.8877555,0.00020332547],"about_ca_topic_score_codex":0.00013134125,"about_ca_topic_score_gemma":0.000027936892,"teacher_disagreement_score":0.9404701,"about_ca_system_score_codex":0.0041860533,"about_ca_system_score_gemma":0.012164194,"threshold_uncertainty_score":0.9999371},"labels":[],"label_agreement":null},{"id":"W4291019728","doi":"10.2217/fon-2022-0484","title":"Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; Rosetrees Trust; Cancer Research UK","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Myeloproliferative neoplasm; Internal medicine; Placebo; Clinical trial; Oncology; Extramedullary hematopoiesis; Bone marrow; Haematopoiesis; Pathology; Stem cell","score_opus":0.02084345738915811,"score_gpt":0.3262002128301859,"score_spread":0.3053567554410278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291019728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94326353,0.001172837,0.0000036118875,0.015247025,0.0016189918,0.0028257342,0.0005351236,0.000161153,0.035172023],"genre_scores_gemma":[0.9817665,0.0006236355,0.0009754239,0.0033319762,0.0027219963,0.004087188,0.0010539826,0.0000996196,0.0053396653],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961163,0.0005958824,0.0008407882,0.000981,0.00050574285,0.00096029113],"domain_scores_gemma":[0.99801105,0.00053539267,0.00031392032,0.0005697068,0.00011924007,0.00045065922],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003557414,0.0006118029,0.0013653517,0.00046090354,0.00045668113,0.000029824658,0.00019688132,0.00032753334,0.0054972027],"category_scores_gemma":[0.00006628998,0.0005244421,0.00032842296,0.000514619,0.00013921194,0.00010900999,0.00019981612,0.00067820033,0.00021178547],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1144464,0.11777818,0.19429514,0.0005935633,0.0037199643,0.027421007,0.040070064,0.00012372225,0.010716173,0.054642033,0.22458397,0.2116098],"study_design_scores_gemma":[0.091035835,0.031529568,0.017857026,0.000078013676,0.0004604751,0.0011088797,0.006282044,0.00006997532,0.0037759277,0.0001703223,0.84708345,0.00054849946],"about_ca_topic_score_codex":0.00037313107,"about_ca_topic_score_gemma":0.00049600116,"teacher_disagreement_score":0.62249947,"about_ca_system_score_codex":0.0028865614,"about_ca_system_score_gemma":0.0010342001,"threshold_uncertainty_score":0.9997207},"labels":[],"label_agreement":null},{"id":"W4292884011","doi":"10.2217/fon-2022-0595","title":"HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Trastuzumab; Internal medicine; Chemotherapy; Oncology; Gastroesophageal Junction; Monoclonal antibody; Cancer; Adenocarcinoma; Antibody; Immunology; Breast cancer","score_opus":0.01669934964258832,"score_gpt":0.2941696805263527,"score_spread":0.2774703308837643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292884011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8731357,0.010947082,0.0026237294,0.058339458,0.008792704,0.009933133,0.0018878193,0.00038383665,0.033956576],"genre_scores_gemma":[0.98493016,0.00012475128,0.005330961,0.0011036212,0.0017814178,0.00062203937,0.00079244876,0.000049059,0.005265516],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985757,0.00007208415,0.0003323778,0.00038639354,0.000239507,0.0003939226],"domain_scores_gemma":[0.9991966,0.00009286123,0.00019946454,0.00034024395,0.00006070356,0.00011010947],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000110311754,0.000226455,0.0006778278,0.00014611924,0.00015122711,0.000005924986,0.00015511074,0.000090384805,0.0012868316],"category_scores_gemma":[0.000011181326,0.00020019987,0.00025282986,0.00022696736,0.00007365236,0.00003887336,0.000121378216,0.00014701251,0.0000107279775],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025889857,0.008106522,0.09516451,0.00076139794,0.0027194791,0.003112798,0.0072390223,0.000051412946,0.003787126,0.0070084073,0.23078515,0.6153743],"study_design_scores_gemma":[0.022223344,0.04139117,0.16770557,0.0000147141445,0.0010452955,0.00048725877,0.0040868632,0.000086050924,0.0022637763,0.000117852294,0.7603283,0.00024983456],"about_ca_topic_score_codex":0.000086843866,"about_ca_topic_score_gemma":0.00005103938,"teacher_disagreement_score":0.61512446,"about_ca_system_score_codex":0.0010843031,"about_ca_system_score_gemma":0.00026274694,"threshold_uncertainty_score":0.9996261},"labels":[],"label_agreement":null},{"id":"W4313891690","doi":"10.2217/fon-2022-0898","title":"Many People with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment up to 8 Years: A Plain Language Summary","year":2022,"lang":"en","type":"review","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"Pharmacyclics","keywords":"Ibrutinib; Medicine; Chlorambucil; Chronic lymphocytic leukemia; Internal medicine; Clinical trial; Oncology; Lymphoma; Leukemia; Chemotherapy","score_opus":0.04235839675099185,"score_gpt":0.3464954461082819,"score_spread":0.3041370493572901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313891690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011975598,0.9745836,0.000011819574,0.00015534012,0.002131713,0.006597911,0.0010380477,0.00047586914,0.0030300498],"genre_scores_gemma":[0.00013350481,0.95451325,0.0008886671,0.00077798875,0.005768875,0.0043544425,0.004502121,0.0006338091,0.028427318],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99147993,0.0007077576,0.0015027942,0.0026381556,0.0013389816,0.0023323728],"domain_scores_gemma":[0.99253863,0.0022883848,0.0007630179,0.0029467915,0.00011367781,0.0013495071],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0005625973,0.0018978065,0.0065775155,0.0010876503,0.0003253258,0.000116590425,0.0014571476,0.0017282921,0.0067842896],"category_scores_gemma":[0.00019850698,0.0013439636,0.0011571794,0.0021156624,0.00024500836,0.00009526211,0.0010637358,0.0008836999,0.0017157497],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004352526,0.00020958885,0.0000024506433,0.0073326654,0.0025066845,0.021925637,0.0031215674,0.000066480316,0.0000046503083,0.00007060212,0.009952565,0.9504546],"study_design_scores_gemma":[0.04616347,0.009660413,0.000018177743,0.005694063,0.004369237,0.009785762,0.0012435946,0.0005440733,0.000008839702,0.0000048293687,0.92125815,0.0012494165],"about_ca_topic_score_codex":0.017654646,"about_ca_topic_score_gemma":0.022645783,"teacher_disagreement_score":0.94920516,"about_ca_system_score_codex":0.698003,"about_ca_system_score_gemma":0.3480107,"threshold_uncertainty_score":0.9995677},"labels":[],"label_agreement":null},{"id":"W4317433563","doi":"10.2217/fon-2022-0919","title":"A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; William Osler Health System; BC Cancer Agency; University of Toronto","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; T790M; Oncology; Internal medicine; Second line; Real world data; First line; Epidermal growth factor receptor; Gefitinib; Cancer; Erlotinib; Data science","score_opus":0.0400914084856207,"score_gpt":0.3892553444016239,"score_spread":0.3491639359160032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317433563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920695,0.000023415389,0.0000017224721,0.0021587105,0.00022962457,0.0012720403,0.0003509463,0.000026903146,0.0038671752],"genre_scores_gemma":[0.99517304,0.000013936627,0.00014981462,0.00027256543,0.00022834969,0.000088849825,0.0010010601,0.000018243676,0.0030541627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899024,0.00009968861,0.00026252968,0.0002820297,0.00016882464,0.00019667755],"domain_scores_gemma":[0.9990974,0.00016050818,0.00013452237,0.00046166452,0.00009494154,0.000050936378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013828327,0.00012414422,0.00032914625,0.0001412811,0.000061322186,0.000005046601,0.000157222,0.000060985974,0.0002983654],"category_scores_gemma":[0.00002264454,0.00006327566,0.00001884191,0.00063112716,0.000051185478,0.000060125003,0.00010724646,0.00018938235,0.000017406244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008439122,0.0067433487,0.9031752,0.00006646458,0.0012182426,0.0004987099,0.014129826,0.000027838967,0.00003117073,0.00004478573,0.021228874,0.04439642],"study_design_scores_gemma":[0.013452689,0.0072335606,0.9583204,0.000054366305,0.00039342314,0.0000040952,0.002644375,0.00002419645,0.000024219462,0.0000063188863,0.017774018,0.00006838471],"about_ca_topic_score_codex":0.0004560123,"about_ca_topic_score_gemma":0.020346012,"teacher_disagreement_score":0.05514516,"about_ca_system_score_codex":0.00015084991,"about_ca_system_score_gemma":0.0003662703,"threshold_uncertainty_score":0.9975301},"labels":[],"label_agreement":null},{"id":"W4321597883","doi":"10.2217/fon-2023-0007","title":"Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Nivolumab; Medicine; Chemotherapy; Lung cancer; Cancer; Internal medicine; Oncology; Immunotherapy; Surgery","score_opus":0.015032802171098278,"score_gpt":0.3127348910883733,"score_spread":0.29770208891727507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321597883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792602,0.0018063943,0.000009291574,0.012695128,0.0020390155,0.0025315273,0.00033920194,0.00009154376,0.0012277103],"genre_scores_gemma":[0.970556,0.0014422077,0.00015623015,0.0030220281,0.002833578,0.0008219101,0.0002746679,0.00012025155,0.020773081],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839646,0.0001351455,0.00051349524,0.00035177197,0.0002034603,0.0003996539],"domain_scores_gemma":[0.9987007,0.0003185596,0.00032239308,0.0004981317,0.000098246666,0.00006197129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010181059,0.00021680168,0.00064837624,0.00014346796,0.00012251895,0.000007672611,0.00023486155,0.0002615752,0.000102008475],"category_scores_gemma":[0.000050718172,0.00014468089,0.00033109725,0.00056008867,0.0001030604,0.000030071487,0.00006302282,0.00023346429,0.0000035321345],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044806592,0.0012577566,0.051974677,0.0014491578,0.0018034815,0.0001991868,0.04914337,0.000019407804,0.037857547,0.0000073029937,0.6968015,0.11468006],"study_design_scores_gemma":[0.056819726,0.0036318067,0.33912078,0.00073068286,0.00078542146,0.00004902804,0.0342297,0.00093215285,0.01590551,0.000016712465,0.54716253,0.00061597355],"about_ca_topic_score_codex":0.0007531041,"about_ca_topic_score_gemma":0.0032908022,"teacher_disagreement_score":0.2871461,"about_ca_system_score_codex":0.00045402235,"about_ca_system_score_gemma":0.0008409022,"threshold_uncertainty_score":0.58999157},"labels":[],"label_agreement":null},{"id":"W4321599750","doi":"10.2217/fon-2022-1015","title":"Plain Language Summary of the iNNOVATE Study: Ibrutinib Plus Rituximab is Well-Tolerated and Effective in People with Waldenström's Macroglobulinemia","year":2023,"lang":"en","type":"letter","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"Pharmacyclics","keywords":"Rituximab; Ibrutinib; Medicine; Internal medicine; Waldenstrom macroglobulinemia; Ofatumumab; Placebo; Oncology; Lymphoma; Chronic lymphocytic leukemia; Leukemia; Pathology; Alternative medicine","score_opus":0.008499668118011266,"score_gpt":0.29985058565332007,"score_spread":0.2913509175353088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321599750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76137084,0.00065769674,9.738549e-7,0.22808963,0.0008248607,0.0047840714,0.000179586,0.00009593167,0.003996423],"genre_scores_gemma":[0.54053646,0.00055074313,0.00038110183,0.39998755,0.015311698,0.001781723,0.001748644,0.0007524347,0.03894967],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99623877,0.0006995914,0.00062664744,0.0008689949,0.00077248603,0.00079353544],"domain_scores_gemma":[0.99752,0.0008989394,0.00034431185,0.0009038706,0.0002443675,0.00008845941],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00067405304,0.00052647095,0.0017232771,0.00042404034,0.000087795874,0.000022119866,0.00043213327,0.001494108,0.0001917896],"category_scores_gemma":[0.00015260025,0.00033331843,0.0001099641,0.0015861623,0.00041993175,0.000029998384,0.0005348386,0.0037985696,0.00006435005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002816714,0.00040135026,0.0040785256,0.0016160879,0.0006814734,0.021610484,0.008805629,0.000005259347,0.00015246792,0.0000060426323,0.9565523,0.0032736326],"study_design_scores_gemma":[0.17829835,0.008970895,0.03146933,0.0023414453,0.0010922765,0.0049844715,0.011581551,0.0010454638,0.0009806684,0.000026792293,0.7580431,0.001165621],"about_ca_topic_score_codex":0.004888816,"about_ca_topic_score_gemma":0.0067768972,"teacher_disagreement_score":0.22083439,"about_ca_system_score_codex":0.0095462985,"about_ca_system_score_gemma":0.008940354,"threshold_uncertainty_score":0.9999119},"labels":[],"label_agreement":null},{"id":"W4323294773","doi":"10.2217/fon-2022-1059","title":"TRUST-II: a global phase II study of taletrectinib in <i>ROS1</i> -positive non-small-cell lung cancer and other solid tumors","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Crizotinib; ROS1; Medicine; Lung cancer; Internal medicine; Oncology; Cancer; Brain metastasis; Clinical trial; Interim analysis; Clinical endpoint; Adverse effect; Adenocarcinoma; Metastasis","score_opus":0.012321025614561127,"score_gpt":0.38565660284578784,"score_spread":0.37333557723122673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323294773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856531,0.0006182887,0.0000026059595,0.0014038685,0.0004937877,0.0012234439,0.00019234717,0.000037797483,0.01037475],"genre_scores_gemma":[0.9969651,0.00007608483,0.00009014524,0.00071024173,0.0003652173,0.0002846941,0.00003039988,0.000019847283,0.0014582608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990245,0.000045403696,0.00026415268,0.00030005796,0.000108682725,0.00025716826],"domain_scores_gemma":[0.9995396,0.000037323156,0.00012061282,0.0001439854,0.000061850944,0.00009658729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009036444,0.0001585293,0.00045845925,0.00011214892,0.00011523836,0.000004043103,0.000053616397,0.000114914445,0.00008859535],"category_scores_gemma":[0.000009471501,0.00012814229,0.00004394662,0.0005052108,0.00005233266,0.000029854158,0.000075822274,0.00014441098,0.000003436623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038145124,0.024214752,0.74335486,0.0004183714,0.0017282311,0.002197044,0.12446934,0.00013373898,0.0059827105,0.00019027953,0.025196964,0.06829922],"study_design_scores_gemma":[0.16571291,0.0747557,0.56235194,0.00066178123,0.004105554,0.00030196234,0.0921715,0.0012095978,0.0037894044,0.00008254082,0.09392966,0.0009274471],"about_ca_topic_score_codex":0.0014958347,"about_ca_topic_score_gemma":0.00412924,"teacher_disagreement_score":0.18100289,"about_ca_system_score_codex":0.0003687603,"about_ca_system_score_gemma":0.00040052543,"threshold_uncertainty_score":0.5225491},"labels":[],"label_agreement":null},{"id":"W4324128598","doi":"10.2217/fon-2022-0713","title":"Significant heterogeneity of published literature comparing radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma","year":2023,"lang":"en","type":"letter","venue":"Future Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Cancer; Radiation oncology; Radiofrequency ablation; Internal medicine; Radiation therapy; Oncology; Family medicine; Ablation","score_opus":0.0769494634989859,"score_gpt":0.3020577114421249,"score_spread":0.225108247943139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324128598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7586999,0.014413704,0.00006207531,0.21028803,0.007772102,0.00685613,0.00046842522,0.00032891467,0.0011107313],"genre_scores_gemma":[0.94231206,0.0014750428,0.00047990915,0.017474495,0.014736348,0.00092229043,0.021870531,0.00023321119,0.00049612205],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964738,0.00044823776,0.00092204404,0.0009626334,0.0005050266,0.00068827445],"domain_scores_gemma":[0.99704915,0.0006074706,0.0008205718,0.0008533084,0.0005044117,0.00016506086],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00051636837,0.00066827936,0.0016595102,0.0006540765,0.0001428191,0.00009002129,0.00028925936,0.00233945,0.00007790258],"category_scores_gemma":[0.00012527498,0.00057657005,0.00075931527,0.0006167389,0.00009497822,0.00021010869,0.00004213051,0.0014810009,0.000023252933],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044197314,0.0004218828,0.549745,0.0019311416,0.0021481419,0.0027649042,0.001021338,5.7873075e-7,0.0027971985,0.00008753245,0.42496055,0.009702008],"study_design_scores_gemma":[0.0136691,0.005821669,0.025355399,0.00019600881,0.001398083,0.00009749072,0.000033343513,0.0018959141,0.0047290805,0.00007009436,0.946098,0.0006357604],"about_ca_topic_score_codex":0.00008942807,"about_ca_topic_score_gemma":0.000009553632,"teacher_disagreement_score":0.5243896,"about_ca_system_score_codex":0.00076486915,"about_ca_system_score_gemma":0.00065701705,"threshold_uncertainty_score":0.9996686},"labels":[],"label_agreement":null},{"id":"W4324128872","doi":"10.2217/fon-2022-0893","title":"Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Radiofrequency ablation; Hepatocellular carcinoma; Ablation; Radiosurgery; Meta-analysis; Sample size determination; Radiation therapy; Radiology; Nuclear medicine; Internal medicine","score_opus":0.11977150862180792,"score_gpt":0.3330833338833962,"score_spread":0.21331182526158832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324128872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740026,0.012434838,0.00008879377,0.0071839164,0.0020141946,0.002495098,0.00003382077,0.00028773473,0.0014589749],"genre_scores_gemma":[0.99278045,0.0018054611,0.00050762045,0.00024915737,0.0016472215,0.000980167,0.0012180246,0.000058988844,0.0007529146],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982942,0.00020270832,0.00036093695,0.00045765302,0.00025339218,0.00043116242],"domain_scores_gemma":[0.9987528,0.00036437222,0.00019584411,0.00036484524,0.0001442624,0.00017789136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004274583,0.00031635948,0.00071826484,0.00030486388,0.0001915763,0.00002045399,0.00009616306,0.00039686775,0.0003252073],"category_scores_gemma":[0.00007712184,0.00021760745,0.00050116424,0.0005026069,0.000040899948,0.00013669067,0.000019516174,0.00019926458,0.00013865708],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009321682,0.00082349597,0.7107282,0.0002705029,0.0048554856,0.0011912723,0.0017864193,0.0000015048302,0.019021507,0.0014838693,0.02237456,0.22814146],"study_design_scores_gemma":[0.024323221,0.008028145,0.07081175,0.000021037094,0.0044971774,0.00009993891,0.00019003161,0.009651152,0.012915506,0.00031121765,0.868682,0.0004687794],"about_ca_topic_score_codex":0.000041170388,"about_ca_topic_score_gemma":0.0000044944813,"teacher_disagreement_score":0.8463075,"about_ca_system_score_codex":0.0003334788,"about_ca_system_score_gemma":0.00029556587,"threshold_uncertainty_score":0.8873774},"labels":[],"label_agreement":null},{"id":"W4324129382","doi":"10.2217/fon-2022-0337","title":"Efficacy and Safety Evaluation of PSOX, DOF and SOX Regimens as Neoadjuvant Chemotherapy for Advanced Gastric Cancer","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Society of Intestinal Research","funders":"","keywords":"Oxaliplatin; Medicine; Docetaxel; Internal medicine; Regimen; Chemotherapy; Oncology; Paclitaxel; Incidence (geometry); Cancer; Gastroenterology; Colorectal cancer","score_opus":0.021038032117836072,"score_gpt":0.3561469879927961,"score_spread":0.33510895587496004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324129382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95222723,0.008820054,0.0001589398,0.031437397,0.0009827451,0.0027055838,0.00003467124,0.00003388601,0.0035995115],"genre_scores_gemma":[0.98564684,0.0038909896,0.0025910146,0.0035402002,0.0008086784,0.0006450517,0.00008762949,0.000035418398,0.0027541688],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999056,0.00007963644,0.00020414959,0.00024129296,0.00024852683,0.00017043744],"domain_scores_gemma":[0.99942964,0.00011311025,0.00016168664,0.00014091397,0.00009785511,0.00005677398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000572904,0.00010719273,0.00034321085,0.00011198334,0.00010220167,0.0000029841453,0.000048316986,0.000051719126,0.0005107954],"category_scores_gemma":[0.000047603484,0.00009415169,0.000043035965,0.00017802957,0.000047957376,0.000028491886,0.00005598513,0.00012081698,3.9370644e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005763083,0.00016248292,0.0037193606,0.000102073616,0.00018283782,0.0000052612886,0.00096291385,0.00015431618,0.0020302453,0.00059963006,0.012980253,0.97333753],"study_design_scores_gemma":[0.040870745,0.0040073902,0.13227116,0.00002720039,0.00073305354,0.00007341989,0.0018603833,0.0006950394,0.00020068939,0.00033755132,0.81877726,0.00014608767],"about_ca_topic_score_codex":0.000033981818,"about_ca_topic_score_gemma":0.000037069643,"teacher_disagreement_score":0.97319144,"about_ca_system_score_codex":0.00028033758,"about_ca_system_score_gemma":0.00022835708,"threshold_uncertainty_score":0.5592851},"labels":[],"label_agreement":null},{"id":"W4362459260","doi":"10.2217/fon-2022-1035","title":"Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called <i>MET</i> exon 14 skipping","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; Lung cancer; Exon; Cancer; Targeted therapy; Oncology; Cancer research; Internal medicine; Mutation; Exon skipping; Genetics; Gene; Biology","score_opus":0.017210099592399008,"score_gpt":0.35186459170477435,"score_spread":0.33465449211237536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362459260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928282,0.001343538,0.00008969786,0.00060014444,0.0005526705,0.0014716088,0.00012919033,0.000020332898,0.0029646098],"genre_scores_gemma":[0.98682183,0.00020914924,0.008076736,0.00014289796,0.00026742008,0.0006367548,0.00015385746,0.00003151734,0.003659817],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99911267,0.000035386285,0.000373107,0.00017276888,0.00011254711,0.00019351943],"domain_scores_gemma":[0.9992211,0.00014802883,0.00027633962,0.00019959843,0.00010735115,0.000047568952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012841875,0.0001264353,0.00045035887,0.00009637374,0.000049192782,0.0000011573561,0.00008257796,0.00012019529,0.00003315499],"category_scores_gemma":[0.000018445277,0.00008057006,0.00013846689,0.0002643557,0.000040579103,0.00001192693,0.000036779435,0.00005990599,0.00000105628],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003591282,0.0041402774,0.13869873,0.0052192006,0.0047547077,0.00013161627,0.22785406,0.0003654018,0.34416437,0.0002890464,0.02028648,0.25050482],"study_design_scores_gemma":[0.045916386,0.0063030636,0.30105144,0.0017390045,0.0050670025,0.000027365215,0.031615604,0.00058280217,0.4092046,0.00003101548,0.1978823,0.0005794164],"about_ca_topic_score_codex":0.00025921923,"about_ca_topic_score_gemma":0.0019362058,"teacher_disagreement_score":0.24992542,"about_ca_system_score_codex":0.00037011874,"about_ca_system_score_gemma":0.0014363324,"threshold_uncertainty_score":0.32855517},"labels":[],"label_agreement":null},{"id":"W4366236771","doi":"10.2217/fon-2022-1196","title":"Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i> -mutant breast cancer during first-line treatment","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"AstraZeneca","keywords":"Medicine; Mutant; Breast cancer; Oncology; Cancer; Line (geometry); Internal medicine; Cancer research; Genetics; Biology; Gene","score_opus":0.030193153996958478,"score_gpt":0.354143198096221,"score_spread":0.32395004409926254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366236771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924985,0.0006492788,0.00067428825,0.0037417389,0.00074455386,0.0014309187,0.00011811462,0.0000761308,0.0000664811],"genre_scores_gemma":[0.9961213,0.0015233253,0.00069209165,0.000075106436,0.0010819458,0.00030982686,0.000022802165,0.00004334655,0.00013028056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982646,0.00010749695,0.0006742477,0.00033734733,0.00021341039,0.00040291515],"domain_scores_gemma":[0.9989976,0.00017486858,0.00033683528,0.0002967924,0.0000882298,0.00010561754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021964467,0.0002560923,0.0010655327,0.00027657615,0.000047395544,0.000002387458,0.00010582764,0.00019496145,0.00013993385],"category_scores_gemma":[0.000015553143,0.00019795077,0.00012819466,0.000552772,0.00007630509,0.00006785778,0.000033074935,0.00021086777,0.0000035527237],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4075116,0.0029891457,0.0006983898,0.00039197406,0.0005624729,0.0008909811,0.007959361,0.0063223457,0.3861565,0.00004201126,0.000029566834,0.18644565],"study_design_scores_gemma":[0.88664687,0.0134319905,0.006895936,0.0010285741,0.0006137905,0.00075287104,0.0028862758,0.0016170022,0.0790986,0.00021456616,0.006299309,0.0005142461],"about_ca_topic_score_codex":0.0010661193,"about_ca_topic_score_gemma":0.0013173936,"teacher_disagreement_score":0.47913527,"about_ca_system_score_codex":0.000703231,"about_ca_system_score_gemma":0.00059380004,"threshold_uncertainty_score":0.8072198},"labels":[],"label_agreement":null},{"id":"W4377220744","doi":"10.2217/fon-2023-0082","title":"Plain Language Summary of the MAIA Study of Daratumumab Plus Lenalidomide and Dexamethasone for the Treatment of People with Newly Diagnosed Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Amgen","keywords":"Daratumumab; Lenalidomide; Medicine; Dexamethasone; Multiple myeloma; Oncology; Internal medicine","score_opus":0.024376566490560227,"score_gpt":0.32797371336154324,"score_spread":0.303597146870983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377220744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939441,0.0012538293,0.00001624127,0.0010530018,0.00012184683,0.0032981036,0.00015612972,0.000016667305,0.00014009503],"genre_scores_gemma":[0.9978033,0.0004156,0.00056497403,0.00002892717,0.00014101714,0.00047865335,0.00005334997,0.000023024853,0.00049116684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987539,0.00019724974,0.00028154763,0.00023067005,0.00026929582,0.0002673249],"domain_scores_gemma":[0.99692357,0.002231654,0.00019341217,0.00046602168,0.00010493519,0.00008042692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022949926,0.0001678639,0.0006382651,0.000102877406,0.00010647952,0.0000033925212,0.00013520259,0.00009624257,0.000019587682],"category_scores_gemma":[0.00018984143,0.00007616087,0.00010328377,0.00037247507,0.00016350669,0.000021152855,0.000059219903,0.00009765826,0.0000011322797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045117978,0.007860994,0.72531956,0.00059297145,0.003962869,0.0005655336,0.06872821,0.00017570282,0.010404812,0.00009304813,0.0036170415,0.1335613],"study_design_scores_gemma":[0.058518704,0.018063286,0.8706998,0.00006882336,0.00058873516,0.00003857748,0.040440712,0.00080611475,0.00673832,0.0000071151503,0.0039382004,0.00009156302],"about_ca_topic_score_codex":0.0016327479,"about_ca_topic_score_gemma":0.0164672,"teacher_disagreement_score":0.1453803,"about_ca_system_score_codex":0.0001300547,"about_ca_system_score_gemma":0.00023667434,"threshold_uncertainty_score":0.9189085},"labels":[],"label_agreement":null},{"id":"W4379599383","doi":"10.2217/fon-2022-0974","title":"Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; William Osler Health System; Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Clinical trial; Cancer; Oncology; Internal medicine; Meta-analysis; Lung cancer","score_opus":0.2703097231449354,"score_gpt":0.48395923251896045,"score_spread":0.21364950937402505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379599383","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021270405,0.99440116,0.0000648543,0.0002121417,0.0006187415,0.0041372473,0.00036399084,0.000015358593,0.00016521713],"genre_scores_gemma":[0.00004594543,0.9960319,0.00056691346,0.00072980684,0.0008952994,0.0010560749,0.00044441482,0.0000773976,0.00015228416],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927789,0.0021346933,0.0033741964,0.0011131036,0.0002010631,0.00039804945],"domain_scores_gemma":[0.9932386,0.002500749,0.0028133453,0.0009870513,0.00019929337,0.0002609471],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0024733152,0.00067444175,0.015710922,0.00026223494,0.000081176106,0.000028304648,0.0004842915,0.0009679293,0.000064826134],"category_scores_gemma":[0.0015939072,0.0004935929,0.0025885438,0.00055750244,0.0003461143,0.000003018098,0.0004500473,0.0005991159,0.00002246718],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009074551,0.0008511209,0.000008366164,0.7610544,0.1938527,0.00018688211,0.000053782718,0.000003263949,0.0000040395153,0.00046798697,0.028079534,0.014530476],"study_design_scores_gemma":[0.0015804515,0.0021888844,0.0000010904766,0.0020890366,0.44822338,0.00008198096,0.000034407334,0.0000012977936,8.5481855e-7,0.000013911909,0.5454835,0.0003012007],"about_ca_topic_score_codex":0.00001432084,"about_ca_topic_score_gemma":0.00021023741,"teacher_disagreement_score":0.7589654,"about_ca_system_score_codex":0.00010014191,"about_ca_system_score_gemma":0.0010122693,"threshold_uncertainty_score":0.99975157},"labels":[],"label_agreement":null},{"id":"W4380291366","doi":"10.2217/fon-2022-1289","title":"Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Comprehensive Cancer Network; Pfizer","keywords":"Crizotinib; Medicine; Lung cancer; Crown (dentistry); Oncology; Internal medicine; Dentistry","score_opus":0.010774628323068091,"score_gpt":0.32511510297901697,"score_spread":0.3143404746559489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380291366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883822,0.00033418657,0.000006239324,0.0034048294,0.00028539912,0.0016415662,0.00016287684,0.00004297503,0.005739713],"genre_scores_gemma":[0.99753976,0.000036840534,0.00025389186,0.00034439212,0.00021910551,0.00022475193,0.0002946317,0.000026995933,0.0010596282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988878,0.00013189027,0.00027050884,0.00029542757,0.00017854238,0.00023584501],"domain_scores_gemma":[0.9990064,0.00026919637,0.00019310908,0.0004129579,0.00007187635,0.000046496738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017630625,0.00016013897,0.00039192234,0.00005741944,0.00011015615,0.000007722334,0.0001655275,0.00007087425,0.000040849023],"category_scores_gemma":[0.000019312678,0.00007474435,0.000034187648,0.0006946066,0.00005805504,0.00003537801,0.000068522044,0.00029370192,0.0000033076167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041924664,0.00071706745,0.910751,0.00004527487,0.0004400449,0.00019578522,0.071166255,0.0021052083,0.00080348644,0.000009868207,0.007492782,0.0020807835],"study_design_scores_gemma":[0.01703934,0.00088096404,0.92977875,0.00020977532,0.0005205779,0.000005734929,0.046991184,0.00048930105,0.0003683748,0.0000012630034,0.003606205,0.000108502034],"about_ca_topic_score_codex":0.0058721662,"about_ca_topic_score_gemma":0.11946287,"teacher_disagreement_score":0.11359071,"about_ca_system_score_codex":0.00020043233,"about_ca_system_score_gemma":0.00056074676,"threshold_uncertainty_score":0.89660466},"labels":[],"label_agreement":null},{"id":"W4382502641","doi":"10.2217/fon-2022-1157","title":"A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency; University of Calgary; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Endometrial cancer; Cancer; Oncology; Internal medicine","score_opus":0.01778791242373024,"score_gpt":0.3120160915822968,"score_spread":0.2942281791585666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382502641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953111,0.00046846818,1.4505373e-7,0.00080408686,0.0004644917,0.0009894127,0.0007724949,0.000017332854,0.0011724596],"genre_scores_gemma":[0.99860066,0.000102140795,0.00003532036,0.00014928794,0.00051999104,0.0000698803,0.00039363164,0.00001303152,0.000116070834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861556,0.000227435,0.00039216745,0.00023447972,0.00034115725,0.00018916886],"domain_scores_gemma":[0.9982561,0.0011462389,0.00020444122,0.00026696225,0.00007505137,0.00005121261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030924802,0.000118913165,0.0005498621,0.0002115749,0.000019795885,0.0000018521309,0.000120860124,0.00010522394,0.00012752782],"category_scores_gemma":[0.00031975043,0.00006325799,0.000049180042,0.001393573,0.00005052911,0.000021240594,0.000062949955,0.0001942782,0.000004712194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07862595,0.0038742328,0.85017556,0.000036685626,0.00062459597,0.00018469772,0.01203678,0.000020385067,0.00019153142,0.0000099294375,0.0039793947,0.050240286],"study_design_scores_gemma":[0.07991207,0.0077662044,0.90225756,0.000065793,0.00019514759,3.5439297e-7,0.0056334673,0.0000022122952,0.00013479759,0.000007874322,0.0039620292,0.000062506166],"about_ca_topic_score_codex":0.008689919,"about_ca_topic_score_gemma":0.01012018,"teacher_disagreement_score":0.052082013,"about_ca_system_score_codex":0.0001446108,"about_ca_system_score_gemma":0.0001495226,"threshold_uncertainty_score":0.9979113},"labels":[],"label_agreement":null},{"id":"W4384926029","doi":"10.2217/fon-2023-0436","title":"Time to Next Treatment in Patients with Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Hazard ratio; Pharmacy; Leukemia; Confidence interval; Family medicine","score_opus":0.028625381904688885,"score_gpt":0.32189952807874594,"score_spread":0.29327414617405706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384926029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98937935,0.00012194664,0.000004620776,0.002205257,0.00031635753,0.0023579209,0.000034260054,0.00031124888,0.005269035],"genre_scores_gemma":[0.98147655,0.0002290404,0.00072810194,0.001634984,0.00238693,0.0006938768,0.0006377287,0.00017446595,0.012038327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653083,0.00015290394,0.0006335412,0.0007964884,0.0006115766,0.0012746622],"domain_scores_gemma":[0.99777716,0.00071948726,0.00014654144,0.0006895733,0.00017355532,0.00049367535],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00037531357,0.000440953,0.0009579652,0.0005658058,0.00015198803,0.000029768013,0.00027147544,0.0004605287,0.0022491554],"category_scores_gemma":[0.00036948128,0.00029758658,0.000104284074,0.0019217003,0.0001615905,0.00012234671,0.00023715066,0.00037033248,0.0056390534],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.08333098,0.0032952467,0.02693828,0.002728096,0.002155558,0.024321308,0.014532725,0.028918913,0.0012451889,0.00020846086,0.1153487,0.69697654],"study_design_scores_gemma":[0.24729654,0.05518282,0.06759451,0.0010420623,0.0003364511,0.00053516234,0.00074002304,0.05696234,0.00062514,0.00002113215,0.56854045,0.0011233564],"about_ca_topic_score_codex":0.000619666,"about_ca_topic_score_gemma":0.0018448422,"teacher_disagreement_score":0.6958532,"about_ca_system_score_codex":0.21307835,"about_ca_system_score_gemma":0.05347647,"threshold_uncertainty_score":0.9999476},"labels":[],"label_agreement":null},{"id":"W4385442656","doi":"10.2217/fon-2023-0228","title":"TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Breast cancer; Triple-negative breast cancer; Internal medicine; Triple negative; Cancer","score_opus":0.05001610890154408,"score_gpt":0.3967505803952925,"score_spread":0.3467344714937484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385442656","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2597716,0.008221367,0.023104852,0.60723025,0.042886764,0.025527623,0.014222128,0.0034895118,0.015545948],"genre_scores_gemma":[0.7269709,0.017763454,0.05472384,0.060981322,0.035734765,0.03005938,0.0036951934,0.0009877854,0.06908336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977624,0.00023157184,0.00050866266,0.00056490983,0.00029675046,0.00063572143],"domain_scores_gemma":[0.99824804,0.0004934901,0.00021327977,0.0003738301,0.00039568462,0.00027565868],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044902143,0.00030962648,0.0007729273,0.00026486118,0.00019510614,0.000019728865,0.00018233819,0.00021219796,0.0025788213],"category_scores_gemma":[0.00014007291,0.00022703905,0.0001760536,0.0008642035,0.00016240517,0.00011212845,0.00004945621,0.0003985622,0.00016176103],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021291452,0.00083386374,0.0005789305,0.000560217,0.00095852057,0.00031306825,0.0025327273,0.000082605526,0.0039185984,0.001979566,0.4137519,0.5531985],"study_design_scores_gemma":[0.02718349,0.0037449435,0.007734699,0.00041048345,0.0004887836,0.0010481016,0.0029824623,0.0012916246,0.0026636913,0.001613897,0.9503112,0.0005266688],"about_ca_topic_score_codex":0.00013616633,"about_ca_topic_score_gemma":0.00097521767,"teacher_disagreement_score":0.55267185,"about_ca_system_score_codex":0.00096871465,"about_ca_system_score_gemma":0.0019610052,"threshold_uncertainty_score":0.998333},"labels":[],"label_agreement":null},{"id":"W4385722927","doi":"10.2217/fon-2023-0135","title":"Plain Language Summary: Can Declines in Prostate-Specific Antigen Level Indicate How Long Patients with Advanced Prostate Cancer Will Live When Treated with Enzalutamide?","year":2023,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Prostate-specific antigen; Prostate; Cancer; Oncology; Urology; Internal medicine; Androgen receptor","score_opus":0.049068405312900805,"score_gpt":0.35826136092005,"score_spread":0.3091929556071492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385722927","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.064682044,0.9206663,7.4936065e-7,0.0020496976,0.00031468057,0.009128813,0.002830162,0.00020069956,0.00012688927],"genre_scores_gemma":[0.00063860964,0.9773909,0.00027642064,0.000091509515,0.00058732997,0.0030816782,0.009303251,0.0003402753,0.008290035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954182,0.00043056833,0.0007361384,0.0013720822,0.000716042,0.0013269783],"domain_scores_gemma":[0.9975092,0.00024819942,0.00077845715,0.00066580996,0.00038017958,0.000418197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029991372,0.0010883095,0.0032532003,0.00096065074,0.0001647305,0.00006351312,0.0003726352,0.000684429,0.00010105272],"category_scores_gemma":[0.000040861036,0.00062804867,0.0002127224,0.0014502235,0.0003873244,0.00019949756,0.00015875875,0.0014361538,0.00003907918],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072853914,0.00077344384,0.071768306,0.011758539,0.0017547663,0.0104074925,0.0050638234,0.000003987713,0.000005404306,0.00000505889,0.0036433686,0.88753045],"study_design_scores_gemma":[0.0138677005,0.004427408,0.023649324,0.023528654,0.0009652665,0.00007187505,0.001397979,0.0000010370308,0.000019845213,0.000004852932,0.9310978,0.00096826674],"about_ca_topic_score_codex":0.0009200466,"about_ca_topic_score_gemma":0.018255215,"teacher_disagreement_score":0.9274544,"about_ca_system_score_codex":0.002274417,"about_ca_system_score_gemma":0.0030958585,"threshold_uncertainty_score":0.99965906},"labels":[],"label_agreement":null},{"id":"W4386407017","doi":"10.2217/fon-2023-0358","title":"Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"Seagen","keywords":"Medicine; Stage (stratigraphy); Family medicine; Regimen; Alternative medicine; Lymphoma; Internal medicine; Pathology","score_opus":0.04817714389186973,"score_gpt":0.3564879811656919,"score_spread":0.3083108372738222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386407017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730016,0.000418292,0.000003466706,0.008113804,0.0013238847,0.0037353374,0.00015185785,0.00023535188,0.013016384],"genre_scores_gemma":[0.981413,0.00060010765,0.00013499864,0.0011175922,0.0023170607,0.0028031878,0.00032698637,0.00004380193,0.011243247],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980625,0.00020550004,0.0003913367,0.0005708332,0.00024086927,0.00052896695],"domain_scores_gemma":[0.99823916,0.00073767506,0.00020398507,0.0005772566,0.00009549981,0.00014641197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002641175,0.00036547726,0.00085295335,0.00015560891,0.00029818589,0.000029347884,0.00017265033,0.0001481665,0.00011111858],"category_scores_gemma":[0.00002405544,0.00019716057,0.00025535497,0.00043800633,0.00009927374,0.00004488507,0.00006402975,0.00007575273,0.00014013344],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043576974,0.021936016,0.27616906,0.00009847883,0.00396568,0.0014430142,0.0070831664,0.00003399324,0.00023782285,0.0045622685,0.10663248,0.5734803],"study_design_scores_gemma":[0.019561304,0.010188617,0.52703464,0.000022095719,0.0008052983,0.000008186969,0.005114613,0.0001239435,0.0002924391,0.0001245115,0.43654838,0.00017596038],"about_ca_topic_score_codex":0.0013450959,"about_ca_topic_score_gemma":0.016859736,"teacher_disagreement_score":0.57330436,"about_ca_system_score_codex":0.0011433661,"about_ca_system_score_gemma":0.000526969,"threshold_uncertainty_score":0.9408128},"labels":[],"label_agreement":null},{"id":"W4387950784","doi":"10.2217/fon-2023-0526","title":"TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Oncology; Olaparib; Placebo; Androgen deprivation therapy; Clinical trial; Androgen receptor; Cancer; Poly ADP ribose polymerase; Gene; Pathology; Biology; Polymerase","score_opus":0.13084474820022168,"score_gpt":0.5230714336123913,"score_spread":0.3922266854121696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387950784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88938123,0.000021108097,0.000017546268,0.0017678842,0.0013236934,0.106576584,0.00007450112,0.000093841496,0.0007435807],"genre_scores_gemma":[0.83581454,0.000045589077,0.00032333325,0.00058398827,0.0018896767,0.16057801,0.00008945276,0.00004885143,0.0006265579],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963118,0.0009024829,0.001447469,0.0005424372,0.00040150023,0.0003943516],"domain_scores_gemma":[0.9982294,0.0004524892,0.00056023797,0.0003442137,0.00026015766,0.00015351782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017554921,0.0002432696,0.0011937195,0.00031220337,0.00006093897,0.000008953164,0.00009997907,0.00020718916,0.00022029628],"category_scores_gemma":[0.00018601264,0.00020637887,0.00013843412,0.0008899193,0.00020038971,0.00009257857,0.00004909299,0.00061653287,0.0000296662],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83237594,0.02042129,0.00804625,0.00043305728,0.0012173717,0.0041725924,0.030460129,0.0007755735,0.008246495,0.00037136133,0.018313538,0.075166404],"study_design_scores_gemma":[0.88837206,0.03797112,0.010495934,0.0001900557,0.00031960141,0.00009138611,0.015286885,0.00083023263,0.0021023673,0.00015234553,0.043850087,0.0003379361],"about_ca_topic_score_codex":0.0003168575,"about_ca_topic_score_gemma":0.0022854463,"teacher_disagreement_score":0.07482847,"about_ca_system_score_codex":0.0004916751,"about_ca_system_score_gemma":0.0019519128,"threshold_uncertainty_score":0.8415886},"labels":[],"label_agreement":null},{"id":"W4388227085","doi":"10.2217/fon-2023-0407","title":"The Effects of Adding Palbociclib to Endocrine Therapy to Treat Advanced Breast Cancer: A Plain Language Summary of a Study Using the PALOMA-2 and PALOMA-3 Trial Results","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Palbociclib; Breast cancer; Medicine; Placebo; Internal medicine; Hormonal therapy; Cancer; Oncology; Clinical trial; Hormone therapy; Gynecology; Metastatic breast cancer; Alternative medicine; Pathology","score_opus":0.014905550092935559,"score_gpt":0.3629975390301803,"score_spread":0.34809198893724475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388227085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98532784,0.0036823929,0.000009881267,0.0060170926,0.0008389154,0.0037503275,0.00018857018,0.00007026504,0.00011471659],"genre_scores_gemma":[0.9955865,0.0010203924,0.0004382651,0.00059255166,0.0013901395,0.0005918635,0.0000145074555,0.000056798515,0.00030897153],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997941,0.00036849396,0.0005024696,0.00041256013,0.00031664502,0.00045881286],"domain_scores_gemma":[0.997316,0.0015957077,0.00026276527,0.0005530708,0.00012629811,0.0001461418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048353904,0.0002696359,0.00074429245,0.00016915437,0.00019247753,0.000009856762,0.00023502756,0.0000900822,0.000009641598],"category_scores_gemma":[0.00023875888,0.00014998247,0.000101597776,0.00083473494,0.0001435598,0.000048149646,0.00014579722,0.00024465617,0.000001576292],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18567732,0.00037113702,0.0015997727,0.00011423422,0.00035838495,0.00024649804,0.023440126,0.00006783451,0.14264259,0.000041515246,0.0006497366,0.6447908],"study_design_scores_gemma":[0.45625848,0.044733763,0.1876684,0.0016480498,0.0009226442,0.0006820232,0.11884111,0.00008835275,0.040615264,0.00013408092,0.1473428,0.0010650412],"about_ca_topic_score_codex":0.0003984303,"about_ca_topic_score_gemma":0.0009903532,"teacher_disagreement_score":0.6437258,"about_ca_system_score_codex":0.00019101087,"about_ca_system_score_gemma":0.0001966861,"threshold_uncertainty_score":0.6116108},"labels":[],"label_agreement":null},{"id":"W4390051577","doi":"10.2217/fon-2023-0649","title":"Prostate-Specific Antigen (PSA) Decline with Apalutamide Therapy is Associated with Longer Survival and Improved Outcomes in Individuals with Metastatic Prostate Cancer: A Plain Language Summary of the TITAN Study","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Placebo; Prostate cancer; Androgen deprivation therapy; Prostate-specific antigen; Internal medicine; Oncology; Prostatectomy; Post-hoc analysis; Urology; Cancer; Pathology","score_opus":0.027742835420446907,"score_gpt":0.3413039054678971,"score_spread":0.31356107004745015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390051577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98768866,0.0019304148,5.100688e-7,0.005713557,0.00009156568,0.0040295925,0.00035078812,0.0000561421,0.00013879502],"genre_scores_gemma":[0.99488443,0.0017832523,0.00013641943,0.0002693895,0.0000584728,0.0005455986,0.00015015283,0.00006583731,0.0021064754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779737,0.00030332358,0.00034214588,0.00046673228,0.00055713416,0.000533321],"domain_scores_gemma":[0.99883425,0.00028148037,0.00025309192,0.00034951366,0.00016909152,0.00011259388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073050836,0.00031472094,0.00089799945,0.00024519884,0.00010878841,0.000025095322,0.0001634766,0.000100327044,0.000039347236],"category_scores_gemma":[0.000024767602,0.00014181655,0.00004405745,0.0011545588,0.00031511454,0.000079732,0.000096693766,0.0004089192,0.0000015646663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005566367,0.0009829163,0.9657058,0.00006391756,0.001451208,0.0006227362,0.019913092,0.0000066998014,0.0012686088,0.000006239917,0.00030723735,0.004105177],"study_design_scores_gemma":[0.024085362,0.0084048,0.9431115,0.00018499586,0.00016394086,0.000016036069,0.021819126,0.000020935133,0.00079814036,0.000015281863,0.0011810681,0.00019885115],"about_ca_topic_score_codex":0.000571465,"about_ca_topic_score_gemma":0.010489514,"teacher_disagreement_score":0.022594336,"about_ca_system_score_codex":0.00023935578,"about_ca_system_score_gemma":0.0006372387,"threshold_uncertainty_score":0.5853395},"labels":[],"label_agreement":null},{"id":"W4390669468","doi":"10.2217/fon-2023-0263","title":"Bacterial Heat Shock Protein Genes During Induction Chemotherapy In Pediatric Patients with Acute Lymphoblastic Leukemia","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"IWK Health Centre; W. Garfield Weston Foundation; Nova Scotia Health Research Foundation; Beatrice Hunter Cancer Research Institute","keywords":"Heat shock protein; Firmicutes; Gene; Leukemia; Bacteroidetes; Medicine; Cancer research; Microbiology; Biology; Immunology; Genetics","score_opus":0.0035952697782344854,"score_gpt":0.22994339109617107,"score_spread":0.22634812131793658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390669468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975118,0.00057557115,0.000022673483,0.00043384108,0.000862452,0.00042960432,0.00001933308,0.000025287565,0.000119416414],"genre_scores_gemma":[0.99516624,0.00046845156,0.00037223173,0.00012909064,0.0032152096,0.00006439577,0.00023794507,0.00003882432,0.0003076377],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989741,0.00006066671,0.00019435589,0.00040269434,0.00006752642,0.0003006757],"domain_scores_gemma":[0.99970037,0.0000035645326,0.000036464775,0.00015658945,0.000038562466,0.00006443254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006264475,0.000175033,0.00018209653,0.00010980263,0.0000574118,0.000022017572,0.00009759062,0.0003650847,0.00004857214],"category_scores_gemma":[0.0000034954173,0.00014245763,0.000040864208,0.0001763207,0.000030149604,0.0000075035155,0.00004107199,0.00015870902,0.000016304783],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012581336,0.00012302386,0.008082601,0.00016841569,0.00005971801,0.000037758153,0.0001512192,0.000018845145,0.9856235,0.000016891241,0.0010832504,0.0033766655],"study_design_scores_gemma":[0.009864289,0.0046995417,0.66457385,0.00009507274,0.00012409873,0.00020198863,0.0000979552,0.000025664156,0.10928308,0.000024068298,0.2101639,0.0008464737],"about_ca_topic_score_codex":0.000019000388,"about_ca_topic_score_gemma":0.00018961627,"teacher_disagreement_score":0.8763404,"about_ca_system_score_codex":0.00029571436,"about_ca_system_score_gemma":0.0006255585,"threshold_uncertainty_score":0.58092535},"labels":[],"label_agreement":null},{"id":"W4392238297","doi":"10.2217/fon-2023-0995","title":"Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"Pfizer","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Oncology; World class; Class (philosophy); Internal medicine; Artificial intelligence; Computer science","score_opus":0.0196711530789508,"score_gpt":0.3296302245845405,"score_spread":0.3099590715055897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392238297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95517814,0.003213439,0.00003220577,0.011424921,0.0009060602,0.002857768,0.00010887538,0.00023971937,0.026038848],"genre_scores_gemma":[0.9948702,0.0003654046,0.0008387739,0.00038271816,0.0006558069,0.00029580478,0.00024831004,0.00006197516,0.002281037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972169,0.0003430007,0.0005307441,0.00069337117,0.00041429795,0.000801732],"domain_scores_gemma":[0.9981497,0.00090766145,0.000075839656,0.00044994737,0.00007333779,0.00034352063],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037914907,0.00035543874,0.00096315355,0.00092958054,0.000047346446,0.000032489792,0.00018412819,0.00028843252,0.0005384365],"category_scores_gemma":[0.00014309361,0.00024980423,0.0001147856,0.0009831,0.00016592971,0.00011916614,0.000045519824,0.0010493689,0.00018359082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04982404,0.008360238,0.55060476,0.0009088621,0.0010983117,0.069695875,0.0035566257,0.000117298834,0.0068293572,0.0013840019,0.02030766,0.28731295],"study_design_scores_gemma":[0.042724237,0.0023184875,0.7577024,0.00031565432,0.00008354282,0.00016580327,0.00038683097,0.00421878,0.00009711898,0.00001902524,0.191737,0.00023112254],"about_ca_topic_score_codex":0.0013906247,"about_ca_topic_score_gemma":0.03644539,"teacher_disagreement_score":0.28708184,"about_ca_system_score_codex":0.0011857869,"about_ca_system_score_gemma":0.0007598401,"threshold_uncertainty_score":0.9999954},"labels":[],"label_agreement":null},{"id":"W4394942521","doi":"10.2217/fon-2023-0679","title":"Belzutifan: a novel therapeutic for the management of von Hippel–Lindau disease and beyond","year":2024,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Disease; Clinical trial; Hypoxia-inducible factors; Renal cell carcinoma; Von Hippel–Lindau disease; Bioinformatics; Cancer research; Oncology; Internal medicine; Gene; Biology","score_opus":0.025831623138017467,"score_gpt":0.34302117389177994,"score_spread":0.3171895507537625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394942521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000064639876,0.9919273,0.00035680024,0.00051454117,0.0047079423,0.0014388113,0.00047146465,0.000008730801,0.0005679027],"genre_scores_gemma":[0.00001720836,0.99001676,0.00039908302,0.0003757804,0.005818228,0.0005899478,0.0003289538,0.000060696606,0.0023933353],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869365,0.000054161395,0.0003559578,0.0005249264,0.00010051606,0.00027080634],"domain_scores_gemma":[0.9991168,0.00004261715,0.00020552373,0.00048990815,0.0000488877,0.00009628606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002364988,0.00034478234,0.0007918489,0.000059775466,0.00007286399,0.000017603674,0.00031153616,0.00043555067,0.000011820441],"category_scores_gemma":[0.0000064281853,0.00021180461,0.00047802026,0.00011023564,0.0001448911,0.0000015328997,0.00022941195,0.00020822014,0.0000042401043],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096593416,0.00007328842,1.5520274e-7,0.010330096,0.0014781653,0.0000026086884,0.000036094192,2.3289056e-7,0.000061199156,0.0048241704,0.009124117,0.9739733],"study_design_scores_gemma":[0.00049284275,0.00020214012,0.000007992118,0.00047579684,0.0069872863,0.000027930622,0.00007995142,0.000002969141,0.000005862544,0.00014703479,0.99135184,0.00021837746],"about_ca_topic_score_codex":0.0000024512617,"about_ca_topic_score_gemma":0.000023350927,"teacher_disagreement_score":0.9822277,"about_ca_system_score_codex":0.000032537955,"about_ca_system_score_gemma":0.0003640332,"threshold_uncertainty_score":0.86371416},"labels":[],"label_agreement":null},{"id":"W4396677006","doi":"10.1080/14796694.2024.2342227","title":"Management of urothelial cancer in patients with chronic kidney disease receiving platinum-based chemotherapy","year":2024,"lang":"en","type":"review","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Université Laval; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cisplatin; Kidney disease; Urothelial cancer; Chemotherapy; Intensive care medicine; Internal medicine; Oncology; Cancer; Disease; Renal function; Bladder cancer; Urology","score_opus":0.015251667884815143,"score_gpt":0.3354459150738934,"score_spread":0.32019424718907824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396677006","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007958714,0.9923922,0.0000051479265,0.0006277143,0.001190342,0.0030362485,0.00073752226,0.00004822423,0.0018830404],"genre_scores_gemma":[0.00024278092,0.99555475,0.00024548365,0.0004202896,0.0010573482,0.0009342169,0.00045389595,0.00014218816,0.0009490457],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99809176,0.00009829413,0.000538897,0.0005914525,0.00032102226,0.00035857005],"domain_scores_gemma":[0.99896216,0.000028656232,0.00026904416,0.0004286544,0.000053690743,0.00025777877],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008298388,0.000509892,0.001733541,0.0002737942,0.000024991854,0.00000814636,0.00016502537,0.00032622894,0.0008995046],"category_scores_gemma":[0.00000431172,0.00032637254,0.0003067616,0.00045800157,0.00007540265,0.00002576847,0.00003998542,0.00047115597,0.000033630127],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011356493,0.0006126395,0.0016380395,0.04677472,0.0011792504,0.0002997713,0.000051576622,0.0000018555094,7.338989e-8,0.000030562394,0.0023500645,0.9459258],"study_design_scores_gemma":[0.007887296,0.0012654266,0.003660807,0.040208288,0.0047048614,0.0000024298342,0.0000053505883,0.000003067694,7.2108935e-7,0.0000066597536,0.94199175,0.00026331918],"about_ca_topic_score_codex":0.000053226682,"about_ca_topic_score_gemma":0.00007420995,"teacher_disagreement_score":0.9456625,"about_ca_system_score_codex":0.001862302,"about_ca_system_score_gemma":0.0038051086,"threshold_uncertainty_score":0.9999188},"labels":[],"label_agreement":null},{"id":"W4397044878","doi":"10.2217/fon-2022-1228","title":"Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Breast cancer; Disease; Oncology; Cancer; Internal medicine","score_opus":0.006321741113262881,"score_gpt":0.29921723161172464,"score_spread":0.29289549049846175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397044878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94101405,0.043284692,0.000022097367,0.013203815,0.00070823624,0.00054285955,0.00088669197,0.000045149736,0.0002923927],"genre_scores_gemma":[0.9934461,0.0042091385,0.0002642235,0.0007586793,0.0005508777,0.00019017041,0.00011175405,0.000033225082,0.00043579863],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990897,0.000026100226,0.00022466815,0.00030199075,0.00013414698,0.00022338846],"domain_scores_gemma":[0.9995112,0.000067702196,0.00006194259,0.00014892948,0.000073953874,0.0001362817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003392381,0.00018500937,0.00041099548,0.00009366224,0.000023721841,0.000005871514,0.000044820896,0.00010113715,0.00038229057],"category_scores_gemma":[0.0000067513784,0.00013332338,0.000044674773,0.00016299977,0.0001222804,0.000086456115,0.000024173962,0.00012172242,0.000006742005],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0082034925,0.0009738949,0.50423396,0.00061825867,0.00027279506,0.00018999311,0.0012646576,0.000054929875,0.001169469,0.0005101064,0.0016333557,0.48087507],"study_design_scores_gemma":[0.006751268,0.0015501672,0.45295918,0.00038518364,0.00017279063,0.00003150509,0.00022359371,0.00010016038,0.00025176187,0.0001888717,0.53720796,0.00017753472],"about_ca_topic_score_codex":0.00011273669,"about_ca_topic_score_gemma":0.0015033314,"teacher_disagreement_score":0.5355746,"about_ca_system_score_codex":0.00036752073,"about_ca_system_score_gemma":0.00030156056,"threshold_uncertainty_score":0.543677},"labels":[],"label_agreement":null},{"id":"W4399553361","doi":"10.1080/14796694.2024.2342224","title":"Real-world comparative effectiveness and safety of pembrolizumab for PD-L1≥50% metastatic non-small-cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Canada Research Chairs; University of Toronto; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Oncology; Internal medicine; PD-L1; Immunotherapy; Cancer; Intensive care medicine","score_opus":0.0218372023544261,"score_gpt":0.36493949076044885,"score_spread":0.34310228840602275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399553361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91923946,0.048107445,0.0024281952,0.0031423834,0.003471662,0.005224495,0.00034967615,0.00009882925,0.01793787],"genre_scores_gemma":[0.99113053,0.003967036,0.0017152838,0.00034520592,0.00069006736,0.0005875306,0.000058120477,0.000039294224,0.0014669205],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988893,0.00015519888,0.0003139161,0.0003189863,0.000093663526,0.00022888098],"domain_scores_gemma":[0.9987994,0.00077979866,0.0001037025,0.00015341306,0.00009239887,0.000071288545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043624258,0.00018783873,0.0007256477,0.00015533816,0.00006104935,0.00000967919,0.000064160486,0.000108600994,0.00017689914],"category_scores_gemma":[0.0000063485572,0.00014217816,0.00015549787,0.00025686613,0.0001351557,0.000040684874,0.000025161795,0.00018378515,0.0000017358428],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25138935,0.001675205,0.011660294,0.055850763,0.010315273,0.00035612166,0.019450556,0.00009822539,0.39733627,0.0055043343,0.061199825,0.18516378],"study_design_scores_gemma":[0.048907325,0.008198408,0.26187968,0.006189446,0.0047058524,0.00024507035,0.0027139876,0.0042459564,0.06471058,0.0002655146,0.5970162,0.00092197635],"about_ca_topic_score_codex":0.00042221494,"about_ca_topic_score_gemma":0.0015326062,"teacher_disagreement_score":0.5358164,"about_ca_system_score_codex":0.00037431795,"about_ca_system_score_gemma":0.00070190284,"threshold_uncertainty_score":0.5797857},"labels":[],"label_agreement":null},{"id":"W4399553470","doi":"10.1080/14796694.2024.2343647","title":"Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Prostate cancer; Castration; Oncology; Internal medicine; Overall survival; Cancer; Hormone","score_opus":0.04179467252351697,"score_gpt":0.4186372159170123,"score_spread":0.3768425433934953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399553470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833647,0.0003190756,0.000010003367,0.004775687,0.0011432135,0.0012459777,0.00012677364,0.0001282005,0.008886357],"genre_scores_gemma":[0.9905838,0.00056063203,0.0013581875,0.0005707228,0.00073829945,0.00024457625,0.00032391364,0.00005007403,0.0055697914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817365,0.00020458913,0.0004377717,0.00044479631,0.00033297876,0.00040621049],"domain_scores_gemma":[0.9987871,0.0004508695,0.00011303147,0.00017880002,0.00026350218,0.0002067204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032204407,0.00022222992,0.0005823937,0.0001849434,0.00010613091,0.000038804137,0.000053122738,0.00010465334,0.00015463495],"category_scores_gemma":[0.000050914932,0.00013288646,0.000119962155,0.00040766818,0.00024741437,0.0001533012,0.000037388403,0.0005856085,0.000040614214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093601726,0.00027304303,0.9648642,0.00013913613,0.00096771243,0.0012897664,0.0011469112,0.0000059517965,0.0000111678855,0.000547915,0.0025065527,0.027311634],"study_design_scores_gemma":[0.004012404,0.0015046649,0.98199666,0.00023282263,0.00047500874,0.000012141241,0.00061132177,0.00010527305,0.000056758905,0.00006259147,0.010776753,0.00015361582],"about_ca_topic_score_codex":0.0006008893,"about_ca_topic_score_gemma":0.004925802,"teacher_disagreement_score":0.027158018,"about_ca_system_score_codex":0.00048114732,"about_ca_system_score_gemma":0.0010795005,"threshold_uncertainty_score":0.5418953},"labels":[],"label_agreement":null},{"id":"W4400775871","doi":"10.1080/14796694.2024.2373687","title":"TURALIO <sup>®</sup> Risk Evaluation and Mitigation Strategy Program (tREMS): 3-year retrospective hepatic safety assessment","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"","keywords":"Medicine; Retrospective cohort study; Risk assessment; Internal medicine; Computer security; Computer science","score_opus":0.030062415351023095,"score_gpt":0.3388680507257841,"score_spread":0.30880563537476097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400775871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753971,0.003513615,0.00006715382,0.0036329485,0.00038742187,0.0026106876,0.00004620675,0.00024838696,0.014096468],"genre_scores_gemma":[0.99298257,0.0008361884,0.0036165658,0.00006862506,0.0010786824,0.00044214644,0.00062270823,0.000031846852,0.00032066554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981021,0.00042045594,0.00032076234,0.00049252366,0.0003861526,0.00027797552],"domain_scores_gemma":[0.9992081,0.00011767108,0.00008901123,0.00021168156,0.00021990818,0.0001536648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077238947,0.0002305738,0.00039638657,0.00015957162,0.00014172692,0.00007081495,0.000044783126,0.00031118066,0.0005625519],"category_scores_gemma":[0.000053213153,0.00017885442,0.00012708892,0.00035473728,0.00008938396,0.0001362738,0.000027109736,0.00046113247,0.00005719387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019084098,0.00034390634,0.6109961,0.00017766687,0.00048012767,0.00021515453,0.0012644816,0.000009970168,0.00016976835,0.0024745124,0.001913615,0.38176385],"study_design_scores_gemma":[0.0038322662,0.00710289,0.7497556,0.00017443656,0.0025948435,0.00021601075,0.0015867251,0.17096826,0.00021570086,0.0020678488,0.0611627,0.00032269323],"about_ca_topic_score_codex":0.0000816413,"about_ca_topic_score_gemma":0.0000717312,"teacher_disagreement_score":0.38144115,"about_ca_system_score_codex":0.0009595417,"about_ca_system_score_gemma":0.00054145814,"threshold_uncertainty_score":0.72934717},"labels":[],"label_agreement":null},{"id":"W4400959505","doi":"10.1080/14796694.2024.2363131","title":"The TALAPRO-3 study design: a plain language summary","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Cancer; Internal medicine; Family medicine; Androgen receptor","score_opus":0.02806034429463618,"score_gpt":0.3820710198024786,"score_spread":0.35401067550784243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400959505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5610472,0.21611552,0.00015146431,0.109012425,0.00717018,0.007984084,0.000044010972,0.0008069591,0.09766813],"genre_scores_gemma":[0.9157517,0.0014776196,0.00036572415,0.0006594778,0.0040320395,0.00060619536,0.000055479653,0.000054713524,0.07699708],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99902344,0.0001821446,0.00011969074,0.00021760074,0.00017988369,0.0002772447],"domain_scores_gemma":[0.99933386,0.0003187991,0.000014074601,0.00021607178,0.00003038395,0.00008679369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048577634,0.000103696795,0.00017523971,0.00006606889,0.00014376818,0.000035844405,0.00009739035,0.00009790462,0.00014113146],"category_scores_gemma":[0.000028419416,0.000051099087,0.000057137768,0.00021863829,0.00008253316,0.00002891177,0.000053246353,0.00035371416,0.0001620362],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034002247,0.0010991861,0.0027085247,0.0001661563,0.0010391562,0.017295381,0.016673835,0.0000014011944,0.0058997446,0.0010196662,0.48049957,0.47019717],"study_design_scores_gemma":[0.0026227685,0.0049167336,0.0034932634,0.000054860066,0.00017115039,0.00021102348,0.01585862,0.000117762844,0.0008670969,0.00014446843,0.97143817,0.000104053164],"about_ca_topic_score_codex":0.000023823764,"about_ca_topic_score_gemma":0.00009733207,"teacher_disagreement_score":0.49093863,"about_ca_system_score_codex":0.0002490856,"about_ca_system_score_gemma":0.00045904983,"threshold_uncertainty_score":0.20837602},"labels":[],"label_agreement":null},{"id":"W4401091657","doi":"10.1080/14796694.2024.2355079","title":"Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"BeiGene","keywords":"Ibrutinib; Medicine; Nausea; Quality of life (healthcare); Waldenstrom macroglobulinemia; Vomiting; Internal medicine; Oncology; Population; Randomized controlled trial; Lymphoma; Nursing; Leukemia","score_opus":0.03221721800051643,"score_gpt":0.3559625639351439,"score_spread":0.3237453459346275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401091657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95833284,0.0017445415,0.0000027649023,0.034153007,0.0011574083,0.0015116028,0.00021569246,0.00005153649,0.0028306204],"genre_scores_gemma":[0.99677646,0.00008964732,0.0002660452,0.00090485887,0.0011162707,0.000030592375,0.00043984407,0.000027069405,0.0003491851],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968207,0.000611861,0.0011291174,0.00045444732,0.00058228953,0.00040158292],"domain_scores_gemma":[0.9974106,0.0014756311,0.0002438677,0.0005554386,0.00012816585,0.00018628886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014245193,0.00016894337,0.00083328347,0.00008900224,0.000042430413,0.00001269948,0.0002250397,0.0003867891,0.00020680121],"category_scores_gemma":[0.0009218569,0.00009528875,0.00009501254,0.00052663055,0.00021381184,0.000040567702,0.00011013659,0.0008624655,0.00006722463],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7379433,0.0021814525,0.015252527,0.0006432163,0.001085722,0.0007831942,0.008909107,0.000043368967,0.00005278055,0.0018823844,0.14241299,0.08880999],"study_design_scores_gemma":[0.75889885,0.009490939,0.16197217,0.0006223799,0.00011261889,0.000040495608,0.0009137818,0.0006142601,0.00003122079,0.0002932249,0.066748366,0.00026168543],"about_ca_topic_score_codex":0.012682995,"about_ca_topic_score_gemma":0.005010491,"teacher_disagreement_score":0.14671963,"about_ca_system_score_codex":0.0070617334,"about_ca_system_score_gemma":0.016419275,"threshold_uncertainty_score":0.99675},"labels":[],"label_agreement":null},{"id":"W4401429946","doi":"10.1080/14796694.2024.2368952","title":"A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Biliary tract cancer; Biliary tract; Internal medicine; Phase (matter); Oncology; Cancer; Gemcitabine","score_opus":0.0364592644706835,"score_gpt":0.35599140225920667,"score_spread":0.3195321377885232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401429946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98020077,0.009249522,0.0000012193256,0.007399151,0.00064833957,0.00089459156,0.0006198318,0.000025211739,0.000961372],"genre_scores_gemma":[0.9982703,0.00021279826,0.000023952984,0.00043716616,0.00067949103,0.00012536116,0.00004846865,0.000023172362,0.00017930123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983829,0.00028217773,0.00044217627,0.00036541125,0.00025857374,0.00026871634],"domain_scores_gemma":[0.99856645,0.0006416235,0.00014032223,0.0005568747,0.000042810072,0.000051945222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041567642,0.00018235252,0.0005482542,0.000056424644,0.00004984569,0.000007689958,0.00021911562,0.00011234927,0.00007140597],"category_scores_gemma":[0.00009313883,0.00008721291,0.000081996266,0.00044257712,0.00015904254,0.000042072876,0.00010058057,0.0004394607,0.0000020062232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028854797,0.010830199,0.4161256,0.0005275332,0.0028675832,0.0031234478,0.34725037,0.000039141843,0.02099974,0.0000729627,0.08199664,0.087312005],"study_design_scores_gemma":[0.01769156,0.0042076614,0.8634105,0.00068391045,0.00087853713,0.000032836764,0.084038295,0.00007722744,0.0016126621,0.000015080005,0.027164558,0.0001871749],"about_ca_topic_score_codex":0.008198467,"about_ca_topic_score_gemma":0.052984018,"teacher_disagreement_score":0.4472849,"about_ca_system_score_codex":0.00012641902,"about_ca_system_score_gemma":0.00044612697,"threshold_uncertainty_score":0.99840605},"labels":[],"label_agreement":null},{"id":"W4401584219","doi":"10.1080/14796694.2024.2379228","title":"Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Myelodysplastic syndromes; Family medicine; Medical record; Gerontology; Internal medicine","score_opus":0.01580949038752389,"score_gpt":0.31466583726212866,"score_spread":0.2988563468746048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401584219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9525764,0.0072476338,0.0000042632128,0.03819157,0.0007467593,0.0006812048,0.00009473952,0.000011567791,0.00044587158],"genre_scores_gemma":[0.85481477,0.1352696,0.00029034892,0.007225818,0.0006920698,0.00019617357,0.0001224626,0.000051097693,0.0013376807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804115,0.00033241877,0.00041766072,0.00044788112,0.000382616,0.00037825477],"domain_scores_gemma":[0.9976538,0.00176827,0.00005534657,0.00026688486,0.000035009332,0.00022072493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058070716,0.00024520088,0.0008392657,0.0001402886,0.000048068352,0.00002315473,0.00016728602,0.00022698528,0.00051144673],"category_scores_gemma":[0.00097291387,0.00014025193,0.00003887781,0.00038201935,0.00012541079,0.000039410148,0.00009782469,0.0010006763,0.000046247053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029553066,0.00023315806,0.7869972,0.0010989697,0.00023205046,0.041298226,0.0010898942,4.640667e-8,0.000035491325,0.000060235474,0.03663064,0.13202858],"study_design_scores_gemma":[0.0014809831,0.0010369783,0.6923942,0.0011333851,0.00016621797,0.00096544233,0.00012539056,0.00021099743,8.137492e-7,0.000007678371,0.30235744,0.00012046436],"about_ca_topic_score_codex":0.19813246,"about_ca_topic_score_gemma":0.68425626,"teacher_disagreement_score":0.4861238,"about_ca_system_score_codex":0.0010278707,"about_ca_system_score_gemma":0.0027889109,"threshold_uncertainty_score":0.8072072},"labels":[],"label_agreement":null},{"id":"W4401729249","doi":"10.1080/14796694.2024.2384257","title":"Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Placebo; Androgen deprivation therapy; Oncology; Internal medicine; Prostate-specific antigen; Cancer; Pathology; Alternative medicine","score_opus":0.04384379995837404,"score_gpt":0.3853748239425174,"score_spread":0.3415310239841433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401729249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8366715,0.15354967,1.4083301e-7,0.007973167,0.00005882413,0.0013868979,0.00016341438,0.00002320758,0.00017321503],"genre_scores_gemma":[0.97603023,0.022893667,0.00017418902,0.00010938186,0.00004161503,0.00014414769,0.000055482542,0.000024573923,0.00052671565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848616,0.00022271552,0.00043835086,0.00033372227,0.00023245437,0.00028661644],"domain_scores_gemma":[0.9993076,0.0001192155,0.00019288063,0.00018091161,0.00009642411,0.000102974576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005393265,0.00018239506,0.00076137687,0.0001504255,0.00005856056,0.000007985358,0.000053051288,0.00009815045,0.00001208247],"category_scores_gemma":[0.000021394386,0.00009017313,0.000025972451,0.00056869414,0.0005199268,0.000063702944,0.00005434899,0.00029895804,2.6529247e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042926786,0.0001940059,0.9426504,0.0018304212,0.00062807894,0.0001428389,0.027668534,0.00000917139,0.002761641,0.00026488968,0.00080072717,0.018756643],"study_design_scores_gemma":[0.008832482,0.0040418054,0.95990056,0.0019962462,0.000080941776,0.000036117144,0.018738318,0.000009690498,0.0013514108,0.000056176723,0.004796622,0.0001596473],"about_ca_topic_score_codex":0.0006840905,"about_ca_topic_score_gemma":0.0047910446,"teacher_disagreement_score":0.13935876,"about_ca_system_score_codex":0.00023325559,"about_ca_system_score_gemma":0.0007317225,"threshold_uncertainty_score":0.36771536},"labels":[],"label_agreement":null},{"id":"W4402456192","doi":"10.1080/14796694.2024.2389769","title":"Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review","year":2024,"lang":"en","type":"review","venue":"Future Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Narrative review; Narrative; Oncology; Internal medicine; Intensive care medicine","score_opus":0.05149807865167884,"score_gpt":0.39485149131668174,"score_spread":0.3433534126650029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402456192","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000063087056,0.9868789,0.0000055125543,0.0016837207,0.0008566449,0.008097787,0.00013909776,0.000072833536,0.0022024713],"genre_scores_gemma":[0.000025810492,0.987889,0.0019178988,0.0009075947,0.0020434423,0.0040544393,0.00070005766,0.00015631579,0.0023054222],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99672806,0.00041022332,0.0009522297,0.0010607258,0.0002820112,0.00056675705],"domain_scores_gemma":[0.9979525,0.00040020817,0.0005543509,0.0005498559,0.0001937089,0.00034937594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039647063,0.0009436441,0.0047546285,0.00031434782,0.00010342674,0.000026881473,0.00018450555,0.00070501526,0.000110805304],"category_scores_gemma":[0.00004586737,0.0005539803,0.0011448677,0.00044294764,0.00019671154,0.000036661506,0.00010384456,0.00090644404,0.000089084126],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014228772,0.00024092419,9.340459e-7,0.14945364,0.00084770104,0.0014626655,0.00055335625,4.1962043e-9,0.000001945153,0.00012562581,0.058712095,0.7884588],"study_design_scores_gemma":[0.0017547414,0.006445393,0.0000053096333,0.025793685,0.0124395015,0.0028836406,0.0001617782,6.75293e-7,0.000009719375,0.0000716451,0.95003724,0.00039669077],"about_ca_topic_score_codex":0.0000059213453,"about_ca_topic_score_gemma":0.0000074462,"teacher_disagreement_score":0.8913251,"about_ca_system_score_codex":0.0007186776,"about_ca_system_score_gemma":0.0018122379,"threshold_uncertainty_score":0.9996912},"labels":[],"label_agreement":null},{"id":"W4402567816","doi":"10.1080/14796694.2024.2394323","title":"A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Biotech; Sanofi Pasteur; AbbVie Biotherapeutics; Regeneron Pharmaceuticals; Karyopharm Therapeutics; Janssen Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Daratumumab; Lenalidomide; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Oncology","score_opus":0.02224847335936487,"score_gpt":0.34278931138209917,"score_spread":0.3205408380227343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402567816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047977,0.004876629,0.000028333596,0.00089909433,0.00028487443,0.0022977828,0.00015383259,0.000034828125,0.00094485324],"genre_scores_gemma":[0.9968593,0.00009970229,0.001612619,0.000083399245,0.0003764706,0.0002536442,0.00004867583,0.00003265077,0.0006335332],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985046,0.00022975272,0.00036197223,0.00034599192,0.00025277093,0.00030495643],"domain_scores_gemma":[0.99769104,0.0016336212,0.000118317235,0.0003404442,0.000093597846,0.00012297537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035094723,0.00019064723,0.00062451133,0.00015457935,0.00010407125,0.0000121582625,0.00012419185,0.00014260074,0.00003384109],"category_scores_gemma":[0.0006386247,0.00011708863,0.00014836735,0.00026782142,0.0001369537,0.000048210393,0.00010337085,0.0002586831,0.0000015498032],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027934136,0.0059631676,0.21094537,0.0032385457,0.0047382927,0.003954205,0.084728874,0.000035788507,0.05972803,0.00039248032,0.011782153,0.58655894],"study_design_scores_gemma":[0.15667337,0.028178426,0.57291985,0.0013813501,0.002570009,0.0006461361,0.1644422,0.013623684,0.021023137,0.000071543654,0.037799597,0.00067070447],"about_ca_topic_score_codex":0.0009620241,"about_ca_topic_score_gemma":0.0029270975,"teacher_disagreement_score":0.58588827,"about_ca_system_score_codex":0.00019227913,"about_ca_system_score_gemma":0.00036244828,"threshold_uncertainty_score":0.4774736},"labels":[],"label_agreement":null},{"id":"W4402838411","doi":"10.1080/14796694.2024.2390821","title":"Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review","year":2024,"lang":"en","type":"review","venue":"Future Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bayer HealthCare","keywords":"Medicine; Radiation oncology; Oncology; MEDLINE; Family medicine; Medical education; Internal medicine; Radiation therapy","score_opus":0.04744542064128006,"score_gpt":0.33670153736017533,"score_spread":0.2892561167188953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402838411","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003040076,0.99525976,0.000022911247,0.0005863099,0.00092279474,0.0024143856,0.0004170634,0.000017384036,0.000055358596],"genre_scores_gemma":[0.00001181059,0.9908305,0.00045319507,0.0049489746,0.00067262317,0.00081797363,0.0020237092,0.0000677538,0.00017346405],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969886,0.0006816197,0.0010336789,0.00079544826,0.00010725684,0.00039343],"domain_scores_gemma":[0.99859315,0.00021281588,0.00033583218,0.00046783526,0.00011093907,0.00027943976],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007995054,0.00050376495,0.002106896,0.00035361794,0.000061772385,0.00007991419,0.00024276442,0.00084046216,0.00001279422],"category_scores_gemma":[0.0012425726,0.00041078444,0.00023456253,0.0004971588,0.000065333545,0.0000065881886,0.00025771008,0.00044148698,0.000031288866],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020948448,0.000025131862,0.0000031392372,0.87751466,0.000488956,0.00023665559,0.0004711537,0.000030624033,0.00019214442,0.00018889614,0.06212155,0.058706127],"study_design_scores_gemma":[0.00013419533,0.0005365917,7.794292e-8,0.08062668,0.001399419,0.00017547589,0.00035209206,0.000027269814,0.0000043395735,0.0000070761794,0.91637003,0.00036673466],"about_ca_topic_score_codex":0.00010605665,"about_ca_topic_score_gemma":0.001381767,"teacher_disagreement_score":0.85424846,"about_ca_system_score_codex":0.0008866867,"about_ca_system_score_gemma":0.0015679845,"threshold_uncertainty_score":0.9998344},"labels":[],"label_agreement":null},{"id":"W4403037895","doi":"10.1080/14796694.2024.2406597","title":"Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"AOP Orphan; Cancer Research UK; Galecto; Incyte; Gilead Sciences; CTI Biopharma; Constellation Pharmaceuticals; Celgene","keywords":"Medicine; Ruxolitinib; Polycythemia vera; Internal medicine; Cancer; Oncology; Myelofibrosis; Bone marrow","score_opus":0.01271030447566842,"score_gpt":0.3285629588500332,"score_spread":0.3158526543743648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403037895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96668947,0.006203141,3.3025773e-7,0.018662395,0.00032292702,0.001524624,0.00007612036,0.000023614664,0.0064973845],"genre_scores_gemma":[0.9957142,0.0005216493,0.00005822522,0.0007094592,0.0007682389,0.000964567,0.00002128131,0.000021474254,0.0012209273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883074,0.00022013437,0.0002138014,0.0002822142,0.00021838446,0.0002347332],"domain_scores_gemma":[0.99922526,0.0003005213,0.000057100857,0.00034348344,0.000025962825,0.000047683687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011945757,0.00020441541,0.00041478284,0.00006963366,0.00006007375,0.000012890955,0.00010621288,0.000102318365,0.00019920482],"category_scores_gemma":[0.000009739003,0.000081235106,0.000098316676,0.000284437,0.000077208824,0.000021108097,0.00002339396,0.00020239907,0.0000075563457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002643037,0.015162669,0.7768756,0.000264102,0.0030389768,0.01026959,0.121518664,0.000013324586,0.0012890921,0.005849013,0.0069953213,0.056080572],"study_design_scores_gemma":[0.02184495,0.026420003,0.604346,0.00062365504,0.0030824498,0.0013501488,0.036133416,0.00004454724,0.007889744,0.00005700718,0.29786724,0.00034084969],"about_ca_topic_score_codex":0.0008051505,"about_ca_topic_score_gemma":0.0060238657,"teacher_disagreement_score":0.29087192,"about_ca_system_score_codex":0.00029644903,"about_ca_system_score_gemma":0.00048492238,"threshold_uncertainty_score":0.33614585},"labels":[],"label_agreement":null},{"id":"W4403099656","doi":"10.1080/14796694.2024.2406117","title":"Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"BeiGene; GlaxoSmithKline; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Lung cancer; Crown (dentistry); Internal medicine; Oncology; Dentistry","score_opus":0.01162281737132365,"score_gpt":0.35224840993712775,"score_spread":0.3406255925658041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403099656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658991,0.004527532,0.0000063025345,0.0064391647,0.001326642,0.0012247605,0.00044636798,0.00004330327,0.02008683],"genre_scores_gemma":[0.9945935,0.00018722976,0.0002631483,0.0005332704,0.0012849885,0.0001676816,0.00020370739,0.000028042756,0.0027384066],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.998856,0.00012549268,0.00034150787,0.00033202316,0.0001426915,0.00020225103],"domain_scores_gemma":[0.9990596,0.00044348542,0.000084044266,0.00031082405,0.000044600176,0.00005740128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022977493,0.00014655676,0.00034374834,0.00008639206,0.000048533275,0.000013863781,0.00011677008,0.00013652086,0.00025024472],"category_scores_gemma":[0.000038976963,0.00009095071,0.000061260966,0.00029548563,0.00003728726,0.00003392105,0.000048282676,0.0003328385,0.000015662454],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007637171,0.005212973,0.19459134,0.0005434081,0.0022178565,0.003324785,0.433663,0.00022872128,0.0040292186,0.00034187135,0.29907352,0.049136125],"study_design_scores_gemma":[0.040924046,0.0051433425,0.5072634,0.0010995464,0.0031151106,0.000021946327,0.14074986,0.0011090749,0.0010374862,0.000042471103,0.29902005,0.00047362436],"about_ca_topic_score_codex":0.0077355094,"about_ca_topic_score_gemma":0.018383827,"teacher_disagreement_score":0.3126721,"about_ca_system_score_codex":0.00027813384,"about_ca_system_score_gemma":0.0005053267,"threshold_uncertainty_score":0.9995281},"labels":[],"label_agreement":null},{"id":"W4403763941","doi":"10.1080/14796694.2024.2416885","title":"Colorectal cancer research priorities in Uganda: perspectives from local key experts and stakeholders","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast","keywords":"Medicine; Key (lock); Colorectal cancer; Cancer; Environmental resource management; Internal medicine; Computer science","score_opus":0.07337515650495452,"score_gpt":0.3884960520496344,"score_spread":0.31512089554467987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403763941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9430844,0.044161167,0.00005333499,0.0066033653,0.0011976863,0.00028844265,0.000019199444,0.000109884124,0.004482485],"genre_scores_gemma":[0.99527913,0.0018287223,0.00019496107,0.00010733516,0.0020252594,0.00014856864,0.0000075038515,0.00002229433,0.0003862278],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986853,0.00015629941,0.00015523769,0.0004486724,0.0002453202,0.00030919953],"domain_scores_gemma":[0.9993655,0.0003106658,0.000016208869,0.00009434416,0.00010128483,0.00011198239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030208542,0.00012696143,0.00029565615,0.00029835073,0.00008897837,0.000038270042,0.00004722347,0.00027160576,0.00025104737],"category_scores_gemma":[0.000059901267,0.00010728314,0.000045608012,0.00040219148,0.00034081415,0.00008260242,0.000053702515,0.00066173205,0.0000067508236],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023205768,0.00031787858,0.015227405,0.00032403143,0.0003696752,0.0022575601,0.1795144,0.000018038763,0.030695394,0.0020664553,0.028804269,0.71719915],"study_design_scores_gemma":[0.004553886,0.01195166,0.14790319,0.0007690095,0.00011212754,0.00043225192,0.2922478,0.0015466788,0.008399672,0.0010114171,0.5305912,0.00048110474],"about_ca_topic_score_codex":0.004303846,"about_ca_topic_score_gemma":0.01514467,"teacher_disagreement_score":0.716718,"about_ca_system_score_codex":0.0010318847,"about_ca_system_score_gemma":0.00066639483,"threshold_uncertainty_score":0.84510815},"labels":[],"label_agreement":null},{"id":"W4403875478","doi":"10.1080/14796694.2024.2418804","title":"Part 1 – Highlights of the San Antonio Breast Cancer Symposium 2023","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Gerontology; Gynecology; Cancer","score_opus":0.006062885189194204,"score_gpt":0.265901607386362,"score_spread":0.2598387221971678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403875478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5482801,0.08004951,0.00003750028,0.26898065,0.037756268,0.0011639637,0.003003264,0.00015487413,0.060573854],"genre_scores_gemma":[0.9866133,0.003976855,0.00005141374,0.0006824773,0.0053097373,0.0001283426,0.000057575384,0.000030167428,0.0031501856],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991625,0.000065331,0.00015451857,0.0003117043,0.0000951474,0.00021079986],"domain_scores_gemma":[0.99953485,0.000016675776,0.000056877045,0.00029081645,0.000061608844,0.00003918356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057679696,0.00015325776,0.00018782757,0.000023906858,0.000078351906,0.000008517195,0.00018810597,0.00019225918,0.00018297734],"category_scores_gemma":[0.0000031330906,0.00009369335,0.00012496077,0.00014202803,0.00014874844,0.0000026442078,0.0001452368,0.000095582574,0.000016296392],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004193309,0.0003120198,0.011867259,0.00021487012,0.001511801,0.00004551692,0.00066443416,0.000035368066,0.2200194,0.0047911904,0.73810714,0.022011641],"study_design_scores_gemma":[0.00032709062,0.00010345147,0.028716894,0.000048096714,0.000110455716,0.00010159064,0.00008423005,0.000002423993,0.022494692,0.000037304762,0.94786066,0.00011310143],"about_ca_topic_score_codex":0.00012803165,"about_ca_topic_score_gemma":0.0012141175,"teacher_disagreement_score":0.43833312,"about_ca_system_score_codex":0.00007992561,"about_ca_system_score_gemma":0.00027272844,"threshold_uncertainty_score":0.3820704},"labels":[],"label_agreement":null},{"id":"W4403875943","doi":"10.1080/14796694.2024.2418797","title":"Part 2 – Highlights of the San Antonio Breast Cancer Symposium 2023","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"","keywords":"Medicine; Breast cancer; Oncology; Cancer; Internal medicine; Gynecology","score_opus":0.009030785945327625,"score_gpt":0.3010043440202266,"score_spread":0.29197355807489894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403875943","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14901873,0.056299575,0.00011240445,0.68792814,0.043157354,0.0017581496,0.0009116451,0.0005490917,0.060264934],"genre_scores_gemma":[0.95486116,0.0028083185,0.00045753023,0.0041847867,0.016843406,0.00022529428,0.000030679334,0.000105205094,0.020483628],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989617,0.000061355284,0.00023057799,0.000281812,0.00019751056,0.00026705553],"domain_scores_gemma":[0.9993311,0.00006201228,0.00007828958,0.0003510076,0.000094810166,0.00008274875],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009090865,0.00016124103,0.00035431204,0.00006536213,0.00005855503,0.000007071277,0.00015649562,0.00018580195,0.0016014499],"category_scores_gemma":[0.000004057012,0.00009333573,0.00013496255,0.00035579412,0.00019955447,0.000062167994,0.000059367583,0.0003007648,0.000046190078],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00302815,0.0007566421,0.009433852,0.0018823366,0.002124076,0.0006601471,0.005907121,0.00011037124,0.24350737,0.048079178,0.30896595,0.37554482],"study_design_scores_gemma":[0.0006937716,0.00016229645,0.019041814,0.0002992729,0.00015945769,0.00065984065,0.00017910794,0.000017035944,0.0040269666,0.00021429158,0.9744468,0.00009938169],"about_ca_topic_score_codex":0.00008631365,"about_ca_topic_score_gemma":0.00035602273,"teacher_disagreement_score":0.8058424,"about_ca_system_score_codex":0.00033650658,"about_ca_system_score_gemma":0.00058908726,"threshold_uncertainty_score":0.9993112},"labels":[],"label_agreement":null},{"id":"W4404275600","doi":"10.1080/14796694.2024.2421151","title":"Inflammatory markers correlate with lymphocytes infiltrating and predict immunotherapy prognosis for esophageal cancer","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Government of Jiangsu Province","keywords":"Medicine; Tumor-infiltrating lymphocytes; Esophageal cancer; Immunotherapy; Oncology; Immunology; Cancer; Internal medicine; Pathology","score_opus":0.008220770756086012,"score_gpt":0.2852142627647132,"score_spread":0.27699349200862716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404275600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89483315,0.08844684,0.00032192492,0.008304857,0.0026503715,0.0023811867,0.00009037671,0.00037631183,0.0025949716],"genre_scores_gemma":[0.9701318,0.012559021,0.005006748,0.003654263,0.00353627,0.0020088982,0.00009054922,0.00016417244,0.0028482736],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887854,0.00005316308,0.00028531378,0.00034721335,0.00013385672,0.0003019185],"domain_scores_gemma":[0.99939835,0.00022629106,0.00008570032,0.0001388633,0.00006685194,0.000083970255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034576145,0.00021700075,0.0003422743,0.00011923602,0.00011597229,0.000043312768,0.00006363391,0.00025401296,0.00019986641],"category_scores_gemma":[0.000011518963,0.00015236741,0.000103341525,0.000194398,0.0001981547,0.00010366566,0.000014161008,0.00021349572,0.0000023881905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02694799,0.00012039866,0.045211367,0.0011990131,0.0024163814,0.00027830154,0.0026303402,0.0000067092305,0.01906952,0.00041004806,0.018482553,0.88322735],"study_design_scores_gemma":[0.012194446,0.004959446,0.106569245,0.0010034487,0.0004503753,0.0009019874,0.0010236638,0.0015525096,0.0021375255,0.00004491584,0.868771,0.00039144576],"about_ca_topic_score_codex":0.00006574555,"about_ca_topic_score_gemma":0.00012201004,"teacher_disagreement_score":0.8828359,"about_ca_system_score_codex":0.00036027777,"about_ca_system_score_gemma":0.0008970477,"threshold_uncertainty_score":0.6213363},"labels":[],"label_agreement":null},{"id":"W4405308923","doi":"10.1080/14796694.2024.2426425","title":"Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; Pfizer","keywords":"Medicine; Prostate cancer; Enzalutamide; Biochemical recurrence; Radiation therapy; Cancer; Oncology; Testosterone (patch); Quality of life (healthcare); Adverse effect; Internal medicine; Prostatectomy; Urology","score_opus":0.013786439810920353,"score_gpt":0.34443305239049077,"score_spread":0.3306466125795704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405308923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944339,0.002541479,0.0000032054384,0.00119047,0.00018279967,0.0011787227,0.00027534633,0.000043369906,0.0001507121],"genre_scores_gemma":[0.9974228,0.0006117442,0.00060400943,0.0000744445,0.000171937,0.00016230621,0.00015812283,0.00002591111,0.00076872663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854386,0.0001868567,0.0002752636,0.00043280708,0.00025015633,0.0003110344],"domain_scores_gemma":[0.99910104,0.0003412581,0.00010082885,0.00023095122,0.000055687862,0.0001702521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000240134,0.00024489922,0.0007901486,0.00015481161,0.000032740696,0.000013210034,0.000058115274,0.00017834362,0.000038366532],"category_scores_gemma":[0.000068572124,0.0000986652,0.000047834368,0.00021340913,0.00022160988,0.000057466466,0.00003749968,0.00028806584,0.0000023138768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016791295,0.00061829796,0.95544636,0.00039926538,0.00045625624,0.00015511518,0.001739021,1.6569116e-7,0.00063963304,0.000033865923,0.00015224109,0.023568466],"study_design_scores_gemma":[0.034030918,0.026369449,0.92421794,0.00053424726,0.0004592816,0.000012380646,0.0022736979,0.000021800282,0.009659152,0.000041047722,0.0020325962,0.00034750788],"about_ca_topic_score_codex":0.0014939839,"about_ca_topic_score_gemma":0.003339789,"teacher_disagreement_score":0.031228457,"about_ca_system_score_codex":0.0004176689,"about_ca_system_score_gemma":0.0006457127,"threshold_uncertainty_score":0.402345},"labels":[],"label_agreement":null},{"id":"W4405417317","doi":"10.1080/14796694.2024.2436342","title":"Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Stage (stratigraphy); Cancer stage; Productivity; Cancer; Family medicine; Gerontology; Internal medicine; Economic growth","score_opus":0.040257847580596424,"score_gpt":0.31565611209725597,"score_spread":0.27539826451665955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405417317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794902,0.010810869,0.000049105784,0.00030785342,0.0013181575,0.00039566777,0.006255992,0.000013033674,0.00135911],"genre_scores_gemma":[0.99541885,0.003442651,0.000047139434,0.000053859127,0.00024844476,0.000060251532,0.000046754514,0.000019393283,0.0006626737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989407,0.000020058897,0.00029770593,0.00047682185,0.000018519422,0.0002462107],"domain_scores_gemma":[0.9993918,0.00012588201,0.00022872302,0.00013209139,0.00004826386,0.000073273855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032458061,0.00016419135,0.00046607078,0.00010829658,0.000055082703,0.000036090776,0.000090117515,0.00015645161,0.00005362304],"category_scores_gemma":[0.00011453741,0.00015570562,0.00007107538,0.000109845816,0.000116935786,0.00024344842,0.00003560832,0.00013939422,0.0000058227715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026895286,0.00011895973,0.93208414,0.0000932446,0.00009315268,8.311981e-7,0.0005743972,0.000006507119,0.000006281796,0.005332669,0.019741148,0.041679725],"study_design_scores_gemma":[0.00059475104,0.0014497656,0.7957033,0.000024903306,0.000006817094,4.0806543e-7,0.0000074903114,0.000033827167,0.000024578516,0.000698392,0.20130068,0.00015511995],"about_ca_topic_score_codex":0.0046791905,"about_ca_topic_score_gemma":0.0011431201,"teacher_disagreement_score":0.18155953,"about_ca_system_score_codex":0.00028513224,"about_ca_system_score_gemma":0.00010289903,"threshold_uncertainty_score":0.70735675},"labels":[],"label_agreement":null},{"id":"W4405453061","doi":"10.1080/14796694.2024.2421152","title":"An early economic evaluation of active surveillance for low-risk ductal carcinoma <i>in situ</i>","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Psychosocial Oncology","funders":"KWF Kankerbestrijding; Cancer Research UK","keywords":"Medicine; Ductal carcinoma; In situ; Carcinoma in situ; Breast cancer; Carcinoma; Oncology; Cancer; Internal medicine","score_opus":0.04332710442107975,"score_gpt":0.38525093509850805,"score_spread":0.3419238306774283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405453061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921265,0.0014065064,0.000044671953,0.00074317475,0.0010897767,0.00053484226,0.00007954299,0.000021805532,0.0039531845],"genre_scores_gemma":[0.99809134,0.000044072473,0.0003303226,0.00011577861,0.0012549333,0.000067689085,0.000057404166,0.000012628254,0.00002585112],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99904734,0.00013379226,0.000219523,0.00027551813,0.00014236996,0.0001814625],"domain_scores_gemma":[0.9994656,0.00010956124,0.00007833495,0.00016047525,0.00012656744,0.00005947736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082113553,0.00009376099,0.00029212426,0.000090990885,0.000023302837,0.00000763988,0.000070339695,0.00015742016,0.00007109631],"category_scores_gemma":[0.000051251747,0.00008503609,0.00007632974,0.000095260744,0.000040764273,0.00012364972,0.000011190021,0.00017405662,0.0000136467925],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006598317,0.00029778644,0.419304,0.0003992508,0.00029382738,0.00022765833,0.0071031535,0.0014115879,0.04547672,0.002983272,0.009348951,0.50655544],"study_design_scores_gemma":[0.003015246,0.002943985,0.9699677,0.00007650709,0.0001923671,0.00007577586,0.0015507479,0.009305114,0.0047646486,0.00063702744,0.007317185,0.00015365583],"about_ca_topic_score_codex":0.0004917818,"about_ca_topic_score_gemma":0.004197566,"teacher_disagreement_score":0.5506637,"about_ca_system_score_codex":0.0006314163,"about_ca_system_score_gemma":0.0007773512,"threshold_uncertainty_score":0.3467671},"labels":[],"label_agreement":null},{"id":"W4405696229","doi":"10.1080/14796694.2024.2442900","title":"Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"review","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone acetate; PARP inhibitor; Androgen receptor; Enzalutamide; Oncology; Internal medicine; PARP1; Cancer research; Androgen deprivation therapy; Abiraterone; Cancer; Poly ADP ribose polymerase; Gene; Biology","score_opus":0.10008847965426025,"score_gpt":0.46419381523950315,"score_spread":0.3641053355852429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405696229","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003376701,0.98799044,0.000060969287,0.003231565,0.00313781,0.0040607606,0.00097584364,0.000089644745,0.00041922077],"genre_scores_gemma":[0.000034375564,0.988167,0.001256948,0.00049820245,0.0019470216,0.004447368,0.0011246313,0.00010880579,0.002415673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977997,0.00022178072,0.00082443666,0.00061856396,0.00019682517,0.00033870497],"domain_scores_gemma":[0.9987276,0.00020112637,0.0004594042,0.00027135672,0.0001941913,0.00014628634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043352722,0.00046017222,0.001972553,0.0002949776,0.000097304684,0.000051093353,0.000085436295,0.00039149323,0.00015233479],"category_scores_gemma":[0.000027434817,0.00034052483,0.00027738174,0.00028635564,0.00012816393,0.00006852622,0.000028053255,0.00051062705,0.00003383762],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039974856,0.00017059577,0.0000010636469,0.048058152,0.0009806574,0.00007602579,0.00043377714,2.7093537e-7,0.000115954834,0.0024331724,0.0433319,0.9039987],"study_design_scores_gemma":[0.002719597,0.0013610659,0.0000069376483,0.006085121,0.0041523925,0.00026671655,0.00007985864,0.00001247256,0.0000134985185,0.000578687,0.98444647,0.00027720272],"about_ca_topic_score_codex":0.000025391626,"about_ca_topic_score_gemma":0.00017159783,"teacher_disagreement_score":0.94111454,"about_ca_system_score_codex":0.00088007475,"about_ca_system_score_gemma":0.0015644672,"threshold_uncertainty_score":0.9999047},"labels":[],"label_agreement":null},{"id":"W4406227864","doi":"10.1080/14796694.2024.2439178","title":"Asciminib versus bosutinib following 2 or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL study","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Bosutinib; Medicine; Myeloid leukemia; Oncology; Side effect (computer science); Internal medicine; Tyrosine-kinase inhibitor; Drug; Imatinib; Pharmacology; Nilotinib; Cancer","score_opus":0.017235741951038337,"score_gpt":0.3434522840867526,"score_spread":0.32621654213571427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406227864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97976744,0.004988883,0.0000016260575,0.0031967713,0.0020699808,0.002045688,0.0000139563645,0.000066189066,0.007849479],"genre_scores_gemma":[0.99293983,0.00016890554,0.00026578415,0.00057477236,0.0005348677,0.00021770629,0.0000262773,0.000037471924,0.005234357],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99774784,0.0003356924,0.00057086826,0.00049987907,0.00034873543,0.00049699534],"domain_scores_gemma":[0.99823296,0.0006201809,0.00019705776,0.00083537603,0.000043606182,0.00007080611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047760163,0.0003296282,0.0008890213,0.00024144199,0.00012430978,0.000009324972,0.00040084412,0.00040124176,0.00018690765],"category_scores_gemma":[0.00026857137,0.00020432321,0.00026228785,0.00079734524,0.00014801319,0.000059118513,0.00025547,0.0007330067,0.000011337805],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.049244966,0.008422371,0.2517708,0.0019697223,0.011206975,0.0106235705,0.13682447,0.0001748746,0.03569643,0.0010369504,0.042035148,0.45099372],"study_design_scores_gemma":[0.15015338,0.010927065,0.5507828,0.0013949478,0.002163374,0.00012069149,0.1169752,0.00020153864,0.004838048,0.000034229095,0.16173495,0.0006737412],"about_ca_topic_score_codex":0.0005202632,"about_ca_topic_score_gemma":0.00855107,"teacher_disagreement_score":0.45031998,"about_ca_system_score_codex":0.008016142,"about_ca_system_score_gemma":0.006951465,"threshold_uncertainty_score":0.9986782},"labels":[],"label_agreement":null},{"id":"W4406468796","doi":"10.1080/14796694.2024.2441107","title":"Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Eli Lilly Japan; Chugai Pharmaceutical; EMD Serono; Genentech; Sierra Oncology; Sun Pharma; Rakuten Medical; STCube; FibroGen; Astellas Pharma; Eisai; Regeneron Pharmaceuticals; Natera; Relay Therapeutics; Seagen; Actuate Therapeutics; BeiGene; Taiho Pharmaceutical; Kyowa Kirin Pharmaceutical Development; Pfizer; Incyte; Daiichi Sankyo Europe; Servier; Gilead Sciences; Japan Society for the Promotion of Science; GlaxoSmithKline; Mersana Therapeutics; Japan Agency for Medical Research and Development; Roivant Sciences; Amgen; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Agonist; Sting; Open label; Oncology; Internal medicine; Receptor; Clinical trial","score_opus":0.016672539311782555,"score_gpt":0.36328153072606967,"score_spread":0.34660899141428714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406468796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99123293,0.00082289206,0.00013698712,0.00030226164,0.0019987023,0.0022873345,0.00011701758,0.000047580845,0.0030542654],"genre_scores_gemma":[0.9949525,0.00001617887,0.0005193178,0.00034133028,0.000040767525,0.00029329446,0.00021669581,0.000026534633,0.003593396],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.998116,0.0003625875,0.00057358254,0.0004468557,0.000036825622,0.00046415426],"domain_scores_gemma":[0.99853075,0.0003615417,0.00036893092,0.0003978391,0.0003189797,0.000021988642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024760235,0.00027304064,0.00085219496,0.0002011748,0.0003436721,0.000020533816,0.00065544725,0.0002742756,0.00013827576],"category_scores_gemma":[0.00016665328,0.000212643,0.0000492819,0.00023453191,0.00020073248,0.00011416272,0.00034639763,0.00032710374,0.000024076624],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21141487,0.055143584,0.004650345,0.00037871004,0.003599133,0.00005499782,0.008016279,0.000029505161,0.39593035,0.004371553,0.032529213,0.28388146],"study_design_scores_gemma":[0.26591107,0.13489515,0.011104194,0.00038444425,0.0006513922,0.000041099014,0.021213066,0.00002486128,0.0662533,0.00009627322,0.49851882,0.0009063044],"about_ca_topic_score_codex":0.00005498669,"about_ca_topic_score_gemma":0.00020073444,"teacher_disagreement_score":0.46598962,"about_ca_system_score_codex":0.00018168137,"about_ca_system_score_gemma":0.0005412998,"threshold_uncertainty_score":0.867133},"labels":[],"label_agreement":null},{"id":"W4406479425","doi":"10.1080/14796694.2025.2449782","title":"Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AstraZeneca","keywords":"Medicine; Ovarian cancer; Genetic testing; Family medicine; Cancer; Biomarker; MEDLINE; Oncology; Internal medicine","score_opus":0.015628567683929017,"score_gpt":0.31745120063273,"score_spread":0.301822632948801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406479425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99215126,0.00042082177,0.0052169748,0.00016033632,0.0005495678,0.0005706635,0.0003284424,0.0000048418956,0.00059710105],"genre_scores_gemma":[0.98316896,0.00018373525,0.015704684,0.0002130181,0.00013268429,0.00023884297,0.0002531804,0.0000152222765,0.00008964475],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999319,0.00007141158,0.00017998107,0.00025225675,0.000059096623,0.00011825529],"domain_scores_gemma":[0.9990332,0.000121894,0.00014500011,0.00024102733,0.00043822062,0.000020624826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008880175,0.000108047585,0.00014097078,0.000045530087,0.00008122032,0.000009224888,0.00018875372,0.000076890676,0.000004281247],"category_scores_gemma":[0.00002735015,0.00008461237,0.0000311184,0.00019103335,0.00013214021,0.000009108322,0.00007928142,0.000043243934,1.319557e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007447487,0.0005895799,0.30265623,0.000114867966,0.00094224105,4.8972885e-7,0.00023258495,0.0012818091,0.013485795,0.00057606056,0.0015209602,0.67785466],"study_design_scores_gemma":[0.0019073939,0.00034969026,0.98489046,0.00003658424,0.00010438916,1.616507e-7,0.0002970738,0.00026051403,0.0005340605,0.000060997692,0.011471768,0.00008692602],"about_ca_topic_score_codex":0.00006488032,"about_ca_topic_score_gemma":0.0013234909,"teacher_disagreement_score":0.6822342,"about_ca_system_score_codex":0.00006016439,"about_ca_system_score_gemma":0.00016734411,"threshold_uncertainty_score":0.34503925},"labels":[],"label_agreement":null},{"id":"W4406482305","doi":"10.1080/14796694.2024.2435208","title":"Avelumab maintenance treatment for advanced urothelial cancer: plain language summary of long-term results from the JAVELIN Bladder 100 study","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Javelin; Medicine; Urothelial cancer; Avelumab; Bladder cancer; Term (time); Oncology; Internal medicine; Urology; Intensive care medicine; Cancer; Immunotherapy; Pembrolizumab; Astronomy","score_opus":0.019722409884365175,"score_gpt":0.35553043528897854,"score_spread":0.33580802540461335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406482305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9522623,0.0082248375,0.00030628138,0.016268836,0.0031281693,0.0070088906,0.004464431,0.00010324519,0.008233002],"genre_scores_gemma":[0.97952455,0.0010691284,0.00064252614,0.0022152083,0.001928003,0.0013637585,0.00044307308,0.000048342245,0.012765387],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99821144,0.00015271117,0.0005273441,0.0005504188,0.00018122641,0.00037686995],"domain_scores_gemma":[0.99841523,0.00051814993,0.00021216195,0.0006302203,0.00014075825,0.00008350763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017539533,0.00031119192,0.0007423966,0.000075989694,0.00013276807,0.000009298872,0.00022449448,0.00020444275,0.00015106266],"category_scores_gemma":[0.0000827959,0.00018897204,0.00020919541,0.00019755222,0.00011255804,0.00003638723,0.00005627464,0.00019031338,0.0000082712495],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.078610264,0.008240918,0.07292565,0.00015713452,0.0058331355,0.00072547497,0.02400986,0.0000416216,0.0070668473,0.0002833125,0.046741314,0.7553645],"study_design_scores_gemma":[0.21110712,0.025685586,0.47727942,0.000926166,0.0053271553,0.000044324446,0.021067804,0.000075827455,0.02365037,0.00026444634,0.2337681,0.0008036575],"about_ca_topic_score_codex":0.002354002,"about_ca_topic_score_gemma":0.010443287,"teacher_disagreement_score":0.7545608,"about_ca_system_score_codex":0.0006413746,"about_ca_system_score_gemma":0.0009944516,"threshold_uncertainty_score":0.7706056},"labels":[],"label_agreement":null},{"id":"W4406486966","doi":"10.1080/14796694.2024.2440277","title":"Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of Alberta; Precision Nanosystems (Canada); University of Ottawa; University of British Columbia; Ottawa Hospital; Queen's University","funders":"National Health and Medical Research Council; Medical Research Council; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Hormone therapy; Cancer; Androgen receptor; Breast cancer","score_opus":0.01844197879047274,"score_gpt":0.35905948134062665,"score_spread":0.3406175025501539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406486966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.944756,0.017772187,0.00020997254,0.026018834,0.0007732327,0.0074988287,0.0012245369,0.00004777697,0.0016986489],"genre_scores_gemma":[0.9411916,0.015689768,0.0045702597,0.0046164924,0.001946875,0.0041924957,0.0005144339,0.0001239539,0.02715409],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852794,0.00018363543,0.00031046843,0.00032154523,0.00027935323,0.00037704228],"domain_scores_gemma":[0.9986671,0.00047171122,0.00017852706,0.00032767362,0.00027739743,0.00007757041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043016294,0.0002186628,0.0007169568,0.00013502629,0.00015043188,0.000010351727,0.00013600472,0.0001261371,0.00003350707],"category_scores_gemma":[0.00008811667,0.00011166198,0.00016564368,0.0004071782,0.0002639523,0.000041053096,0.000050852654,0.00030356584,8.0063376e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8431498,0.00091502053,0.0013746206,0.00046487266,0.0024718137,0.0002485987,0.009087046,0.000031243166,0.0079176845,0.0005379612,0.036756862,0.09704452],"study_design_scores_gemma":[0.36951017,0.033604946,0.0039802436,0.0006320326,0.0012804286,0.000045655812,0.008639638,0.0001225853,0.07777204,0.00056536274,0.5034718,0.0003750861],"about_ca_topic_score_codex":0.00017613308,"about_ca_topic_score_gemma":0.0009367989,"teacher_disagreement_score":0.47363958,"about_ca_system_score_codex":0.0005606968,"about_ca_system_score_gemma":0.0018397615,"threshold_uncertainty_score":0.45534435},"labels":[],"label_agreement":null},{"id":"W4406852237","doi":"10.1080/14796694.2025.2454895","title":"Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Discontinuation; Internal medicine; Oncology; Pediatrics; Intensive care medicine","score_opus":0.017927463657704014,"score_gpt":0.3361532998949089,"score_spread":0.31822583623720485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406852237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652815,0.00009380472,0.000061784354,0.027131166,0.00014502901,0.0034198416,0.00021143389,0.00007866312,0.003576795],"genre_scores_gemma":[0.9841292,0.0005662822,0.005901867,0.0029709209,0.00015879369,0.0017356813,0.00074058474,0.00004059283,0.003756115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867415,0.00006452886,0.00029446618,0.00048214168,0.00013031873,0.00035440666],"domain_scores_gemma":[0.99904007,0.00020635013,0.00015956564,0.00025654858,0.00015130853,0.00018616373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006163743,0.00034292173,0.0009151633,0.0001782673,0.00020564544,0.000020321799,0.000037448095,0.0001084147,0.0000459656],"category_scores_gemma":[0.0000064975675,0.0001812224,0.00007058346,0.00019613758,0.00005854318,0.000040026647,0.000016788079,0.00008477251,0.0000025561026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016695153,0.0017760328,0.947758,0.00010871468,0.00069684925,0.000018753992,0.0002775065,5.1063216e-7,0.0000014651201,0.0012889424,0.0018775025,0.04452619],"study_design_scores_gemma":[0.016922144,0.021063652,0.9218842,0.00017437455,0.00039422035,0.0000053221956,0.00016518179,0.0000053197377,0.00019396732,0.000011744247,0.03904074,0.00013917056],"about_ca_topic_score_codex":0.0010158356,"about_ca_topic_score_gemma":0.014797576,"teacher_disagreement_score":0.044387016,"about_ca_system_score_codex":0.0007186507,"about_ca_system_score_gemma":0.000424812,"threshold_uncertainty_score":0.82573944},"labels":[],"label_agreement":null},{"id":"W4407918416","doi":"10.1080/14796694.2025.2466416","title":"Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiative","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Real world data; Lung cancer; Clinical trial; Mesothelioma; Immunotherapy; Intensive care medicine; Oncology; Cancer; Internal medicine; Pathology; Data science","score_opus":0.10770230903221834,"score_gpt":0.501525485878789,"score_spread":0.39382317684657064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407918416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002137378,0.9214489,0.0000026232065,0.012868392,0.0016028004,0.001519029,0.00011625097,0.00003338096,0.062387243],"genre_scores_gemma":[0.00002281312,0.9901182,0.00086227915,0.0010875734,0.00262079,0.0013326558,0.00067934894,0.00004012485,0.0032362218],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99693877,0.0008676184,0.00060527655,0.0006754124,0.0004476202,0.00046529828],"domain_scores_gemma":[0.99462515,0.004244851,0.00029445224,0.0004992137,0.00023571205,0.00010060968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011056648,0.00034423487,0.0016122188,0.00053866755,0.00012757935,0.000034675897,0.00045903798,0.0004340144,0.00056645146],"category_scores_gemma":[0.00031207103,0.00020812365,0.00031901177,0.0009774936,0.00013289959,0.00005541468,0.0003149924,0.0018060234,0.00010471947],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012806623,0.00028419512,0.00079972675,0.0031071901,0.0005196151,0.00074724597,0.00068570307,0.0000018006194,1.0899924e-7,0.0007771969,0.06320581,0.92974335],"study_design_scores_gemma":[0.0006563704,0.00025744765,0.000452022,0.035104994,0.0006138329,0.000019505032,0.0007864014,0.0000016920304,0.000001166409,0.00015100671,0.9618162,0.00013937001],"about_ca_topic_score_codex":0.0008908505,"about_ca_topic_score_gemma":0.0067771454,"teacher_disagreement_score":0.929604,"about_ca_system_score_codex":0.0053165206,"about_ca_system_score_gemma":0.0037608796,"threshold_uncertainty_score":0.9985019},"labels":[],"label_agreement":null},{"id":"W4408042402","doi":"10.1080/14796694.2025.2459548","title":"CAMBRIA-1 &amp; CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Endocrine system; Metastatic breast cancer; Cancer; Gynecology; Hormone","score_opus":0.04278605245297019,"score_gpt":0.4233400671943058,"score_spread":0.3805540147413356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408042402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9241165,0.017439604,0.0010003517,0.036373325,0.010738851,0.0029482192,0.0011843113,0.00030543967,0.0058933822],"genre_scores_gemma":[0.9710181,0.008103689,0.0026201913,0.0038113412,0.006975313,0.0011263125,0.00022730544,0.0001452662,0.0059724892],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99636656,0.00063330424,0.0010458226,0.0007424962,0.00038575404,0.0008260715],"domain_scores_gemma":[0.9977984,0.00065019017,0.0003586788,0.00065273116,0.00030835008,0.00023163689],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009913598,0.0005120931,0.0020524699,0.00042303148,0.000120037475,0.00002792011,0.00027332944,0.00038175224,0.0014414983],"category_scores_gemma":[0.00016684539,0.0004160871,0.00029868644,0.0007556111,0.0002560235,0.00015885063,0.00006106567,0.0008548122,0.000024123783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24911979,0.00086931785,0.0017562557,0.00008435282,0.0010492832,0.00048329917,0.0011593836,0.00002423236,0.015002175,0.0012264473,0.00643661,0.7227889],"study_design_scores_gemma":[0.16797557,0.0024684311,0.018373948,0.00023890182,0.00030316124,0.00023192746,0.00080305245,0.0000089532905,0.0013482746,0.00016241096,0.8076933,0.0003920927],"about_ca_topic_score_codex":0.00303327,"about_ca_topic_score_gemma":0.007771135,"teacher_disagreement_score":0.80125666,"about_ca_system_score_codex":0.0017750175,"about_ca_system_score_gemma":0.0020919605,"threshold_uncertainty_score":0.9998291},"labels":[],"label_agreement":null},{"id":"W4408207552","doi":"10.1080/14796694.2025.2471200","title":"Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Docetaxel; Abiraterone acetate; Abiraterone; Oncology; Internal medicine; Pharmacology; Prostate cancer; Cancer; Androgen receptor","score_opus":0.09705332580578253,"score_gpt":0.4455255526695369,"score_spread":0.3484722268637544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408207552","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002428291,0.9889656,0.0000025263896,0.00039377142,0.0012428708,0.0018478206,0.000100875375,0.000042509484,0.004975763],"genre_scores_gemma":[0.0007220549,0.99531466,0.00032625624,0.000037930222,0.00035448506,0.00024059374,0.0005515036,0.00004391521,0.002408579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972846,0.0004377413,0.00089626666,0.0005875154,0.0002696942,0.00052420306],"domain_scores_gemma":[0.9983455,0.0005749097,0.00044163916,0.0003839456,0.00008995507,0.00016405071],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038000994,0.00049417064,0.004344922,0.00071604876,0.000059711143,0.000014254554,0.00021271194,0.00091308367,0.00008090086],"category_scores_gemma":[0.000060276405,0.00035422412,0.00024678354,0.00071096246,0.00022505195,0.000046891248,0.00022597621,0.0012421093,0.000019575817],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024006239,0.00039140138,0.00021188178,0.03981874,0.0008772356,0.000412149,0.0011266102,0.0000015214365,0.000007886076,0.00017705809,0.0016945878,0.9528803],"study_design_scores_gemma":[0.011465769,0.0016902306,0.0003806936,0.011125081,0.0020360143,0.00007577522,0.0005800265,0.0000055879573,0.00002742727,0.000041789426,0.972275,0.00029659676],"about_ca_topic_score_codex":0.00015854016,"about_ca_topic_score_gemma":0.0007976177,"teacher_disagreement_score":0.9705804,"about_ca_system_score_codex":0.0011216612,"about_ca_system_score_gemma":0.0023151452,"threshold_uncertainty_score":0.999891},"labels":[],"label_agreement":null},{"id":"W4408236824","doi":"10.1080/14796694.2025.2463318","title":"A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; Medicine; Oncology; Lung cancer; Chemotherapy; Internal medicine; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.004826428086192625,"score_gpt":0.321617607089152,"score_spread":0.3167911790029594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408236824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98626304,0.0006248028,0.000018495397,0.007436786,0.0003548859,0.003042553,0.00018040431,0.0000149739235,0.0020640602],"genre_scores_gemma":[0.99630046,0.000058330977,0.00009249114,0.0026113666,0.00014898836,0.00028511885,0.00020541875,0.000020902757,0.00027693223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988009,0.0002064058,0.00036046238,0.0002751569,0.00016710105,0.00019001489],"domain_scores_gemma":[0.99781907,0.0014363457,0.0002502253,0.00035844778,0.000101566824,0.000034329936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016595141,0.0001857828,0.00045854846,0.00008314799,0.000065277134,0.000003815758,0.00015018292,0.000115562994,0.000025173982],"category_scores_gemma":[0.00010082446,0.00009458338,0.00005507966,0.0003631726,0.00007085109,0.000022280821,0.000031034644,0.00026308995,7.495493e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11599864,0.0151146585,0.44727114,0.0010277131,0.005163094,0.00046605064,0.24461485,0.0020956814,0.005102632,0.00010491642,0.031198801,0.13184181],"study_design_scores_gemma":[0.104035005,0.007035037,0.86323214,0.0012261489,0.00089655846,5.2011245e-7,0.0082169585,0.00022338369,0.010731311,0.000014314608,0.0041859117,0.0002027013],"about_ca_topic_score_codex":0.0020371827,"about_ca_topic_score_gemma":0.005960903,"teacher_disagreement_score":0.415961,"about_ca_system_score_codex":0.00033564842,"about_ca_system_score_gemma":0.0005448405,"threshold_uncertainty_score":0.38569984},"labels":[],"label_agreement":null},{"id":"W4408237108","doi":"10.1080/14796694.2025.2468578","title":"A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Medicine","score_opus":0.025476626718189566,"score_gpt":0.38500189559359743,"score_spread":0.35952526887540787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408237108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540656,0.0046534,0.00004932421,0.026534447,0.0052223573,0.0028074796,0.00013684205,0.000052808755,0.006477746],"genre_scores_gemma":[0.9734297,0.0009644599,0.0025248588,0.004052512,0.0031355768,0.0006719946,0.00024351562,0.00005542524,0.014921976],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887,0.00013358505,0.00033264857,0.00027128521,0.000098657874,0.0002938306],"domain_scores_gemma":[0.99851125,0.0009256861,0.00012671582,0.00025111233,0.00010193479,0.00008330737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028681522,0.00019191786,0.0006424204,0.00013082715,0.00009001637,0.000005091417,0.00013353792,0.00025718947,0.00027372446],"category_scores_gemma":[0.0003025607,0.00011631503,0.00012626719,0.00037653593,0.00015587884,0.000024174797,0.00008353024,0.00021503012,0.0000014935489],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63842285,0.00232663,0.0007590862,0.00045348975,0.0013863246,0.00018942516,0.0020771744,0.000003819713,0.013645442,0.0040114922,0.19663937,0.1400849],"study_design_scores_gemma":[0.24173662,0.016159257,0.0029614542,0.00008811264,0.0015188104,0.00007413293,0.0014325199,0.00006577951,0.005023786,0.00017049258,0.7305946,0.00017443889],"about_ca_topic_score_codex":0.0001357754,"about_ca_topic_score_gemma":0.0021277631,"teacher_disagreement_score":0.5339552,"about_ca_system_score_codex":0.0002421309,"about_ca_system_score_gemma":0.0007491565,"threshold_uncertainty_score":0.47431895},"labels":[],"label_agreement":null},{"id":"W4408457164","doi":"10.1080/14796694.2025.2475728","title":"The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer","keywords":"Medicine; Real world evidence; Value (mathematics); Oncology; Internal medicine; Intensive care medicine","score_opus":0.024923823832679836,"score_gpt":0.41306330247154305,"score_spread":0.3881394786388632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408457164","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005101315,0.9929569,0.0000041552403,0.00079048163,0.00052649894,0.003867035,0.00009470418,0.000014448374,0.0012356582],"genre_scores_gemma":[0.0007049539,0.99607056,0.000786667,0.00008251172,0.00015341376,0.00087604835,0.00036146736,0.000026840324,0.00093755824],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839264,0.00019243333,0.0006652211,0.00031615084,0.00014657338,0.00028699863],"domain_scores_gemma":[0.9977563,0.0012093887,0.00056244084,0.00028057588,0.00014889208,0.000042393523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026067748,0.00024783183,0.0013224392,0.00030907473,0.00006902919,0.0000059008908,0.00016349794,0.00022763197,0.000021545384],"category_scores_gemma":[0.00016651112,0.00013451446,0.00021154877,0.0006456319,0.00007943953,0.000044448607,0.00003377417,0.00029070023,0.0000011024438],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030244485,0.0002750803,0.012210861,0.0077401823,0.0005862633,0.000030910593,0.001014048,0.000002066697,2.434408e-7,0.0006343298,0.0009974582,0.9762061],"study_design_scores_gemma":[0.0025098156,0.00090864213,0.009112644,0.016396994,0.0016176593,0.0000027522103,0.0004711545,0.0000014047333,5.7343357e-7,0.000044576584,0.96880174,0.00013204754],"about_ca_topic_score_codex":0.00021155072,"about_ca_topic_score_gemma":0.0035394288,"teacher_disagreement_score":0.97607404,"about_ca_system_score_codex":0.0010800718,"about_ca_system_score_gemma":0.0032030956,"threshold_uncertainty_score":0.56821537},"labels":[],"label_agreement":null},{"id":"W4408808751","doi":"10.1080/14796694.2025.2479374","title":"Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; McGill University; University of Calgary","funders":"Pfizer","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Bone metastasis; Androgen deprivation therapy; Oncology; Metastasis; Cancer","score_opus":0.02622886707316352,"score_gpt":0.3772367480505685,"score_spread":0.351007880977405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408808751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95395535,0.00034786883,7.576037e-7,0.03340776,0.0004288247,0.0027969864,0.000024936167,0.000011372155,0.009026131],"genre_scores_gemma":[0.9836372,0.00071674224,0.00006332776,0.00035962742,0.00008167123,0.00093247346,0.000116599236,0.000010916621,0.014081441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986255,0.00020637036,0.00034513947,0.000357151,0.0001476296,0.00031818906],"domain_scores_gemma":[0.99930894,0.00019785571,0.00006998281,0.00019856988,0.00014819355,0.00007647253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012617995,0.00017110578,0.0004977447,0.0003718116,0.000046929483,0.000008261505,0.000045593846,0.00005047221,0.000033294844],"category_scores_gemma":[0.000030802363,0.00012733755,0.00003012213,0.00078551244,0.0000451578,0.00004001043,0.000018704352,0.00021526002,0.0000034264392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004760635,0.0026513347,0.9061845,0.000102340746,0.0005454347,0.0036874674,0.011906751,0.000071690745,0.00043539747,0.0009619082,0.002888424,0.065804094],"study_design_scores_gemma":[0.011983874,0.0017819565,0.944066,0.0001062452,0.00019374372,0.000018395933,0.015539668,0.00023651567,0.00083779544,0.000059727667,0.025039915,0.0001362024],"about_ca_topic_score_codex":0.94600874,"about_ca_topic_score_gemma":0.9991573,"teacher_disagreement_score":0.06566789,"about_ca_system_score_codex":0.0056937267,"about_ca_system_score_gemma":0.006002342,"threshold_uncertainty_score":0.9996327},"labels":[],"label_agreement":null},{"id":"W4408833196","doi":"10.1080/14796694.2025.2476929","title":"Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Oncology; Internal medicine; Antigen; Cancer; Immunology","score_opus":0.024508294236586032,"score_gpt":0.3871047592680317,"score_spread":0.36259646503144566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408833196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96633184,0.007736804,3.3374184e-7,0.020244878,0.00011677066,0.004802188,0.00029408172,0.000026949541,0.00044614228],"genre_scores_gemma":[0.98962575,0.0063177072,0.000049637347,0.0006666011,0.00008714352,0.00089419715,0.00011603942,0.000027336506,0.0022156073],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99758214,0.00080545584,0.00032680706,0.00047308588,0.00025774707,0.00055477244],"domain_scores_gemma":[0.9984674,0.00097525085,0.00009864241,0.00029249364,0.00006027016,0.00010596646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076487963,0.00035246648,0.00084392325,0.00051243755,0.00009014103,0.000028705503,0.00008302586,0.00012240387,0.0000118652415],"category_scores_gemma":[0.000068600486,0.00016322243,0.00008804437,0.0006149364,0.00013780958,0.000065656925,0.000030987023,0.00040567585,0.00000523282],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9040466,0.002059973,0.030005824,0.00006743945,0.00077092776,0.011546966,0.029551364,0.0000512024,0.006732816,0.000081248865,0.0017939871,0.013291665],"study_design_scores_gemma":[0.14405899,0.02774781,0.79546,0.0003165339,0.00022429579,0.000087410626,0.018549675,0.00008567204,0.002212667,0.00003757773,0.010922748,0.00029661224],"about_ca_topic_score_codex":0.00050286605,"about_ca_topic_score_gemma":0.002536673,"teacher_disagreement_score":0.7654542,"about_ca_system_score_codex":0.001487186,"about_ca_system_score_gemma":0.001152944,"threshold_uncertainty_score":0.6656018},"labels":[],"label_agreement":null},{"id":"W4408838099","doi":"10.1080/14796694.2025.2474789","title":"Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Amgen","keywords":"Medicine; Docetaxel; KRAS; Oncology; Internal medicine; Lung cancer; Cancer; Cancer research; Colorectal cancer","score_opus":0.00967252552037447,"score_gpt":0.36812172813231336,"score_spread":0.3584492026119389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408838099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8200203,0.032748446,0.0008297219,0.01558929,0.005784713,0.008528978,0.00063523167,0.0004651439,0.11539813],"genre_scores_gemma":[0.82945293,0.0032359527,0.007902115,0.0071569984,0.004313339,0.007824829,0.0057651536,0.00021175241,0.13413692],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863887,0.000060443115,0.00030876236,0.00043331296,0.00010104569,0.0004575916],"domain_scores_gemma":[0.9990267,0.00021820836,0.00013367666,0.00030537753,0.00016283445,0.00015321148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010726607,0.00027543984,0.00058184,0.00018474452,0.00016622129,0.000018589095,0.00012678636,0.00032099962,0.00018427998],"category_scores_gemma":[0.000040806157,0.00022089487,0.000179988,0.00035696352,0.00005357226,0.000049474755,0.00003668874,0.0002276473,0.000012661285],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025709117,0.004644473,0.059111685,0.004562752,0.009440602,0.0019627274,0.020764934,0.00015216014,0.033215657,0.0018638038,0.67080075,0.16777135],"study_design_scores_gemma":[0.068781264,0.0040286137,0.009986225,0.000564148,0.00891437,0.0000390011,0.004894629,0.0011320987,0.008564052,0.000041624393,0.89246553,0.0005884162],"about_ca_topic_score_codex":0.0008376307,"about_ca_topic_score_gemma":0.0019704888,"teacher_disagreement_score":0.22166483,"about_ca_system_score_codex":0.0011756596,"about_ca_system_score_gemma":0.0015748473,"threshold_uncertainty_score":0.9007831},"labels":[],"label_agreement":null},{"id":"W4408956663","doi":"10.1080/14796694.2025.2481022","title":"Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Cochrane Library; Internal medicine; MEDLINE; Oncology; Checklist; Meta-analysis; Incidence (geometry); Systematic review","score_opus":0.02311140128761007,"score_gpt":0.41173944101363935,"score_spread":0.3886280397260293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408956663","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000025925974,0.98899764,0.0000032912044,0.0026751563,0.001337213,0.0049836016,0.00069823716,0.000017276465,0.0012849667],"genre_scores_gemma":[0.0000034696775,0.9931729,0.00038413648,0.0030545837,0.00055036886,0.0006440343,0.00077408814,0.000033152926,0.0013832734],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99555796,0.0019222148,0.0016904612,0.00042073432,0.00014969999,0.00025891108],"domain_scores_gemma":[0.9950862,0.001517481,0.0020111594,0.00081964035,0.0004785214,0.00008698198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049288245,0.00044049282,0.0059886654,0.0002025197,0.000059078568,0.0000019786844,0.00029210886,0.00046277329,0.00009525089],"category_scores_gemma":[0.0020759315,0.00021920785,0.0011587961,0.00090606534,0.00016468768,0.000023658657,0.00011263171,0.0006379829,0.000011984547],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024305544,0.0002101965,0.000012891193,0.97268766,0.0009663633,0.000060563383,0.00008128188,7.57434e-8,0.0000041047797,0.0011039138,0.008765647,0.01608301],"study_design_scores_gemma":[0.0003299097,0.00054338906,0.000033090346,0.7320343,0.01086811,0.00036832667,0.000014136332,2.3700888e-7,0.0000028347633,0.000015184483,0.25569305,0.00009742666],"about_ca_topic_score_codex":0.0000045941647,"about_ca_topic_score_gemma":0.000002563049,"teacher_disagreement_score":0.2469274,"about_ca_system_score_codex":0.00036864015,"about_ca_system_score_gemma":0.0017466396,"threshold_uncertainty_score":0.8939037},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4408990988","doi":"10.1080/14796694.2025.2470106","title":"A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Abiraterone acetate; Prednisone; Medicine; Prostate cancer; Internal medicine; Oncology; Cancer; Androgen deprivation therapy","score_opus":0.008952118645876158,"score_gpt":0.29775299261104465,"score_spread":0.2888008739651685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408990988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97937375,0.0011221367,0.000016038517,0.016100645,0.00010715749,0.0027192368,0.00043061914,0.000010265201,0.00012014955],"genre_scores_gemma":[0.99795705,0.00005583794,0.0005718508,0.00075178075,0.00005466186,0.00030993068,0.00004045602,0.000015479643,0.0002429796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998476,0.0005790909,0.0001950756,0.0003459867,0.0002259289,0.00017791237],"domain_scores_gemma":[0.9988763,0.00041584973,0.00026563444,0.0002695984,0.00013530187,0.00003733289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003708004,0.0001881015,0.00043994383,0.0000659483,0.00011106652,0.000045019897,0.00007288362,0.000061264574,0.0000051732363],"category_scores_gemma":[0.000048370337,0.00009257653,0.000017678178,0.00030284593,0.00025352262,0.00011330932,0.000042896256,0.00029065195,7.652658e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035951972,0.0011255323,0.86883444,0.00027710796,0.0013593326,0.00011717234,0.05739057,0.000035817342,0.0095199095,0.000019696377,0.0023209583,0.02304751],"study_design_scores_gemma":[0.026283432,0.0020502396,0.9562302,0.00056359364,0.00035105782,0.0000036442316,0.01235236,0.000021491718,0.0014346233,0.000015898253,0.0005941981,0.00009923448],"about_ca_topic_score_codex":0.0006928912,"about_ca_topic_score_gemma":0.011784139,"teacher_disagreement_score":0.08739581,"about_ca_system_score_codex":0.00018184532,"about_ca_system_score_gemma":0.00031042445,"threshold_uncertainty_score":0.65758264},"labels":[],"label_agreement":null},{"id":"W4409271532","doi":"10.1080/14796694.2025.2488635","title":"Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Observational study; Pathology","score_opus":0.015846928618200307,"score_gpt":0.2868730438023099,"score_spread":0.2710261151841096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409271532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8701632,0.00048559663,0.000022969984,0.010343423,0.0011104754,0.0005613015,0.0004249915,0.00007528805,0.116812766],"genre_scores_gemma":[0.9770934,0.00033036814,0.0035110135,0.005121136,0.0011325987,0.0000773526,0.001248944,0.000024272465,0.011460928],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847686,0.000093892246,0.0004956444,0.00044454265,0.00019902345,0.00029004394],"domain_scores_gemma":[0.9989589,0.00022810188,0.00019540777,0.00035739847,0.00008965001,0.00017054897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008633783,0.00022362232,0.0005070479,0.00010003128,0.000120292985,0.000017071505,0.000080844104,0.00018178798,0.00016328813],"category_scores_gemma":[0.00007294259,0.00017098949,0.00010909064,0.00021530267,0.00012405805,0.00004726129,0.00011538987,0.000258851,0.000019828512],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046828713,0.013459755,0.24761422,0.001340329,0.0023233101,0.0067707556,0.003545159,0.000013013062,0.010897592,0.07546724,0.398831,0.1929089],"study_design_scores_gemma":[0.014212798,0.00091640744,0.2191803,0.00011922771,0.000248882,0.000023131008,0.00039282412,0.00007701799,0.00047428423,0.0011904051,0.7629807,0.00018402137],"about_ca_topic_score_codex":0.004243935,"about_ca_topic_score_gemma":0.0017928773,"teacher_disagreement_score":0.3641497,"about_ca_system_score_codex":0.00029047488,"about_ca_system_score_gemma":0.0003691537,"threshold_uncertainty_score":0.6972749},"labels":[],"label_agreement":null},{"id":"W4409565762","doi":"10.1080/14796694.2025.2485015","title":"STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Royal Ottawa Mental Health Centre","funders":"Exelixis; American Society of Clinical Oncology","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.01271133484206635,"score_gpt":0.32109144347390917,"score_spread":0.30838010863184284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409565762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848655,0.00067797134,0.000008267715,0.0007262509,0.0016846606,0.0016889025,0.0000196408,0.000044632965,0.0102841845],"genre_scores_gemma":[0.9980012,0.00007836375,0.00009733869,0.00043603816,0.00023568464,0.000071110175,0.00007792454,0.00002712802,0.00097518245],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99797434,0.00015059182,0.0006638868,0.00046489734,0.00034764563,0.0003986717],"domain_scores_gemma":[0.9987823,0.0001143821,0.0002671482,0.0005376574,0.00021266383,0.00008584317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022591896,0.0002916528,0.00094377546,0.00039885947,0.000103418075,0.0000073631813,0.0002108689,0.00030561013,0.00036413138],"category_scores_gemma":[0.00003069098,0.0002290514,0.00011236482,0.000771148,0.00015235296,0.000061234365,0.000099699995,0.00041434192,0.0000037284453],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8727134,0.017708294,0.02253571,0.00015603587,0.0013597333,0.00015225778,0.0054146433,0.000014053107,0.00051705044,0.000105302635,0.00634996,0.07297358],"study_design_scores_gemma":[0.7384975,0.06428271,0.105936095,0.000178809,0.0005594638,0.000014332106,0.0052059432,0.000029494286,0.00043297277,0.0000071626364,0.08454674,0.00030879737],"about_ca_topic_score_codex":0.000399049,"about_ca_topic_score_gemma":0.0015492641,"teacher_disagreement_score":0.13421589,"about_ca_system_score_codex":0.0006189631,"about_ca_system_score_gemma":0.00083438645,"threshold_uncertainty_score":0.9340445},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4409774343","doi":"10.1080/14796694.2025.2489319","title":"Order of treatment with ALK inhibitors and its effect on people with lung cancer in the real world: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; EMD Serono; Jazz Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Sanofi; G1 Therapeutics; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Plain language; Oncology; Order (exchange); Intensive care medicine; Internal medicine; Linguistics","score_opus":0.003513448381446309,"score_gpt":0.33379465714999235,"score_spread":0.33028120876854605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409774343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9569722,0.0025291636,0.0000012629257,0.005215929,0.00012128871,0.0010643059,0.000027243621,0.000013131346,0.034055486],"genre_scores_gemma":[0.995643,0.0003209409,0.0000632675,0.00051070197,0.00015835204,0.00045345604,0.000038466536,0.000009988073,0.0028017932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945575,0.00008086779,0.00009585396,0.00016512786,0.00007517623,0.0001272487],"domain_scores_gemma":[0.999608,0.00016927917,0.00004644807,0.00011971151,0.000028176792,0.000028395141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006218969,0.000120715275,0.00028282675,0.00013549124,0.000040301147,0.00000353542,0.000028534303,0.000055686483,0.00002729073],"category_scores_gemma":[0.000003969788,0.00005424314,0.000018389204,0.00040996756,0.00002901812,0.000017793847,0.0000072935895,0.000097753815,4.0039652e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009449599,0.0014745168,0.826901,0.00064137636,0.0018305419,0.0007773258,0.038567085,0.00013179421,0.001028542,0.0023105992,0.006911206,0.10997637],"study_design_scores_gemma":[0.049329564,0.044998437,0.76342154,0.0021626062,0.0044304235,0.00009977063,0.011937871,0.00024549098,0.0031145737,0.000011847682,0.11984578,0.000402107],"about_ca_topic_score_codex":0.0020824706,"about_ca_topic_score_gemma":0.0627933,"teacher_disagreement_score":0.112934574,"about_ca_system_score_codex":0.00044467856,"about_ca_system_score_gemma":0.000513531,"threshold_uncertainty_score":0.9543083},"labels":[],"label_agreement":null},{"id":"W4410406044","doi":"10.1080/14796694.2025.2489339","title":"Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Gilead Sciences","keywords":"Docetaxel; Medicine; Lung cancer; Oncology; Internal medicine; Cancer","score_opus":0.0034647502534123713,"score_gpt":0.296094019994754,"score_spread":0.2926292697413416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410406044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98583823,0.000687267,0.0000067810843,0.00061974523,0.00037705692,0.0014019437,0.00006260543,0.0000076202937,0.010998775],"genre_scores_gemma":[0.99782574,0.000019000345,0.000111576875,0.00031792367,0.00005895179,0.0001308249,0.000025222595,0.000011270742,0.0014995171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991999,0.00007894143,0.00024382783,0.0001876896,0.0001359786,0.00015366128],"domain_scores_gemma":[0.9993846,0.000055777793,0.00015573206,0.0002860109,0.00008580524,0.00003209228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007258106,0.00012050331,0.00037636227,0.00011535167,0.000036418525,0.0000019755505,0.000110916655,0.0000942321,0.0000467596],"category_scores_gemma":[0.000008217507,0.000070790105,0.000043172655,0.0003603781,0.000045638888,0.000021483673,0.000047523714,0.00017384603,3.7530117e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010467408,0.002743291,0.97795457,0.00024021162,0.00030268825,0.000019273226,0.0101719,0.00005818598,0.00014101161,0.00003590197,0.002466319,0.0048199333],"study_design_scores_gemma":[0.015798548,0.001716894,0.971646,0.00022984255,0.00067240663,8.3066584e-7,0.0068314876,0.000017151147,0.0004352428,0.0000031670133,0.0025787621,0.000069683134],"about_ca_topic_score_codex":0.0021223577,"about_ca_topic_score_gemma":0.0108153345,"teacher_disagreement_score":0.014751808,"about_ca_system_score_codex":0.00045147698,"about_ca_system_score_gemma":0.0006907286,"threshold_uncertainty_score":0.60352105},"labels":[],"label_agreement":null},{"id":"W4410522286","doi":"10.1080/14796694.2025.2500915","title":"A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca; University College London; Cancer Research UK; F. Hoffmann-La Roche; CRUK Lung Cancer Centre of Excellence; University College London Hospitals NHS Foundation Trust; Pfizer","keywords":"Atezolizumab; Medicine; Chemotherapy; Oncology; Lung cancer; Internal medicine; Cancer; Intensive care medicine; Immunotherapy; Pembrolizumab","score_opus":0.02306044395468954,"score_gpt":0.35097972535087146,"score_spread":0.3279192813961819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410522286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984612,0.0006874633,0.00015936827,0.0077603296,0.00015225976,0.0026759773,0.000033888085,0.000035529672,0.0038832123],"genre_scores_gemma":[0.99308676,0.00005516212,0.00081079226,0.0038746023,0.00014123743,0.0006723295,0.000045146662,0.000040452363,0.0012735219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985504,0.00011774962,0.00035346017,0.00037973156,0.00021800106,0.00038062892],"domain_scores_gemma":[0.99903965,0.00015753224,0.00021664883,0.00038760397,0.00011545211,0.00008314033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014838856,0.00027477706,0.0007025717,0.00015623613,0.000082725026,0.000011056981,0.0001444887,0.00014058256,0.00012544749],"category_scores_gemma":[0.00000585511,0.00016169158,0.000060424227,0.00050605845,0.00011398304,0.000030371477,0.00001626458,0.00028387047,0.0000011143379],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04463618,0.014855202,0.7230503,0.0010108618,0.004020006,0.00097032404,0.13363883,0.004051392,0.01432126,0.00004175279,0.010746498,0.04865741],"study_design_scores_gemma":[0.170793,0.016128192,0.625249,0.0025395881,0.0035846126,0.000025160529,0.055132385,0.005360615,0.09382129,0.000007239445,0.026423233,0.00093568367],"about_ca_topic_score_codex":0.001219687,"about_ca_topic_score_gemma":0.012752078,"teacher_disagreement_score":0.12615682,"about_ca_system_score_codex":0.0007478063,"about_ca_system_score_gemma":0.0011830434,"threshold_uncertainty_score":0.7115959},"labels":[],"label_agreement":null},{"id":"W4410770658","doi":"10.1080/14796694.2025.2511587","title":"Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Glioma; Mutant; Clinical trial; Oncology; Indigo; Internal medicine; Cancer research; Genetics; Biology; Gene","score_opus":0.028939306623785556,"score_gpt":0.4262713615564876,"score_spread":0.397332054932702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410770658","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029759973,0.98372054,0.0000011440841,0.0036454366,0.001503765,0.0036654589,0.00011402523,0.000031607826,0.007020404],"genre_scores_gemma":[0.0002347211,0.9951109,0.00040778745,0.000086479726,0.0029311557,0.0010040125,0.00016169155,0.00003082855,0.000032392403],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969704,0.00040032723,0.001336117,0.00079249527,0.00017241479,0.00032824036],"domain_scores_gemma":[0.99790555,0.00059387874,0.0006987363,0.00055715296,0.00010099024,0.00014368622],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039868354,0.00045314207,0.0030908354,0.0007913915,0.000073628515,0.000012444132,0.00019428856,0.0009694682,0.000042952775],"category_scores_gemma":[0.00008009761,0.000321165,0.0005702945,0.0009798373,0.00019864603,0.000064222295,0.00018323146,0.000631979,0.000007028416],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071577396,0.001982066,0.00029317715,0.008055597,0.0005111152,0.0002678118,0.00011913134,1.7618e-8,4.0602023e-7,0.01918681,0.0021101905,0.9667579],"study_design_scores_gemma":[0.016617585,0.0013932062,0.00078927027,0.004756389,0.0025707427,0.000113475544,0.0012479243,4.034023e-8,0.0000011016889,0.00026623163,0.9720424,0.00020167249],"about_ca_topic_score_codex":0.0000051275224,"about_ca_topic_score_gemma":0.00008319573,"teacher_disagreement_score":0.9699322,"about_ca_system_score_codex":0.0003654333,"about_ca_system_score_gemma":0.0006198822,"threshold_uncertainty_score":0.99992406},"labels":[],"label_agreement":null},{"id":"W4410950112","doi":"10.1080/14796694.2025.2502318","title":"rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Cabazitaxel; Prostate cancer; Androgen receptor; Abiraterone acetate; Oncology; Internal medicine; Docetaxel; Randomized controlled trial; Clinical endpoint; Clinical trial; Androgen deprivation therapy; Pharmacology; Cancer","score_opus":0.01713607726596698,"score_gpt":0.3317622043259618,"score_spread":0.3146261270599948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410950112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790488,0.0012038806,0.0000026655991,0.011667565,0.0012574313,0.004864821,0.00003471898,0.0000509133,0.0018692381],"genre_scores_gemma":[0.9849986,0.00088835036,0.0009088865,0.0026343062,0.001079547,0.0015127497,0.00042429243,0.000059788636,0.0074935104],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99792606,0.0006061128,0.0004969042,0.0003301346,0.00030611604,0.0003346483],"domain_scores_gemma":[0.99859655,0.00045149738,0.00021883716,0.000348387,0.00022529946,0.00015945434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056407345,0.00020964484,0.0010952806,0.00022480452,0.000082823004,0.000007661271,0.00017655473,0.00030696273,0.00009666892],"category_scores_gemma":[0.0008655952,0.00010950192,0.00015699622,0.00087847124,0.00036339433,0.00004631119,0.00006458842,0.00048248342,0.0000038861835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9512183,0.00208727,0.017676307,0.000098787066,0.00047137542,0.00001060903,0.0005517105,2.3903445e-7,0.0006178711,0.000112892936,0.021192934,0.0059617204],"study_design_scores_gemma":[0.9238865,0.0025187018,0.0024490762,0.00024078669,0.0002973759,0.0000013443074,0.00007390027,0.000014481614,0.0070032068,0.0000704066,0.063342035,0.000102230086],"about_ca_topic_score_codex":0.00013189594,"about_ca_topic_score_gemma":0.00017069664,"teacher_disagreement_score":0.042149104,"about_ca_system_score_codex":0.00035206723,"about_ca_system_score_gemma":0.0017569932,"threshold_uncertainty_score":0.4465359},"labels":[],"label_agreement":null},{"id":"W4410968310","doi":"10.1080/14796694.2025.2510890","title":"Patient, caregiver experiences in metastatic castration-resistant prostate cancer: insights from a multi-national survey","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Johnson and Johnson","keywords":"Medicine; Prostate cancer; Family medicine; Pill; Caregiver burden; Urination; Disease; Internal medicine; Cancer; Nursing","score_opus":0.05312816492137521,"score_gpt":0.3882538557149905,"score_spread":0.33512569079361526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410968310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867372,0.007430668,0.0000086473165,0.0022492805,0.000717146,0.00078306894,0.00021084811,0.000021403848,0.0018417506],"genre_scores_gemma":[0.99599075,0.0005022437,0.0005486559,0.00045383436,0.00010404489,0.00072909094,0.00044386988,0.000008914835,0.0012185733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986077,0.0002482739,0.00028526818,0.00034340055,0.00027891112,0.00023643345],"domain_scores_gemma":[0.9992138,0.0001997632,0.00007820376,0.00012367715,0.00030201825,0.0000825498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114804214,0.00014622026,0.00033680015,0.00022169718,0.000086063556,0.000017437993,0.00007409642,0.00009981479,0.00018908296],"category_scores_gemma":[0.00007588431,0.00010547153,0.000043477317,0.0004649347,0.00013051662,0.00008489594,0.000037045287,0.00021359953,0.000008844233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022997947,0.0056842077,0.5024289,0.00047338157,0.002017046,0.0032785847,0.3023585,0.00018397877,0.02437952,0.0022127999,0.045351844,0.08863331],"study_design_scores_gemma":[0.0149067715,0.0012432429,0.85049343,0.00025244098,0.00010513194,0.0000072154094,0.04172655,0.0004960276,0.0040682084,0.00048794266,0.085912555,0.00030048328],"about_ca_topic_score_codex":0.0048633986,"about_ca_topic_score_gemma":0.03942484,"teacher_disagreement_score":0.34806457,"about_ca_system_score_codex":0.00078307797,"about_ca_system_score_gemma":0.002176414,"threshold_uncertainty_score":0.97810316},"labels":[],"label_agreement":null},{"id":"W4411249025","doi":"10.1080/14796694.2025.2514402","title":"Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"MSD Italia","keywords":"Merkel cell carcinoma; Medicine; Immunotherapy; Oncology; Internal medicine; Carcinoma; Cancer research; Cancer","score_opus":0.014809492180150275,"score_gpt":0.31033339140170524,"score_spread":0.295523899221555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411249025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742534,0.01419045,0.00013723581,0.007386652,0.0005978692,0.0011953426,0.000009014041,0.000012775952,0.0022172558],"genre_scores_gemma":[0.9953751,0.0012099962,0.0005103499,0.0010247818,0.00016407321,0.000072068346,0.000011708242,0.0000089683745,0.0016229524],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993061,0.00009021732,0.00025555046,0.00015092561,0.000072704715,0.00012453886],"domain_scores_gemma":[0.99947536,0.00016310184,0.00009981029,0.00018232643,0.00004124089,0.000038184957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012808264,0.00010032813,0.00031193838,0.00007623218,0.000085631495,0.0000021854394,0.000071297305,0.00017962142,0.00007341442],"category_scores_gemma":[0.00003929474,0.00006263358,0.000064794054,0.00020896563,0.000087447275,0.000022415428,0.000032140848,0.00017151555,8.6553575e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38137418,0.018143471,0.00753711,0.00062837335,0.00045286096,0.00017712239,0.004675015,0.00050468615,0.26015672,0.0014995065,0.024581874,0.30026907],"study_design_scores_gemma":[0.5274625,0.009269633,0.020747803,0.000207964,0.0004044897,0.000022506403,0.0005443035,0.00087666896,0.054140776,0.0008937526,0.38517824,0.00025136114],"about_ca_topic_score_codex":0.00002540625,"about_ca_topic_score_gemma":0.000027797218,"teacher_disagreement_score":0.36059636,"about_ca_system_score_codex":0.00006362322,"about_ca_system_score_gemma":0.00040637792,"threshold_uncertainty_score":0.25541234},"labels":[],"label_agreement":null},{"id":"W4411281412","doi":"10.1080/14796694.2025.2511470","title":"LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research","funders":"Genentech; Astellas Pharma; Eisai; EMD Serono; Rakuten Medical; Daiichi Sankyo Europe; Sanofi; Exelixis; Amgen; Relay Therapeutics; Gilead Sciences; Pfizer; Break Through Cancer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Agios Pharmaceuticals","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.04745932149046059,"score_gpt":0.42577289509448113,"score_spread":0.3783135736040205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411281412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9517723,0.028146386,0.00020433532,0.011315425,0.0019212763,0.0020466438,0.00007957502,0.000056438177,0.004457651],"genre_scores_gemma":[0.9713837,0.017272567,0.0023363335,0.0045083784,0.00074011576,0.0003367219,0.00008786706,0.00005336408,0.0032809705],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972036,0.0005336538,0.0013082328,0.0004195468,0.00019165673,0.00034330008],"domain_scores_gemma":[0.9983431,0.0006644195,0.00045136214,0.0003598979,0.00009495906,0.000086278094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015084147,0.00028705908,0.0017369377,0.0005379044,0.00005524331,0.000013329849,0.00014288342,0.00024606928,0.0007028147],"category_scores_gemma":[0.00023323405,0.0002011276,0.00025994633,0.0006342083,0.00018424248,0.00006226351,0.000037606784,0.00033400024,0.0000029630169],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22236313,0.002517056,0.00029257004,0.0004900023,0.0010658216,0.00021448304,0.0021942032,6.7605646e-7,0.05838554,0.00071067415,0.01077268,0.7009932],"study_design_scores_gemma":[0.20735209,0.010173896,0.0036891364,0.00062552805,0.00073169504,0.00027362668,0.0027560245,0.000120733464,0.017232183,0.00038208227,0.75630283,0.00036015833],"about_ca_topic_score_codex":0.00013807794,"about_ca_topic_score_gemma":0.00052857294,"teacher_disagreement_score":0.7455302,"about_ca_system_score_codex":0.0003104381,"about_ca_system_score_gemma":0.0010705311,"threshold_uncertainty_score":0.8201745},"labels":[],"label_agreement":null},{"id":"W4411453748","doi":"10.1080/14796694.2025.2513219","title":"Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"BeiGene; Sanofi; AstraZeneca; Pfizer","keywords":"Brentuximab vedotin; Medicine; Oncology; Internal medicine; Lymphoma; Diffuse large B-cell lymphoma; Medical physics; Hodgkin lymphoma","score_opus":0.0047277561266267035,"score_gpt":0.26764125658082977,"score_spread":0.2629135004542031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411453748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98632693,0.0009172781,0.0000019976092,0.0030899872,0.00029740468,0.0014173803,0.000026339276,0.00002435049,0.00789834],"genre_scores_gemma":[0.99728197,0.00009789517,0.000057384346,0.00040886737,0.000060492308,0.00027592923,0.000065422544,0.0000130980625,0.0017389159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988989,0.00019404254,0.00025481876,0.0002642498,0.00015950015,0.00022847154],"domain_scores_gemma":[0.999249,0.00016273781,0.00011932539,0.00038149982,0.00004361139,0.00004386708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000133488,0.00018532161,0.0004973185,0.00013591819,0.00006411738,0.000006001591,0.00010245464,0.00013383836,0.000023660057],"category_scores_gemma":[0.000015460299,0.000103953855,0.00008611921,0.00039257391,0.000035123074,0.000024480447,0.00006445669,0.00006896035,0.0000060758653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009104252,0.102112345,0.86727184,0.0000788909,0.0002386726,0.0002974874,0.006986972,9.129651e-7,0.00022674404,0.0006842356,0.0016376579,0.019553794],"study_design_scores_gemma":[0.090658344,0.0036326167,0.88172305,0.000089379886,0.00034670206,0.000019452373,0.007952477,0.000029633595,0.0036200823,0.000012517029,0.011826844,0.00008891594],"about_ca_topic_score_codex":0.0008551398,"about_ca_topic_score_gemma":0.012704482,"teacher_disagreement_score":0.09847973,"about_ca_system_score_codex":0.0011502577,"about_ca_system_score_gemma":0.00053260115,"threshold_uncertainty_score":0.7089399},"labels":[],"label_agreement":null},{"id":"W4411842050","doi":"10.1080/14796694.2025.2475730","title":"Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Disease; Oncology; Cancer; Internal medicine; Androgen receptor","score_opus":0.017160304996255038,"score_gpt":0.4120309966057451,"score_spread":0.39487069160949007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411842050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028103552,0.9861189,2.6654013e-7,0.002655418,0.00037911488,0.007741385,0.002217883,0.000033652464,0.00057233375],"genre_scores_gemma":[0.000014607532,0.9870722,0.00003683588,0.00034122978,0.00041306557,0.003046443,0.0019257001,0.00005298826,0.0070969253],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976973,0.00029832017,0.0005479779,0.0005508454,0.00035189794,0.0005536771],"domain_scores_gemma":[0.99819815,0.00024670534,0.00045216893,0.00074539497,0.0001405585,0.00021702802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014357087,0.00053823285,0.0025280046,0.00009346966,0.00012072092,0.000008687993,0.0002216113,0.00020339928,0.00020751925],"category_scores_gemma":[0.00004276192,0.00023051337,0.00045843067,0.00056114316,0.00022363917,0.000034021414,0.00007921119,0.00035612905,0.000014459688],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012119794,0.0006467473,0.00050999864,0.072633065,0.0007715513,0.00030548297,0.00039173503,2.1948216e-7,7.370507e-8,0.000014758299,0.0017498034,0.9217646],"study_design_scores_gemma":[0.003515603,0.0018461351,0.00071804965,0.047877286,0.0034960932,0.000007539069,0.000088461195,8.708409e-8,0.000002338887,0.0000032514838,0.94225675,0.00018839371],"about_ca_topic_score_codex":0.000049964197,"about_ca_topic_score_gemma":0.00020651662,"teacher_disagreement_score":0.94050694,"about_ca_system_score_codex":0.0014475844,"about_ca_system_score_gemma":0.0032237903,"threshold_uncertainty_score":0.9400062},"labels":[],"label_agreement":null},{"id":"W4412008298","doi":"10.1080/14796694.2025.2521871","title":"The significance of mitochondrial DNA changes during the onset and progression of head and neck squamous cell carcinoma","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal College of Physicians and Surgeons of Canada","funders":"","keywords":"Medicine; Head and neck squamous-cell carcinoma; Mitochondrial DNA; Head and neck; Basal cell; Oncology; Head and neck cancer; Cancer research; Internal medicine; Pathology; Cancer; Biology; Genetics; Surgery; Gene","score_opus":0.02303350771498091,"score_gpt":0.34729497971041423,"score_spread":0.3242614719954333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412008298","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011090343,0.9832152,1.5443626e-7,0.0018365106,0.00096161396,0.0016475911,0.00006262908,0.000009170275,0.0011767853],"genre_scores_gemma":[0.0040166313,0.9936881,0.00008232076,0.000054703025,0.0010815568,0.00029457684,0.000010091314,0.000016718026,0.00075530395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986891,0.00024796114,0.00039069582,0.00029541727,0.00014449342,0.00023233962],"domain_scores_gemma":[0.9983783,0.0008000922,0.00037740433,0.00031216533,0.00007668248,0.00005536683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016700421,0.00025124368,0.0016567158,0.00007109598,0.00018657188,0.000005118891,0.00013411598,0.0003257156,0.000005598693],"category_scores_gemma":[0.000090317844,0.00011631727,0.00012152295,0.00017521747,0.00037530123,0.000008565337,0.00016079913,0.00039387937,3.8361787e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005201109,0.00011282859,0.0004074047,0.060028173,0.00009254499,0.000039072125,0.00087294425,7.3342203e-9,0.00010064429,0.000032179913,0.0049642003,0.9328299],"study_design_scores_gemma":[0.0012395496,0.0016851263,0.0017884625,0.0044179033,0.00065785646,0.00007768828,0.00028542604,1.8419975e-7,0.00012887338,0.000004115707,0.989618,0.00009681216],"about_ca_topic_score_codex":0.000026717094,"about_ca_topic_score_gemma":0.00041745408,"teacher_disagreement_score":0.98465383,"about_ca_system_score_codex":0.00007464617,"about_ca_system_score_gemma":0.0005615418,"threshold_uncertainty_score":0.47432807},"labels":[],"label_agreement":null},{"id":"W4412072814","doi":"10.1080/14796694.2025.2529151","title":"Advancing treatment in HER2-positive metastatic breast cancer: the role of tucatinib","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Cancer; Trastuzumab","score_opus":0.029248126771143183,"score_gpt":0.4596720816154097,"score_spread":0.4304239548442665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412072814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010546382,0.97969455,0.0000014605029,0.003669325,0.00059534,0.0030071563,0.0005530552,0.000016356495,0.012452222],"genre_scores_gemma":[0.000033955002,0.994793,0.00032455975,0.00020894673,0.0008966037,0.0021847447,0.00012719874,0.000047860394,0.0013831255],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99697953,0.00094761164,0.0007567417,0.0004895733,0.00029807878,0.0005284589],"domain_scores_gemma":[0.99770105,0.0010568135,0.0003618131,0.0005861127,0.00016411471,0.00013012424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005265289,0.0004113024,0.0028624288,0.0003531352,0.000052713196,0.000006769812,0.00032087349,0.00034842012,0.00056528335],"category_scores_gemma":[0.000094238465,0.00023503412,0.00042033682,0.0008601822,0.0001611564,0.00002163282,0.000111224435,0.00087000045,0.000025122661],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000090124704,0.000428445,0.000099525605,0.010003757,0.0004986886,0.00012958985,0.00056266284,0.0000010211264,0.0000018821011,0.00018660628,0.0012470863,0.9867506],"study_design_scores_gemma":[0.0007582447,0.0008219481,0.00014302396,0.015575246,0.0015770199,0.00034053496,0.0009040503,0.000002841725,0.000009037405,0.000038787446,0.9796882,0.00014104489],"about_ca_topic_score_codex":0.0022949448,"about_ca_topic_score_gemma":0.004380224,"teacher_disagreement_score":0.9866096,"about_ca_system_score_codex":0.00398903,"about_ca_system_score_gemma":0.010922685,"threshold_uncertainty_score":0.9998345},"labels":[],"label_agreement":null},{"id":"W4412724750","doi":"10.1080/14796694.2025.2535280","title":"SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"Seagen; Pfizer","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Antibody-drug conjugate; Chemotherapy; Metastatic Urothelial Carcinoma; Antibody; Immunotherapy; Cancer; Urothelial carcinoma; Monoclonal antibody; Immunology; Bladder cancer","score_opus":0.012634334458240302,"score_gpt":0.3140959120053023,"score_spread":0.301461577547062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412724750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9257101,0.0028907002,0.0008506494,0.009862917,0.0014494288,0.0024450198,0.000068319445,0.0001721851,0.056550693],"genre_scores_gemma":[0.98759353,0.00007661296,0.0044351597,0.002497759,0.00040262908,0.00025243702,0.00004963448,0.000046050987,0.0046462],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826217,0.00015777216,0.00037315997,0.00050209515,0.00021843065,0.00048636968],"domain_scores_gemma":[0.99918664,0.00010363524,0.000101741345,0.00037453923,0.00009502425,0.00013841536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010628311,0.00031258113,0.0007475092,0.00022044641,0.0000917405,0.000018708773,0.00015057628,0.00017287597,0.00044240497],"category_scores_gemma":[0.000040857536,0.00020683347,0.000076184675,0.00043681348,0.00012725584,0.00009024121,0.000054154138,0.00040426737,0.000032483927],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15266189,0.008232995,0.10664618,0.0018147908,0.0016463469,0.015011286,0.00499958,0.0002586305,0.012675911,0.0030927202,0.012493292,0.68046635],"study_design_scores_gemma":[0.17936681,0.020782067,0.3336727,0.0016528156,0.0020677757,0.0015716917,0.005134701,0.000379234,0.0064258208,0.00067538343,0.4471184,0.0011525821],"about_ca_topic_score_codex":0.00028061104,"about_ca_topic_score_gemma":0.0017968271,"teacher_disagreement_score":0.6793138,"about_ca_system_score_codex":0.0005394647,"about_ca_system_score_gemma":0.001814924,"threshold_uncertainty_score":0.84344244},"labels":[],"label_agreement":null},{"id":"W4414167802","doi":"10.1080/14796694.2025.2550930","title":"Plain language summary of a systematic review of palbociclib treatment for advanced/ metastatic breast cancer in older patients","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Incyte; Seagen; Gilead Sciences; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Palbociclib; Metastatic breast cancer; Plain language; Breast cancer; MEDLINE","score_opus":0.010316438650245988,"score_gpt":0.35812746572584897,"score_spread":0.34781102707560296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414167802","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14082947,0.8168104,0.0007354042,0.012317286,0.001614736,0.022579245,0.0028095173,0.00008620677,0.0022177242],"genre_scores_gemma":[0.84221435,0.09343115,0.022550484,0.014199866,0.0006548684,0.018263375,0.0008667179,0.00023549408,0.0075837206],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99860334,0.00013344982,0.00069726823,0.00022173971,0.00013134256,0.00021287397],"domain_scores_gemma":[0.9988036,0.0002694925,0.00039144928,0.00031295902,0.00017861262,0.00004387495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017636875,0.00018422164,0.001467228,0.00015858912,0.000014834571,8.7012114e-7,0.00009666052,0.000074464675,0.00009583797],"category_scores_gemma":[0.000080825725,0.0001299451,0.0001643711,0.00030984337,0.000062488645,0.000042785636,0.000021563414,0.00008183874,7.0339064e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002436204,0.0019452837,0.0055968384,0.8829904,0.0009236957,0.00002737169,0.0020642902,0.000013605045,0.00126511,0.00048018614,0.00052425434,0.10173277],"study_design_scores_gemma":[0.05650252,0.004400621,0.042111833,0.8703033,0.0056053083,0.00008938016,0.0071134698,0.000057622277,0.0038483422,0.00039824547,0.00898556,0.0005838344],"about_ca_topic_score_codex":0.00005069191,"about_ca_topic_score_gemma":0.00022355655,"teacher_disagreement_score":0.72337925,"about_ca_system_score_codex":0.0005777945,"about_ca_system_score_gemma":0.00035054272,"threshold_uncertainty_score":0.5299007},"labels":[],"label_agreement":null},{"id":"W4414948966","doi":"10.1080/14796694.2025.2557174","title":"A plain language summary of LocoMMotion – an observational study of treatments used for pretreated multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Legend Biotech","keywords":"Observational study; Multiple myeloma; Plain language; MEDLINE; English language","score_opus":0.0831085566720721,"score_gpt":0.41474552715769386,"score_spread":0.33163697048562174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414948966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955462,0.00015310259,0.00007229079,0.00034195394,0.00012847787,0.0027239656,0.00019670033,0.000031278145,0.00080603786],"genre_scores_gemma":[0.99491334,0.000009558833,0.0021791302,0.00004996961,0.00010044061,0.0003564555,0.0012286649,0.000014363341,0.0011481023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987814,0.00018725867,0.0003552672,0.00026045495,0.00020413705,0.00021152447],"domain_scores_gemma":[0.99887,0.00036305396,0.0001432356,0.00031788315,0.00021450224,0.000091312366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016947798,0.00014815747,0.00050910277,0.00023193765,0.000058233512,0.0000030405815,0.00009856655,0.0001651352,0.00005366079],"category_scores_gemma":[0.00015799809,0.00011585485,0.00008918902,0.00027991226,0.00005005306,0.000060953975,0.000035452733,0.000095091375,0.0000015734576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063776146,0.01251497,0.91259795,0.00024392162,0.0012746776,0.000086319764,0.0022267366,0.000009343566,0.023444582,0.0001877007,0.0009015215,0.04013463],"study_design_scores_gemma":[0.029111076,0.010649798,0.9455347,0.000069476846,0.00031141884,0.0000057414236,0.0032389902,0.0008994399,0.008628451,0.00003077202,0.0014484836,0.00007164414],"about_ca_topic_score_codex":0.00039711504,"about_ca_topic_score_gemma":0.0015102156,"teacher_disagreement_score":0.040062986,"about_ca_system_score_codex":0.00021570554,"about_ca_system_score_gemma":0.0002869438,"threshold_uncertainty_score":0.47244236},"labels":[],"label_agreement":null},{"id":"W4414948984","doi":"10.1080/14796694.2025.2560134","title":"A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency; University of Alberta; Alberta Cancer Foundation","funders":"National Cancer Institute","keywords":"Daratumumab; Multiple myeloma; Dexamethasone; Plain language; Stem cell","score_opus":0.014462611549110644,"score_gpt":0.2932345295906881,"score_spread":0.2787719180415774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414948984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192405,0.0008310231,0.00015509306,0.0013361049,0.00014210152,0.0047807917,0.00047098097,0.000025462004,0.00033439387],"genre_scores_gemma":[0.99677306,0.00007974856,0.0012524194,0.00029221454,0.00008890227,0.0007127119,0.000052154184,0.000028060487,0.0007207374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981323,0.00032609262,0.0004126421,0.00044744485,0.00030174246,0.0003798084],"domain_scores_gemma":[0.9976134,0.0012765591,0.00022422774,0.00049097935,0.00021732533,0.00017753031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022048003,0.00025927235,0.0010814095,0.00021389485,0.00012522168,0.000008521554,0.00020116381,0.00016352414,0.000012961154],"category_scores_gemma":[0.00013435478,0.00016023936,0.00010268658,0.0005144462,0.00008921418,0.00003566396,0.0000806998,0.00025648778,6.763008e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18558495,0.009122577,0.5667663,0.0027148896,0.0029876265,0.0015993629,0.13983168,0.0001140339,0.039787654,0.00005209642,0.008267012,0.04317177],"study_design_scores_gemma":[0.08989153,0.010324757,0.78336203,0.00079552364,0.00072995643,0.00004666246,0.08082809,0.00033663752,0.03147106,0.0000025684396,0.0019687081,0.00024246272],"about_ca_topic_score_codex":0.0011808139,"about_ca_topic_score_gemma":0.02978376,"teacher_disagreement_score":0.2165957,"about_ca_system_score_codex":0.00020274059,"about_ca_system_score_gemma":0.0004470019,"threshold_uncertainty_score":0.98792017},"labels":[],"label_agreement":null},{"id":"W4415965680","doi":"10.1080/14796694.2025.2582807","title":"Thyroid cancers reveal significant age- and gender-specific associations in papillary, medullary, and multinodularity types in Ha’il, Saudi Arabia: retrospective analysis","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"West Park Healthcare Centre","funders":"University of Hail","keywords":"Thyroid; Thyroid cancer; Medullary thyroid cancer; Retrospective cohort study; Cancer; Thyroid hormones; Medullary cavity","score_opus":0.017709230361629292,"score_gpt":0.3042675091880909,"score_spread":0.2865582788264616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415965680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9620007,0.020048518,0.000017398632,0.012506933,0.00033845933,0.0006727609,0.000112840506,0.000031521562,0.0042708223],"genre_scores_gemma":[0.98387647,0.014090903,0.00067491725,0.0007655968,0.00018315979,0.0001271328,0.00009496849,0.000012060523,0.00017479845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983727,0.00019539468,0.00037587175,0.0005746156,0.00016035099,0.0003210897],"domain_scores_gemma":[0.9992432,0.00019135878,0.00013446104,0.0002452932,0.00008068564,0.00010502559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034741845,0.0002098129,0.0008543723,0.00044345413,0.00009365784,0.000020161533,0.00006171189,0.00027448684,0.000033355034],"category_scores_gemma":[0.00008449595,0.00018712836,0.00009418158,0.0010009838,0.00012456052,0.000044143653,0.00006219742,0.0004278577,0.0000016939915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016515968,0.00036780385,0.98377615,0.000042114832,0.00085060426,0.0004907342,0.001184705,0.00003439063,0.0005874947,0.001694009,0.006700777,0.004106081],"study_design_scores_gemma":[0.0030935963,0.00036967464,0.98326516,0.000028626284,0.0006358682,0.0000074871905,0.00051192625,0.00004374807,0.00009680169,0.0007251375,0.011081829,0.00014012758],"about_ca_topic_score_codex":0.0014870599,"about_ca_topic_score_gemma":0.024906259,"teacher_disagreement_score":0.0234192,"about_ca_system_score_codex":0.002407769,"about_ca_system_score_gemma":0.00031398045,"threshold_uncertainty_score":0.99288666},"labels":[],"label_agreement":null},{"id":"W4416187331","doi":"10.1080/14796694.2025.2577633","title":"Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Bayer","keywords":"Biochemical recurrence; Prostate cancer; Clinical endpoint; Prostatectomy; Prostate-specific antigen; Placebo; Radiation therapy; Glutamate carboxypeptidase II; Adjuvant","score_opus":0.01653389836474592,"score_gpt":0.3473627806221141,"score_spread":0.3308288822573682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416187331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977561,0.013741963,0.000012850416,0.006481208,0.00047342322,0.0007867525,0.000047042413,0.000021263588,0.0008744804],"genre_scores_gemma":[0.97170365,0.026466705,0.00032798777,0.0002818094,0.00021412405,0.00022349332,0.00008463108,0.000010672633,0.0006868998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989424,0.0000962511,0.0002715142,0.0002810391,0.00014982198,0.00025900314],"domain_scores_gemma":[0.9994205,0.000079644546,0.00010462499,0.00020316667,0.0001344411,0.000057594094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001967851,0.00012412944,0.00038831623,0.00020232679,0.00003452147,0.000003962461,0.00009584533,0.00020849511,0.000079754514],"category_scores_gemma":[0.000048277794,0.00009107084,0.000047307592,0.00053893763,0.00014255254,0.00003740819,0.000043786156,0.00033936033,0.0000039510874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00796134,0.00054418034,0.58041596,0.00020669623,0.00023132405,0.00007356173,0.0011282734,0.00001825607,0.0253837,0.0005739774,0.007964829,0.3754979],"study_design_scores_gemma":[0.03457401,0.0033272794,0.6021405,0.000647845,0.00014880582,0.000019771293,0.0007213714,0.00025923023,0.23352715,0.002130896,0.12219528,0.00030784038],"about_ca_topic_score_codex":0.00048112875,"about_ca_topic_score_gemma":0.0001892703,"teacher_disagreement_score":0.37519005,"about_ca_system_score_codex":0.000543925,"about_ca_system_score_gemma":0.0010341963,"threshold_uncertainty_score":0.37137613},"labels":[],"label_agreement":null},{"id":"W4416307752","doi":"10.1080/14796694.2025.2589058","title":"Clinical outcomes and healthcare resource use in triple-class exposed patients with relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Johnson and Johnson","keywords":"Multiple myeloma; Resource use; Health care; Healthcare system; MEDLINE; Clinical trial","score_opus":0.03811956074926689,"score_gpt":0.3619815659137525,"score_spread":0.32386200516448566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416307752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98989886,0.00038513154,0.0000064196734,0.006531528,0.0004031889,0.0014122825,0.000044014632,0.00005867096,0.0012598921],"genre_scores_gemma":[0.99256206,0.00014553312,0.0016374064,0.0028219265,0.00015166262,0.00010389326,0.00022138018,0.000028702052,0.0023274298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997489,0.00054326,0.00057901937,0.00057783583,0.00029230324,0.00051857904],"domain_scores_gemma":[0.99749035,0.0013845298,0.00013820946,0.0004672174,0.0001580703,0.00036162377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034266236,0.00025467624,0.00083330274,0.00032768003,0.000106411106,0.000017730705,0.00011016604,0.00047607083,0.000031667634],"category_scores_gemma":[0.0010126695,0.00017421828,0.00009958805,0.0003119976,0.00019573029,0.00010173568,0.00010907053,0.0008164844,0.0000143916695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007514615,0.0013539589,0.90703344,0.00007951605,0.00018844572,0.00034786633,0.00015611139,1.702361e-7,0.000008610948,0.00007708558,0.0031428628,0.08009733],"study_design_scores_gemma":[0.03242726,0.002733876,0.8157341,0.00010106949,0.000046671947,0.0000065190397,0.00025572407,0.000025616453,0.000007453936,0.000010031707,0.14854394,0.000107765],"about_ca_topic_score_codex":0.00023203681,"about_ca_topic_score_gemma":0.003810499,"teacher_disagreement_score":0.14540108,"about_ca_system_score_codex":0.00038695408,"about_ca_system_score_gemma":0.0004938769,"threshold_uncertainty_score":0.7104415},"labels":[],"label_agreement":null},{"id":"W4416598843","doi":"10.1080/14796694.2025.2589057","title":"LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"MEDLINE; Cancer; Chemotherapy; Clinical trial; Radiation therapy","score_opus":0.012988930198728882,"score_gpt":0.3348446924409227,"score_spread":0.3218557622421938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416598843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91306823,0.000048645445,9.873116e-7,0.00047452992,0.0002546823,0.0769111,0.000011435797,0.00004203069,0.009188349],"genre_scores_gemma":[0.9627389,0.0000022557667,0.000093786744,0.00039866654,0.0001145886,0.036409963,0.000008263821,0.000014071575,0.00021955855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981859,0.00024529942,0.00044169498,0.00049263466,0.000331258,0.0003032447],"domain_scores_gemma":[0.9989513,0.00006516071,0.00018249717,0.0004823787,0.000245942,0.000072676536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020210184,0.00024725462,0.000811189,0.00023559803,0.00006873008,0.0000049659893,0.00014416012,0.00009494894,0.000034988676],"category_scores_gemma":[0.000022057087,0.00018482924,0.00006208641,0.001031131,0.00009982221,0.000035908186,0.00009626072,0.00026390565,0.000001765247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009211126,0.007815489,0.97351736,0.00017125455,0.00036233137,0.00021915058,0.0020472775,0.000014413686,0.0000012419912,0.000024437577,0.0040456224,0.0025703122],"study_design_scores_gemma":[0.03467915,0.016304404,0.9382646,0.00012609437,0.00029198697,9.3023243e-7,0.0055263955,0.000009696966,0.000005888106,0.0000041325748,0.0046553896,0.00013131308],"about_ca_topic_score_codex":0.008228968,"about_ca_topic_score_gemma":0.1707942,"teacher_disagreement_score":0.16256523,"about_ca_system_score_codex":0.001621185,"about_ca_system_score_gemma":0.0012364594,"threshold_uncertainty_score":0.9983753},"labels":[],"label_agreement":null},{"id":"W4416790102","doi":"10.1080/14796694.2025.2592722","title":"A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma Europe; Astellas Pharma; Bayer HealthCare","keywords":"Enzalutamide; Prostate cancer; Plain language; Cancer; Prostate","score_opus":0.011137181841712232,"score_gpt":0.31419172156580727,"score_spread":0.303054539724095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416790102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98545575,0.009806792,0.0000025045788,0.0011394329,0.00014482338,0.0028357324,0.00029471287,0.00001329901,0.00030698016],"genre_scores_gemma":[0.9975369,0.00053576677,0.00025142636,0.000164995,0.000038827544,0.0002769558,0.00008451286,0.000020921365,0.0010896715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979212,0.00043457357,0.0005373239,0.0003589246,0.00040991072,0.00033803168],"domain_scores_gemma":[0.99889046,0.00022533601,0.00026638497,0.00035459167,0.00017873413,0.00008447014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042851348,0.00023591638,0.00085618324,0.00028679165,0.00008009219,0.000009108541,0.00012193638,0.000080721926,0.000033573786],"category_scores_gemma":[0.00007525669,0.00013620885,0.00005823583,0.00066644565,0.00026751458,0.00007449236,0.00010696833,0.00032076842,3.8127692e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051256977,0.008919293,0.87685287,0.0019722977,0.0027249963,0.00097808,0.027638039,0.00020037006,0.0058061047,0.0002788041,0.003244985,0.020127205],"study_design_scores_gemma":[0.0537621,0.0068823094,0.90589887,0.00068451435,0.001346634,0.000018109338,0.02141012,0.000038090348,0.0061827074,0.000039002258,0.003499837,0.00023768416],"about_ca_topic_score_codex":0.00213689,"about_ca_topic_score_gemma":0.01705232,"teacher_disagreement_score":0.02904604,"about_ca_system_score_codex":0.00044847035,"about_ca_system_score_gemma":0.0010848707,"threshold_uncertainty_score":0.95155954},"labels":[],"label_agreement":null},{"id":"W4417105636","doi":"10.1080/14796694.2025.2577005","title":"Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); McGill University Health Centre","funders":"Celgene; Pfizer","keywords":"Lymphoblastic Leukemia; Disease; Plain language; Stem cell; Cancer; Transplantation; Leukemia; Acute leukemia","score_opus":0.005246984083700796,"score_gpt":0.2637353523276733,"score_spread":0.25848836824397253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417105636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97886825,0.00041065534,0.00095273217,0.001657528,0.0003723806,0.0009446116,0.00014822301,0.00013557044,0.016510028],"genre_scores_gemma":[0.98485106,0.00022526579,0.0009955141,0.00096542004,0.00024319046,0.000095607764,0.00009986213,0.00006920624,0.012454896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971943,0.00026018475,0.00063095236,0.0006178125,0.0005268621,0.0007698718],"domain_scores_gemma":[0.9974631,0.0012096987,0.00024028528,0.00065831956,0.00019184282,0.00023676697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035350485,0.00044645078,0.0014498018,0.00054799183,0.00012762204,0.000015497444,0.00042366996,0.00060277985,0.00015318008],"category_scores_gemma":[0.0000579752,0.00032203965,0.00020255239,0.00084904494,0.00023053307,0.000096617514,0.00015886287,0.00064680306,0.000028275397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031891223,0.0035486403,0.5398252,0.010861778,0.009849068,0.015339677,0.18651143,0.00038053925,0.07544484,0.0028650088,0.05358336,0.06989926],"study_design_scores_gemma":[0.06493934,0.01431276,0.8221741,0.0058719465,0.005621823,0.0031059296,0.044403967,0.008891549,0.014498566,0.00007104589,0.014561778,0.0015471913],"about_ca_topic_score_codex":0.00049077836,"about_ca_topic_score_gemma":0.0021434422,"teacher_disagreement_score":0.28234893,"about_ca_system_score_codex":0.0035687827,"about_ca_system_score_gemma":0.005322772,"threshold_uncertainty_score":0.99992317},"labels":[],"label_agreement":null},{"id":"W4417187153","doi":"10.1080/14796694.2025.2599082","title":"Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; Jewish General Hospital","funders":"Seagen; Bristol-Myers Squibb","keywords":"Nivolumab; Brentuximab vedotin; Lymphoma; Ipilimumab; Chemoimmunotherapy; Immunotherapy","score_opus":0.009151288919165883,"score_gpt":0.2901132775739707,"score_spread":0.2809619886548048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417187153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8652391,0.011658593,0.00037920312,0.019221934,0.0065623447,0.0026379016,0.00020141651,0.0003203398,0.0937792],"genre_scores_gemma":[0.97321844,0.0006131826,0.0014108851,0.0057729017,0.0012121194,0.00059118797,0.0002931165,0.00004447296,0.016843684],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834156,0.000075519085,0.0003736603,0.00050530536,0.00015673893,0.000547238],"domain_scores_gemma":[0.9987587,0.00030818803,0.0001416526,0.00049195066,0.00012809214,0.0001714538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001589285,0.00028460973,0.00070283015,0.0001746407,0.00018427156,0.000017447337,0.00015021191,0.0004681401,0.00013737133],"category_scores_gemma":[0.00006792293,0.00023160568,0.0002939237,0.00020066636,0.000060790768,0.00005150207,0.0000907816,0.00013065146,0.0001368743],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005410805,0.06318782,0.01234014,0.0006779583,0.00081664504,0.00075681147,0.0010526433,7.0793214e-7,0.0011363443,0.015798166,0.6813858,0.21743613],"study_design_scores_gemma":[0.11391326,0.001987825,0.017022148,0.000067026165,0.00046616167,0.00004819122,0.00040698095,0.00008168562,0.0013280578,0.0001374021,0.86437315,0.00016811515],"about_ca_topic_score_codex":0.00004546941,"about_ca_topic_score_gemma":0.00014266407,"teacher_disagreement_score":0.21726802,"about_ca_system_score_codex":0.001685316,"about_ca_system_score_gemma":0.0011619017,"threshold_uncertainty_score":0.9444605},"labels":[],"label_agreement":null},{"id":"W4417427056","doi":"10.1080/14796694.2025.2598016","title":"Diagnostic accuracy and safety of image-guided transperineal versus transrectal prostate biopsy for clinically significant prostate cancer: a GRADE-assessed systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diagnostic accuracy; Prostate; Prostate biopsy; Prostate cancer; Biopsy; MEDLINE","score_opus":0.04685428374219517,"score_gpt":0.39584589066345377,"score_spread":0.3489916069212586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417427056","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12671503,0.632081,0.0013342171,0.17929827,0.0010387357,0.051897194,0.0069214203,0.00020279453,0.0005113835],"genre_scores_gemma":[0.68568295,0.29002297,0.0058907573,0.0026505669,0.000108041735,0.0148361195,0.00043161522,0.00006243382,0.0003145696],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970862,0.0002827935,0.0014539016,0.0006476744,0.0001773288,0.00035208344],"domain_scores_gemma":[0.9947301,0.0038,0.00052400347,0.00038825852,0.00036951806,0.00018808884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007241842,0.0003804517,0.0040126243,0.00017602262,0.00009347164,0.000021003127,0.00010859363,0.00016381896,0.000070480084],"category_scores_gemma":[0.0007597929,0.00024961293,0.00081041665,0.00061190495,0.00022524585,0.000082144776,0.000026460344,0.00019326169,5.923779e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009218436,0.002346494,0.00660181,0.63372606,0.3390162,0.0003525116,0.0020963908,0.000025524188,0.0012638483,0.0010205128,0.0016522832,0.0026799026],"study_design_scores_gemma":[0.013270458,0.0035712519,0.0061776135,0.00283193,0.9711279,0.000026700378,0.00034731528,0.00008449473,0.0006261645,0.00007105182,0.001531817,0.000333288],"about_ca_topic_score_codex":0.00012630636,"about_ca_topic_score_gemma":0.00015700133,"teacher_disagreement_score":0.6321117,"about_ca_system_score_codex":0.00017814229,"about_ca_system_score_gemma":0.0005446897,"threshold_uncertainty_score":0.9999956},"labels":[],"label_agreement":null},{"id":"W7117573986","doi":"10.1080/14796694.2025.2610171","title":"The first United Arab Emirates expert consensus recommendations for the diagnosis and management of early and advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Research Society","funders":"","keywords":"Lung cancer; Delphi method; Delphi; MEDLINE; Cancer; Cornerstone; Treatment of lung cancer; Consensus conference","score_opus":0.018985541569063753,"score_gpt":0.3397855648429782,"score_spread":0.3208000232739145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117573986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5071282,0.07161041,0.00008337203,0.41336963,0.001458775,0.0038233052,0.00009417908,0.000026099859,0.0024060647],"genre_scores_gemma":[0.6861084,0.29272103,0.0029226625,0.0065236166,0.00029914474,0.009461199,0.000041791496,0.000027083528,0.0018950539],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99940854,0.000028174687,0.00017918904,0.00018875129,0.000042094878,0.00015325884],"domain_scores_gemma":[0.99845374,0.0011434715,0.000089698355,0.00018818387,0.000088609944,0.00003629814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011545897,0.000111995876,0.00020687668,0.000046643196,0.0002771156,0.00001309092,0.000060886447,0.00006994392,0.000013779925],"category_scores_gemma":[0.000010251668,0.00006136577,0.000040671395,0.00015125205,0.000099391225,0.000010381291,0.000051862135,0.000077211094,2.2431774e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001478213,0.00081298826,0.23879673,0.0015541516,0.0026668983,0.000027536436,0.003980744,0.000027319711,0.00007000063,0.006885934,0.3790625,0.364637],"study_design_scores_gemma":[0.0039318907,0.00046261295,0.08678618,0.0003609469,0.0006787735,0.0000022034822,0.0021212653,0.00015984608,0.0006912247,0.0000449904,0.9046921,0.00006794118],"about_ca_topic_score_codex":0.00025607605,"about_ca_topic_score_gemma":0.0012986137,"teacher_disagreement_score":0.52562964,"about_ca_system_score_codex":0.00016295134,"about_ca_system_score_gemma":0.00007296322,"threshold_uncertainty_score":0.25024235},"labels":[],"label_agreement":null}]}